WO2009086303A2 - Method for altering the lifespan of eukaryotic organisms - Google Patents
Method for altering the lifespan of eukaryotic organisms Download PDFInfo
- Publication number
- WO2009086303A2 WO2009086303A2 PCT/US2008/088016 US2008088016W WO2009086303A2 WO 2009086303 A2 WO2009086303 A2 WO 2009086303A2 US 2008088016 W US2008088016 W US 2008088016W WO 2009086303 A2 WO2009086303 A2 WO 2009086303A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compounds
- lifespan
- compound
- cells
- assay
- Prior art date
Links
- RYBWDGAALCAZQR-UHFFFAOYSA-N Cc([nH]nc1nc2N(C)C(N3C)=O)c1c(OC(c1ccccc1)=O)c2C3=O Chemical compound Cc([nH]nc1nc2N(C)C(N3C)=O)c1c(OC(c1ccccc1)=O)c2C3=O RYBWDGAALCAZQR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to methods for altering lifespan. Specifically, the invention relates to methods of increasing the lifespan of eukaryotic organisms.
- caloric restriction (synonymously, dietary restriction ) extends lifespan in a range of non-human organisms including budding yeast (Saccharomyces cerevisiae), worms (Caenorhabditis elegans), the fruit fly (Drosophila melanogaster), and the mouse (Mus musculus).
- CR caloric restriction
- resveratrol a plant product that is a component of red wine
- these components can also be characterized by identifying compounds that alter the CR response and then determining what molecules those compounds interact with.
- sirtuins may be involved in the CR response, there is evidence to suggest that there are other CR-based longevity pathways, e.g., compounds unrelated to resveratrol that activate SIRTl (identified by in vitro biochemical screen using purified SIRTl) and have important physiological effects in mice.
- SIRTl is the mammalian homolog of the budding yeast silent information regulator 2 (SIR2), which encodes a histone deacetylase that has been implicated in the control of lifespan and the mitigation of age- associated diseases by CR regulatory mechanisms.
- SIR2 budding yeast silent information regulator 2
- Identification of these pathways may be made by understanding the molecular effects of compounds identified as acting outside previously characterized pathways and, once identified, the components of these pathways may serve as new target molecules for modulating the CR response. See, e.g., Petrascheck et al., Nature (2007) 450:553-557.
- compound-based screens have another distinct advantage, in that the compounds identified by these screens have utility not simply for their usefulness in identifying the components of the CR pathway(s) but also because these compounds themselves, or in modified form, may be used as drugs for stimulating the CR response.
- a compound shown in a particular model system e.g., yeast, worms, fruit fly, mouse
- resveratrol for example, has low bioavailability and therefore is not necessarily a particularly suitable compound for altering the CR response.
- DeaD cell-based phenotypic "Death of Daughters"
- U.S. Patent Application Serial No. 10/790,456 to Goldfarb the contents of which are herein incorporated in their entirety by reference.
- the DeaD assay allows for the high throughput screening of compounds in yeast cells for those compounds that extend or shorten what is termed
- replicative aging i.e., aging as defined as the number of divisions an individual yeast cell undergoes before dying.
- yeast because cell division is asymmetric, it is straightforward to distinguish a newly formed small “daughter” cell from the larger "mother” cell that gave rise to the daughter by division, and therefore it is possible to monitor the number of divisions a mother cell undergoes by distinguishing these cells from their progeny. Typically this discrimination is done by a trained microscopist, and, although straightforward, is extremely labor- and time-intensive.
- the DeaD assay makes use of yeast strains that have been genetically engineered so that daughter cells die, thereby allowing for replicative assays based on the growth properties of bulk populations of cells which, because the daughters die, are essentially mothers only, i.e., methods that are quick and require relatively little labor to perform, since they are based on bulk properties (absorbance) rather than on detailed microscopic analyses.
- the high throughput screening of compounds in yeast cells performed with the DeaD assay may be done on yeast cells exposed to the test compounds only; alternatively, or in addition, the DeaD assay may be done with yeast cells also treated with an agent or agents that alter longevity or other aspects of the CR response, in order to identify test compounds which counter the effects of this agent or agents.
- the Sir2 protein like the other sirtuins, is a NAD + -dependent deacetylase which produces nicotinamide (also referred to herein as NIC or NAM) as a reaction product.
- Nicotinamide in turn acts as a non-competitive inhibitor of the Sir2 protein and Sir2-like enzymes in vitro and, in vivo, and can accelerate yeast ageing by inhibiting Sir2. see, e.g., Anderson et al., Nature (2003) 423: 181-185. Therefore, in addition to using the DeaD assay to screen for compounds altering the CR response in untreated yeast cells, additional information on compounds altering the CR response can be obtained by using yeast cells treated with nicotinamide, i.e., in a situation where compounds are selected based on their ability to counter the longevity-shortening effects of nicotinamide.
- the present invention is directed to methods for altering the lifespan of eukaryotic organisms comprising the steps of: providing a lifespan altering compound and administering an effective amount of the compound to a eukaryotic organism, such that the lifespan of the eukaryotic organism is increased.
- Examples of eukaryotic organisms include single- and multi-cellular organisms, including higher-order organisms (such as mammals, which includes humans).
- the compound is identified using the DeaD assay as a high- throughput method to screen compounds for their effects on longevity and CR-related disease states.
- the compound has an EC50 of 10 ⁇ M or less. Examples of such compounds are provided as compounds 1-245 of Table 1. In another embodiment, the compound has an EC50 of 5 ⁇ M or less and examples of such compounds are provided as the first 77 compounds listed in Table 1. In yet other embodiments, the compound is selected from group of consisting of SID 14724551, SID 14732512, SID 7972147 and SID 17511642. [0015] In one aspect, the present invention is directed to the identification of lifespan altering compounds by the high-throughput screening of compounds using the DeaD assay, including their ability to alleviate the longevity-shortening effects of nicotinamide.
- the present invention is directed to the method of use of compounds obtained by this screening.
- Compounds having desired criteria such as EC50, can be selected.
- the invention is also directed to the use of compounds with common substructures or scaffolds identified by analysis of the common structural features of the compounds identified in the present invention, including, but not limited to, the scaffolds defined in Figure 6.
- the present invention is also directed to methods for isolating one or more components of the cellular pathway(s) that mediate the effects of the compounds of the present invention, with non-limiting examples of such methods provided in Example 8.
- Figure 1 provides plots demonstrating that the DeaD assay lifespan responds properly to SIR2 expression levels
- Panel A Relative DeaD lifespans are normalized to the lifespan of the parental SIR2 + strain (SIR2)
- SIR2 + strain SIR2 + strain
- the integration of a series of promoters of increasing strength upstream of the chromosomal SIR2 gene shows that decreased expression (weak CYC promoter) shortens DeaD lifespan, and elevated SIR2 expression (strong TEF and GDP promoters) extend lifespan Panel B
- Figure 2 provides plots demonstrating that DeaD lifespan is reduced by nicotinamide Panel A Under growth in glucose (nonpermissive conditions) DeaD lifespans are reduced in a dose-dependent fashion by increasing concentrations of nicotinamide Panel B Under growth in galactose (permissive conditions) these concentrations of nicotinamide do not alter growth
- the lines shown in panel A correspond to (top to bottom) 0, 0 5, 0 75, and
- Figure 3 provides a plot showing DeaD assays for compound SID 855620 (nalidixic acid) in the presence and absence of nicotinamide
- the nalidixic acid was incubated with growing cells under nonpermissive conditions at concentrations of 2 5, 5 0, and 10 uM (micromolar) in the presence and absence of 1 5 mM nicotinamide Control expe ⁇ ments for growth in the presence and absence of nicotinamide without the drug are included
- the last three entries showing the line labeling are all results obtained with 1 5 mM nicotinamide and, respectively, 2 5, 5 or 10 uM nalidixic acid
- the data lines shown in this figure correspond to (topmost to bottommost as they appear at the extreme ⁇ ght side of the data lines) 2 5, 10, or 5 uM nalidixic acid (no nicotinamide), blank cells (labeled "no NIC"), 5 or 10 uM nalidixic acid plus
- Figure 4 provides standard microdissection lifespans for nicotinamide in the presence of nalidixic acid and 5 mM nicotinamide Three experiments that included three concentrations of nalidixic acid all increased mean lifespans (shown in parentheses) and maximum lifespans
- "#864" refers to nalidixic acid, e g , the second entry in the legend iefers to 54 uM nalidixic acid, the third entry refers to 107 uM nalidixic acid, etc
- the number presented in parentheses in the figure legend refers to the mean lifespan of the population m each experiment presented m this Figure, e g , the control population (5 mM nicotinamide only) has a mean lifespan of 14 2 generations, etc
- Figure 5 provides the structure of nalidixic acid, a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum that is an
- Figure 6A-6C provide scaffold analyses of the data of the assays of the present invention in order to identify common structural scaffolds for the active compounds defined in the assays.
- This figure shows 12 such scaffolds; scaffolds cl-c3 (6A), and in particular cl, have a low likelihood of occurring in the data by chance, and therefore serve as likely scaffolds for further defining compounds able to produce the results of the assays of the present invention.
- Figure 6B is ccl, cc2 and cc3a
- Figure 6C is cc3b, cc4, cc5, cc6, cc7 and cc8.
- Figure 7 provides the structures of SIDs A) 14732512, B) 14724551, C) 17511642, and D) 7972147 containing the cl scaffold and identified in the 775 assay as "active.”
- Figure 8 provides the structures of SIDs A) 7972920, B) 14732962, C) 4245034, and D) 842694 containing the cl scaffold and identified in the 775 assay as "inactive.”
- Figure 9 provides the structures of SIDs A) 14724551 , B) 14732512, and C) 17511642 containing the cl scaffold and identified in the 809 assay as "active.”
- Figures 10-12 provide microdissection assays for a number of the compounds presented in Table 2. Table 3 provides the data used to generate Figures 10-12.
- Figures 13-14 provide DeaD lifespan assays for a variety of compounds as provided in these Figures.
- Figure 15 provides an example of an assay of one of the compounds of the invention (compound 3-11; see Table 2) in C. elegans.
- Figure 16 presents Table 1 which shows the results of 809 DeaD assay
- Figure 17 presents Table 2 which shows examples of commercially available LAC compounds.
- Figure 18 presents Table 3 which shows data for Figures 10-12.
- Figure 19 presents Table 4 which shows the names of Compounds 1-77 from Table
- the present invention provides a method for altering the lifespan of eukaryotic organisms comprising the steps of: providing a lifespan altering compound and administering an effective amount of the compound to a eukaryotic organism, such that the lifespan of the eukaryotic organism is increased.
- a lifespan altering compound is a compound that reverses the lifespan shortening effect of a lifespan shortening agent (such as nicotinamide or environmental agents such as paraquat) and/or increases the lifespan of a eukaryotic organism (which is not exposed to or treated with a lifespan shortening agent).
- Lifespan as used herein means the number of times a cell or cell population can divide (replicative lifespan) or the length of time (e.g. days or years) a cell or organism survives before dying (chronological lifespan).
- the LAC may alter the lifespan through CR, dietary restriction (DR), or some other pathway.
- the LAC reverses the effect of an agent (such as NIC) that shortens the lifespan of an eukaryotic organism.
- a LAC increases the replicative lifespan of yeast cells in the DeaD assay.
- a LAC increases the replicative lifespan of yeast cells in the presence or absence of a lifespan shortening agent (such as NIC).
- a LAC increases the replicative lifespan of yeast cells in the presence or absence of an environmental agent (such as paraquat).
- a LAC has an EC50 value of 5 micromolar or less in the DeaD assay.
- a LAC has an EC50 value of 10 micromolar or less in the DeaD assay.
- a LAC increases the lifespan of an higher organism such as C. elegans.
- a LAC increases the lifespan of a mammal such as a human.
- an effective amount of a LAC increases or decreases the lifespan of an eukaryotic organism.
- an effective amount of a LAC increases the lifespan of an eukaryotic organism by a statistically significant amount compared to the lifespan of an untreated organism. The lifespan of an untreated organism may be determined in parallel or may be obtained from separately conducted studies (control).
- an effective amount of a LAC increases the lifespan of an eukaryotic organism by at least 5%.
- an effective amount of a LAC increases the lifespan of an eukaryotic organism by at least 10, 15, 20, 25, 35, 50%, or 100% over control.
- eukaryotic organisms include single- and multi-cellular organisms, including higher-order organisms (such as mammals, which includes humans).
- the present method can be used in order to generally increase the lifespan of the cells of a eukaryotic organism and to protect its cells against stress and/or against apoptosis. While not intending to be bound by any particular theory, it is believed that use of the present method is similar to subjecting the subject to hormesis, i.e., mild stress that is beneficial to organisms and may extend their lifespan.
- the present method can be used for treating or preventing a disease or condition induced or exacerbated by cellular senescence in a subject; for extending the lifespan of a subject; for treating or preventing a disease or condition relating to lifespan; for treating or preventing a disease or condition relating to the proliferative capacity of cells; for treating or preventing a disease or condition resulting from cell damage or death.
- the present method may be used to prevent aging and aging-related consequences or diseases, such as stroke, heart disease, heart failure, arthritis, high blood pressure, and Alzheimer's disease.
- Other conditions that can be treated include ocular disorders, e.g., associated with the aging of the eye, such as cataracts, glaucoma, and macular degeneration.
- the present method may also be used to treat chronic diseases associated with cell death in order to protect the cells from cell death.
- Exemplary diseases include those associated with neural cell death, neuronal dysfunction, or muscular cell death or dysfunction, such as Parkinson's disease, Alzheimer's disease, multiple sclerosis, amniotropic lateral sclerosis, and muscular dystrophy; AIDS; fulminant hepatitis; diseases linked to degeneration of the brain, such as Creutzfeld- Jakob disease, retinitis pigmentosa and cerebellar degeneration; myelodysplasis such as aplastic anemia; ischemic diseases such as myocardial infarction and stroke; hepatic diseases such as alcoholic hepatitis, hepatitis B and hepatitis C; joint-diseases such as osteoarthritis; atherosclerosis; alopecia; damage to the skin due to UV light; lichen planus; atrophy of the skin; cataract; and graft rejections.
- Parkinson's disease Alzheimer's disease, multiple sclerosis, amniotropic lateral sclerosis, and muscular dystrophy
- Cell death can also be caused by surgery, drug therapy, chemical exposure or radiation exposure.
- the present method may also be used to treat acute diseases, e.g., damage to an organ or tissue, e.g., a subject suffering from stroke or myocardial infarction or a subject suffering from a spinal cord injury or may also be used to repair an alcoholic's liver.
- the invention provides a method extending the lifespan of a eukaryotic cell, extending the proliferative capacity of a eukaryotic cell, slowing ageing of a eukaryotic cell, promoting the survival of a eukarotic cell, delaying cellular senescence in a eukaryotic cell, mimicking the effects of calorie restriction, increasing the resistance of a eukaryotic cell to stress, or preventing apoptosis of a eukaryotic cell, by contacting the cell with a compound of the present invention.
- eukaryotic cells particularly primary eukaryotic cells (i.e., cells obtained from an organism, e.g., a human), may be kept alive in a cell culture.
- Embryonic stem (ES) cells and pluripotent cells, and cells differentiated therefrom, may also be treated with a compound of the present invention to keep the cells, or progeny thereof, in culture for longer periods of time.
- Such cells can also be used for transplantation into a subject, e.g., after ex vivo modification.
- eukaryotic cells that are intended to be preserved for long periods of time may be treated using the method of the present invention.
- the cells may be in suspension (e.g., blood cells, serum, biological growth media, etc.) or in tissues or organs.
- blood collected from an individual for purposes of transfusion or blood to be used for forensic activity may be treated using the present invention to preserve the blood cells for longer periods of time.
- Other cells that may be treated to extend their lifespan or protect against apoptosis include cells for consumption, e.g., cells from non-human mammals (such as meat) or plant cells (such as vegetables).
- the method of the present invention may also be applied during developmental and growth phases in mammals, plants, insects or microorganisms, in order to, e.g., alter, retard or accelerate the developmental and/or growth process.
- the present method can be used to treat cells useful for transplantation or cell therapy, including, for example, solid tissue grafts, organ transplants, cell suspensions, stem cells, bone marrow cells, etc.
- the cells or tissue may be an autograft, an allograft, a syngraft or a xenograft.
- the cells or tissue may be treated according to the present method prior to administration/implantation, concurrently with administration/implantation, and/or post administration/implantation into a subject.
- the cells or tissue may be treated prior to removal of the cells from the donor individual, ex vivo after removal of the cells or tissue from the donor individual, or post implantation into the recipient.
- cells may be treated using the method of the present invention to increase their lifespan or prevent apoptosis.
- skin can be protected from aging (e.g., developing wrinkles, loss of elasticity, etc.) by treating skin or epithelial cells with the method of the present invention.
- Exemplary skin afflictions or skin conditions that may be treated in accordance with the methods described herein include disorders or diseases associated with or caused by inflammation, sun damage or natural aging.
- the present method can find utility in the prevention or treatment of contact dermatitis (including irritant contact dermatitis and allergic contact dermatitis), atopic dermatitis (also known as allergic eczema), actinic keratosis, keratinization disorders (including eczema), epidermolysis bullosa diseases (including penfigus), exfoliative dermatitis, seborrheic dermatitis, erythemas (including erythema multiforme and erythema nodosum), damage caused by the sun or other light sources, discoid lupus erythematosus, dermatomyositis, psoriasis, skin cancer and the effects of natural aging.
- contact dermatitis including irritant contact dermatitis and allergic contact dermatitis
- atopic dermatitis also known as allergic eczema
- actinic keratosis also known as allergic eczema
- the method of the present invention may be used for the treatment of wounds and/or burns to promote healing, including, for example, first—, second- or third-degree burns and/or a thermal, chemical or electrical burns.
- the compound can be delivered to a eukaryotic organism using any available method and route suitable for compound delivery, including oral, parenteral, subcutaneous, intraperitoneal, intrapulmonary, and intranasal routes. It will be recognized by those of skill in the art that the form and character of the particular dosing regimen employed in the method of the invention will be dictated by the route of administration and other well- known variables, such as the size and age of the eukaryotic organism.
- Administration of the compound could be performed in conjunction with any conventional therapies that are intended to treat a disease or disorder associated with aging including topical, oral, or injectable.
- Administration of the LAC can also be done by exposing or contacting the cell or cells to an environment (such a growth or culture medium) containing an effective amount of a LAC.
- the compound is identified using the DeaD assay as a high- throughput method to screen compounds for their effects on longevity and CR-related disease states.
- Other embodiments include, use of these compounds to more precisely identify the structural features of these compounds that are responsible for their activity, methods of identifying the cellular pathway(s) that mediate the activity of these compounds, and methods of extrapolating these results to higher organisms.
- “activity” refers generally to the ability of a compound to exert a CR effect, or a CR-like effect.
- the precise meaning of “activity” depends upon the assay used, for example, whether the assay involves a single concentration of nicotinamide (Example 2) or multiple concentrations of this compound as are required to define an EC50 activity (Example 3).
- “activity” as used herein, encompasses both of these meanings.
- the LAC is selected from the compounds of Table 1. These compounds are identified by their SID (substance identifier) number which is readily recognized by those having skill in the art.
- the SID number is a field in the PubChem database of chemical molecules maintained by the National Center for Biotechnology Information (NCBI), a component of the National Library of Medicine, which is part of the United States National Institutes of Health (NIH).
- NBI National Center for Biotechnology Information
- NH National Institutes of Health
- the LAC is selected from the first 77 compounds listed in Table 1. These IUPAC and common names of the first 77 compounds listed in Table 1 are listed in Table 4. Further, Compound 15 from Table 4 has the following structure:
- the compound is selected from the group consisting of the compounds listed in Table 2. In various embodiments, the compound is selected from group of consisting of SID 14724551, SID 14732512, and SID 1751 1642.
- EXAMPLE 1 Validation Of The DeaD Assay
- the DeaD assay was developed as a high throughput proxy for conventional microdissection assays used to determine yeast replicative ageing. In order to verify the ability of this assay to produce results corresponding to conventional microdissection assay results, the data of Figure 1 were obtained using either the DeaD assay (panel A) or via microdissection (panel B). As this figure shows, increased SIR2 expression increases lifespan similarly between the DeaD assay and conventional microdissection.
- Figure 2 shows additional confirmation of the validity of the DeaD assay; specifically, the data of Figure 2 show that nicotinamide reduces the lifespan of the DeaD strain in a dose-dependent fashion (panel A) without altering growth under permissive conditions (panel B).
- Panel A the data of Figure 2 show that nicotinamide reduces the lifespan of the DeaD strain in a dose-dependent fashion (panel A) without altering growth under permissive conditions (panel B).
- the DeaD assay was used to screen a 132,796 compound library for the ability of compounds in the library to counter the lifespan-shortening effect of nicotinamide.
- Assays were conducted as follow. Cells were streaked out on a YPGaI agar plate and grown for 48 hours at 30 0 C. Four colonies were selected, 50 mL of YPGaI medium in a flask was inoculated and grown at 30 0 C with shaking CVN. OD600 was measured. The OD should be ⁇ 0.7 for the cells to be in log phase. The cells were centrifuged, washed once and resuspended in CSMM-D restrictive growth medium. OD600 was measured again. The culture was diluted to an OD600 of 0.002 in CSMM-D restrictive medium. The culture was pre- incubated in a flask with shaking at 30 0 C for 4 hours.
- OD600 was measured for reference. Nicotinamide (negative control), medium alone (positive control) and compounds in the presence of nicotinamide were plated with DMSO at 10 x concentration (final concentrations: nicotinamide 1.5 mM, compounds 10 uM, DMSO 0.25%) in 384-well plates: 5 uL/well. The yeast was added to the plates: 45 uL/well. Plates were incubated at 30C in a humidified chamber. After 48 hours incubation, plates were shaken for 30 seconds and OD615 was read in an EnVision (PerkinElmer) multilabel plate reader.
- EnVision PerkinElmer
- YPGaI medium was prepared as 10 grams yeast extract, 20 grams peptone, 900 mL water, autoclave at 121 0 C for 15 minutes, add 100 niL sterile 20% (w/v) galactose.
- CSMM-D (Complete Synthetic Minimal Medium-Dextrose) (restrictive) medium was prepared as 6.7 grams yeast nitrogen base without amino acids, 2.0 grams Drop-out mix complete (DOC) (USBiological Cat. no. D9515), 100 mL 20% (w/v) dextrose, water to 1.0 L, then filter sterilize. Results
- the data of this Example define about 900 compounds showing "activity” in overcoming nicotinamide inhibition as judged by the criteria provided above.
- Such "activity” is a useful criterion for measuring the ability of a compound to overcome nicotinamide inhibition, however, it is only one such measure of "activity.”
- this criterion should be supplemented with, e.g., the effect of a compound's dose-dependency (see Example 3 below), the effect of a compound using microdissection assays, etc.
- EXAMPLE 3 The "809" DeaD Assay Screen Of The Dose-Dependencies Of The Top 500 Compounds Identified In Example 1 To Obtain A 50% Effective Concentration (EC50) Value [0063] As already discussed, Example 2 provides data using the "775" DeaD assay to determine compounds that counter the lifespan-reducing effects of 1.5 mM nicotinamide, with this Example indentifying about 900 "active" compounds.
- Example compounds were screened in an 8-point 2-fold dilution series ranging from 0.078 to 10 uM in the presence of 1.5 mM nicotinamide.
- the percent activation of lifespan i.e. percent reversal of nicotinamide effect on lifespan, was calculated using the optical density in control wells with cells treated with 1.5 mM nicotinamide as full lifespan shortening effect of nicotinamide (0% activation), and wells with cells grown in medium without nicotinamide as an indicator of 100% activation.
- Assays were conducted as follow. Cells (DeaD strain BB579) were streaked out on a YPGaI agar plate and grown for 48 hours at 30 0 C. Four colonies were selected, 50 mL of YPGaI medium in a flask was inoculated and grown at 30C with shaking O/N. OD600 was measured. The OD should be ⁇ 0.7 for the cells to be in log phase. The cells were centrifuged, washed once and resuspended in CSMM-D restrictive growth medium. OD600 was measured again. The culture was diluted to an OD600 of 0.002 in CSMM-D restrictive medium.
- the culture was pre-incubated in a flask with shaking at 30 0 C for 4 hours. At the end of the preincubation, OD600 was measured for reference. Nicotinamide (negative control), CSMM-D medium alone (positive control) and compounds in the presence of nicotinamide were plated with DMSO at 10 x concentration (final concentrations: nicotinamide 1.5 mM, compounds 0.078-10 uM, DMSO 0.5%) in 384-well plates: 5 uL/well. The yeast was added to the plates: 45 uL/well. Plates were incubated at 30 0 C in a humidified chamber.
- YPGaI medium was prepared as 10 grams yeast extract, 20 grams peptone, 900 mL water, autoclave at 121 0 C for 15 minutes, add 100 mL sterile 20% (w/v) galactose.
- CSMM-D (Complete Synthetic Minimal Medium- Dextrose) (restrictive) medium was prepared as 6.7 grams yeast nitrogen base without amino acids, 2.0 grams Drop-out mix complete (DOC) (USBiological Cat. no. D9515), 100 mL 20% (w/v) dextrose, water to 1.0 L, then filter sterilize. Results
- EXAMPLE 5 Microdissection Results To Verify The Data of Example 4 for Nalidixic Acid
- EXAMPLE 6 Microdissection Results To Verify The Data of Example 4 for The Other
- Example 4 In order to verify the data of Example 4 for the top 70 compounds of Example 3 other than nalidixic acid, microdissection assays are performed, and results are obtained using controls and experimental conditions as provided for the experiments of Figure 4.
- lifespan assays of the present invention are useful for defining compounds that alter longevity in yeast, and by the likely conservation of these mechanisms during evolution as supplemented by, when necessary, experimental validation of data obtained in yeast to higher organisms, to higher organisms including humans. See also Example 9 below.
- the Examples given above provide compound screens in yeast using the DeaD assay that define a small active subset of about 70 compounds of the original approximately 132,000 originally screened, where activity is defined by EC50 in the DeaD assays as discussed above.
- These compounds by themselves, provide potential drug molecules for intervention in altering longevity or diseases associated with the CR effect, as well as molecules that may be used to identify potentially previously uncharacterized or unknown CR pathways.
- it is particularly advantageous to extrapolate from these particular compounds to identify the key functional aspect(s) of these molecules that underpin their activity in the DeaD assays given in the previous Examples, e.g., functional moieties or other activity-conferring chemical structures, scaffolds, side-groups, etc.
- group “cl” of Figure 6 refers to the chemical scaffold shown in the cl row of Figure 6.
- this scaffold is found as a substructure (i.e., in its complete form within a compound comprising at least this structure, but generally containing further chemical structure) of 3 "active" hits of the assays of the present invention.
- the likelihood of this occurring can be calculated to be relatively rare; therefore, there is a reasonable probability that the cl scaffold is important for the interaction(s) of the active compounds of the invention with the cellular mechanisms mediating the activity of these compounds.
- Further explication of the results shown in Figure 6 may be made via the PubChem website.
- This search identifies 351 compounds in the entire PubChem database of about 10 million compounds (of which about 132,000 were used for the activity assays of the present invention; see above) as containing this substructure. [0077] Of these 351 compounds, 21 are found in PubChem bioactivity assays.
- This latter group may be displayed by clicking on the "BioAssay” tab of the PubChem page displayed after the search is conducted and then changing the "Display” dropdown format from “Summary” to "PubChem BioActivity Summary.”
- scaffold c3 corresponds to the SMILES string
- scaffold cl for example defines a common structure shared by three compounds having high activity in, e.g., the 809 assay, with these three compounds shown in Figure 9.
- EXAMPLE 8 Pathway Identification
- the compounds of the present invention may be used directly to treat disease, extend longevity, etc., either in their present form or in varied forms as would be designed by, e.g., a medicinal chemist (see also Example 9 below). These compounds may additionally be used to identify the pathway(s) which mediate their activities in vivo, since, as already discussed, knowledge of these pathways would allow for the design of other compounds interacting with these pathways, or for compounds interfering with the normal interactions of the components of these pathways, etc.
- EXAMPLE 10 Additional Compound DeaD and Microdissection Assays
- DeaD assay strain BB579 was grown overnight in SCRaff/Gal (2% raffinose/0.1% galactose) to early log phase and then diluted to an OD600 of 0.0001 in SCD or SCRaff/Gal with or without 0.75 mM nicotinamide and containing the concentration of chemical indicated. Cultures were grown at 30°C in a BioScreen and the OD600 recorded every 20 minutes.
- DeaD lifespan was calculated by dividing the culture OD600 at 60 hours in SCD by the culture OD600 at 24 hours in SCRaff/Gal, and then normalizing this value to the "no drug" control.
- the protocol was similar, except that all cultures were in SCD with 0.75 mM nicotinamide, and the OD600 at 60 hours was normalized to the same value for the "no drug” control.
- wild-type strain FY839 was grown overnight in YPGlycerol to mid-log phase and spread on YPD plates containing 5 mM nicotinamide and the concentration of chemical (S 1-6 or S 1-9) indicated.
- Figure 15 provides an example of an assay of one of the compounds of the present invention in worms (C. elegans), in this case compound 3-11.
- the worm C. elegans is a powerful system to investigate aging and lifespan.
- NAM has been shown to reduce C. elegans lifespan in a Pncl and SIR2- ortholog dependent fashion (Van der Horst et al., Mech. Ageing Develop. 128:346-349, 2007).
- compound 3-11 identified using the DeaD assay, reproducibly extends the lifespan of C. elegans, partially reversing the lifespan shortening effect of 25 niM NAM in worms.
- This result is validation that the DeaD assay is capable of discovering small molecules that alter aging and lifespan in metazoan animals like worms.
- This result dismisses the concern that the DeaD assay might produce results that are only relevant to this fungus. This is demonstratably not the case.
- the use of the DeaD assay for screening compounds that alter the CR response is described, and data are presented for the results of those screenings.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2008345225A AU2008345225A1 (en) | 2007-12-21 | 2008-12-22 | Method for altering the lifespan of eukaryotic organisms |
JP2010539936A JP2011507910A (en) | 2007-12-21 | 2008-12-22 | Methods for changing the lifetime of eukaryotes |
EP08867410A EP2219646A4 (en) | 2007-12-21 | 2008-12-22 | Method for altering the lifespan of eukaryotic organisms |
CA2709784A CA2709784A1 (en) | 2007-12-21 | 2008-12-22 | Method for altering the lifespan of eukaryotic organisms |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1636207P | 2007-12-21 | 2007-12-21 | |
US61/016,362 | 2007-12-21 | ||
US2380108P | 2008-01-25 | 2008-01-25 | |
US61/023,801 | 2008-01-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009086303A2 true WO2009086303A2 (en) | 2009-07-09 |
WO2009086303A3 WO2009086303A3 (en) | 2009-12-30 |
Family
ID=40789381
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/088016 WO2009086303A2 (en) | 2007-12-21 | 2008-12-22 | Method for altering the lifespan of eukaryotic organisms |
Country Status (6)
Country | Link |
---|---|
US (1) | US8642660B2 (en) |
EP (1) | EP2219646A4 (en) |
JP (1) | JP2011507910A (en) |
AU (1) | AU2008345225A1 (en) |
CA (1) | CA2709784A1 (en) |
WO (1) | WO2009086303A2 (en) |
Cited By (150)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010001365A1 (en) * | 2008-07-04 | 2010-01-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Nitrogen heterocycle derivatives as proteasome modulators |
WO2010006130A3 (en) * | 2008-07-09 | 2010-04-22 | Envivo Pharmaceuticals, Inc. | Pde-10 inhibitors |
WO2010034738A3 (en) * | 2008-09-24 | 2010-10-07 | Basf Se | Pyrazole compounds for controlling invertebrate pests |
EP2310016A1 (en) * | 2008-08-05 | 2011-04-20 | Omeros Corporation | Pde10 inhibitors and related compositions and methods |
WO2010072805A3 (en) * | 2008-12-24 | 2011-04-28 | Unilever Plc | Method and composition for skin color modulation |
CN102190598A (en) * | 2011-03-28 | 2011-09-21 | 浙江工业大学 | Cyclopropane oxime ester derivatives and preparation method and application thereof |
JP2011213655A (en) * | 2010-03-31 | 2011-10-27 | Eci Inc | Inhibitor of interaction between front protein and ccr2b or ccr5 |
EP2405751A1 (en) * | 2009-03-12 | 2012-01-18 | Apogee Biotechnology Corporation | Sphingosine kinase inhibitor prodrugs |
EP2411529A2 (en) * | 2009-03-27 | 2012-02-01 | Zacharon Pharmaceuticals, Inc. | N-linked glycan biosynthesis modulators |
CN102382127A (en) * | 2011-09-23 | 2012-03-21 | 复旦大学 | Myocardial small molecular compound for idiosyncratically promoting proliferation of myocardial cells and application thereof |
WO2012097196A1 (en) * | 2011-01-12 | 2012-07-19 | Acea Biosciences Inc. | Pyrazolopyrimidine derivatives and uses as anticancer agents |
JP2012518038A (en) * | 2009-02-18 | 2012-08-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Heterocyclic compounds that modulate the CB2 receptor |
WO2012127214A1 (en) | 2011-03-18 | 2012-09-27 | Pronoxis Ab | Quinolinone derivatives for use in the treatment of an autoimmune disease and/or an inflammatory disease |
EP2520566A1 (en) * | 2011-05-06 | 2012-11-07 | Orion Corporation | New Pharmaceutical Compounds |
WO2012062905A3 (en) * | 2010-11-12 | 2013-01-03 | Deutsches Krebsforschungszentrum (Dkfz) | Chromene derivatives and their analoga as wnt pathway antagonists |
CN102947272A (en) * | 2010-05-12 | 2013-02-27 | 沃泰克斯药物股份有限公司 | 2 -aminopyridine derivatives useful as inhibitors of atr kinase |
CN102964279A (en) * | 2012-12-12 | 2013-03-13 | 中国药科大学 | Kappa-opioid receptor agonists with peripheral analgesic effect |
CN102993193A (en) * | 2011-03-09 | 2013-03-27 | 四川大学 | Use of nitrogen-3-isoxazolyl-3-4-thienyl-pyrimidyl sulfonyl propanamide derivative in preparing anti-tumor medicines |
CN103097340A (en) * | 2010-07-16 | 2013-05-08 | 安吉奥斯医药品有限公司 | Therapeutically active compositions and their method of use |
JP2013518129A (en) * | 2010-01-28 | 2013-05-20 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | Compositions and methods for improving proteasome activity |
US8518960B2 (en) | 2007-05-23 | 2013-08-27 | Siga Technologies, Inc. | Antiviral drugs for treatment or prevention of dengue infection |
CN103282354A (en) * | 2010-09-01 | 2013-09-04 | 拜耳知识产权有限责任公司 | N-(tetrazol-5-l)- and n-(triazol-5-yl)arylcarboxamides and use thereof as herbicides |
WO2013131931A1 (en) | 2012-03-06 | 2013-09-12 | Compound Handling B.V. | Aminomethylene pyrazolones with therapeutic activity |
CN103373936A (en) * | 2012-04-16 | 2013-10-30 | 南京大学连云港高新技术研究院 | Acetaminophen containing phenylacetamide derivatives and preparation methods thereof |
US8642597B2 (en) | 2007-08-27 | 2014-02-04 | Basf Se | Pyrazole compounds for controlling invertebrate pests |
JP2014065729A (en) * | 2008-04-29 | 2014-04-17 | Novartis Ag | Spiro-indole derivative for treating parasitic diseases |
CN103739594A (en) * | 2012-10-17 | 2014-04-23 | 南京大学 | Schiff base derivatives containing pyrazine ring and triazole structure and preparation method of the derivatives |
US8710056B2 (en) | 2009-07-06 | 2014-04-29 | Basf Se | Pyridazine compounds for controlling invertebrate pests |
CN103755659A (en) * | 2014-02-25 | 2014-04-30 | 山东大学 | 6-cinnamon acyl-2H-benzo [b] [1, 4] oxazine-3 (4H)-ketone compound and application thereof |
US8729083B2 (en) | 2008-09-24 | 2014-05-20 | Basf Se | Pyrazole compounds for controlling invertebrate pests |
CN103804273A (en) * | 2014-01-27 | 2014-05-21 | 贵州大学 | Oxindole and ninhydrin bis-quaternary carbon splicing derivative and preparation method thereof |
WO2014091446A1 (en) * | 2012-12-13 | 2014-06-19 | Novartis Ag | Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors |
WO2014057080A3 (en) * | 2012-10-12 | 2014-07-10 | H. Lundbeck A/S | N-(2-(cyclic amine)ethyl)benzamide derivatives as p2x7 inhibitors |
WO2014117919A1 (en) | 2013-02-04 | 2014-08-07 | Merck Patent Gmbh | Positive allosteric modulators of mglur3 |
US8865744B1 (en) | 2013-05-17 | 2014-10-21 | Boehringer Ingelheim International Gmbh | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
US8895606B2 (en) | 2010-08-24 | 2014-11-25 | Actelion Pharmaceuticals Ltd. | Proline sulfonamide derivatives as orexin receptor antagonists |
CN104193690A (en) * | 2014-08-11 | 2014-12-10 | 广西大学 | 3,4,5-trihydroxy gallic acrylamide benzene sulfonamide derivatives as well as preparation method and application thereof |
CN104193686A (en) * | 2014-08-11 | 2014-12-10 | 广西壮族自治区中医药研究院 | N-gallic amide-pyrimidine phenyl sulfonamide derivative as well as preparation method and application thereof |
CN104230912A (en) * | 2014-09-03 | 2014-12-24 | 中国科学院福建物质结构研究所 | Quinoline derivative as well as preparation method and application thereof |
CN104262289A (en) * | 2014-10-09 | 2015-01-07 | 武汉大学 | Benzothiazole derivative and anti-tumor purpose thereof |
EP2832233A1 (en) | 2013-07-30 | 2015-02-04 | IMAX Discovery GmbH | 1H-pyrrole-2,4-dicarbonyl-derivatives and their use as flavoring agents |
WO2015022200A1 (en) * | 2013-08-13 | 2015-02-19 | Ernst-Moritz-Arndt-Universität Greifswald | Metallo-acylhydrazone complexes and use thereof in preventing the development of or eliminating tumoral resistance to cytostatics and for treating tumours (anti-tumour agents) |
CN104592065A (en) * | 2015-02-13 | 2015-05-06 | 佛山市赛维斯医药科技有限公司 | Halogenated benzene sulfonyl hydrazine GPR119 agonist, preparation method and application thereof |
CN104592066A (en) * | 2015-02-13 | 2015-05-06 | 佛山市赛维斯医药科技有限公司 | Benzenesulfonyl hydrazide compound as well as preparation method and application thereof |
US9029639B2 (en) | 2009-07-06 | 2015-05-12 | Basf Se | Pyridazine compounds for controlling invertebrate pests |
CN104610105A (en) * | 2015-02-13 | 2015-05-13 | 佛山市赛维斯医药科技有限公司 | GPR119 agonist containing alkyl substituted benzenesulfonyl hydrazine as well as preparation method and application thereof |
CN104610103A (en) * | 2015-02-13 | 2015-05-13 | 佛山市赛维斯医药科技有限公司 | GPR119 agonist containing benzenesulfonyl hydrazine and halogenated benzene structures as well as preparation method and application thereof |
CN104628612A (en) * | 2015-02-13 | 2015-05-20 | 佛山市赛维斯医药科技有限公司 | Nitrile benzenesulfonylhydrazine type GPR119 agonist, preparation method and application thereof |
CN104649938A (en) * | 2015-02-13 | 2015-05-27 | 佛山市赛维斯医药科技有限公司 | Nitrobenzenesulfonyl hydrazide type GPR119 agonist, as well as preparation method and application thereof |
US9067922B2 (en) | 2013-04-19 | 2015-06-30 | Pfizer Limited | Chemical compounds |
JP2015120710A (en) * | 2008-08-29 | 2015-07-02 | ゼンション・リミテッドXention Limited | Novel potassium channel blocker |
JP2015520152A (en) * | 2012-05-11 | 2015-07-16 | リセット セラピューティークス, インコーポレイテッド | Carbazole-containing sulfonamides as cryptochrome modulators |
CN104817509A (en) * | 2015-04-13 | 2015-08-05 | 安徽省逸欣铭医药科技有限公司 | Lesinurad analog and preparation method and medical application thereof |
CN104829546A (en) * | 2015-04-13 | 2015-08-12 | 天津师范大学 | Double-triazole substituted ethoxy benzene compound and preparation method and application thereof |
US9125414B2 (en) | 2009-07-24 | 2015-09-08 | Basf Se | Pyridine derivatives compounds for controlling invertebrate pests |
CN104961706A (en) * | 2015-07-06 | 2015-10-07 | 成都知普莱生物医药科技有限公司 | Method for synthesizing insulin degrading enzyme inhibitor ML345 |
EP2806875A4 (en) * | 2012-01-25 | 2015-10-21 | Proteostasis Therapeutics Inc | Proteasome activity modulating compounds |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9181231B2 (en) | 2011-05-03 | 2015-11-10 | Agios Pharmaceuticals, Inc | Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia |
US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
WO2015186063A1 (en) | 2014-06-03 | 2015-12-10 | Novartis Ag | Naphthyridinedione derivatives |
WO2015186061A1 (en) | 2014-06-03 | 2015-12-10 | Novartis Ag | Pyridopyrimidinedione derivatives |
WO2015186062A1 (en) | 2014-06-03 | 2015-12-10 | Novartis Ag | PYRIMIDO[4,5-b]QUINOLINE-4,5(3H,10H)-DIONE DERIVATIVES |
WO2015192077A1 (en) * | 2014-06-12 | 2015-12-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Heterocyclic compounds and methods of use thereof |
US9221792B2 (en) | 2010-12-17 | 2015-12-29 | Agios Pharmaceuticals, Inc | N-(4-(azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase M2 (PMK2) modulators |
CN105377849A (en) * | 2013-06-17 | 2016-03-02 | 巴斯夫欧洲公司 | Substituted pyrimidinium compounds and derivatives for combating animal pests |
WO2016032569A1 (en) * | 2014-08-29 | 2016-03-03 | Celladon Corporation | Quinolines and their use for treating endoplasmic reticulum stress-caused diseases |
CN105452248A (en) * | 2013-05-23 | 2016-03-30 | 新加坡科技研究局 | Purine diones as WNT pathway modulators |
US9315454B2 (en) | 2010-01-15 | 2016-04-19 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
US9328077B2 (en) | 2010-12-21 | 2016-05-03 | Agios Pharmaceuticals, Inc | Bicyclic PKM2 activators |
US9365545B2 (en) | 2013-03-15 | 2016-06-14 | Agios Pharmaceuticals, Inc | Therapeutic compounds and compositions |
CN105732468A (en) * | 2016-04-07 | 2016-07-06 | 昆明理工大学 | N'-(2-(1H-indole-3-yl)acetyl)arylhydrazide compound and preparation method and application thereof |
US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
US9422276B2 (en) | 2011-11-25 | 2016-08-23 | Bayer Intellectual Property Gmbh | Use of aryl and hetaryl carboxamides as endoparasiticides |
CN105963301A (en) * | 2016-04-26 | 2016-09-28 | 兰州大学 | Lead compound using human FKBP51 protein as target as well as screening method and application thereof |
WO2016185423A1 (en) | 2015-05-19 | 2016-11-24 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
EP2956470A4 (en) * | 2013-02-15 | 2016-12-07 | Univ Michigan Regents | Compositions and methods relating to hindering dot1l recruitment by mll-fusion proteins |
US9586880B2 (en) | 2008-12-23 | 2017-03-07 | President And Fellows Of Harvard College | Small molecule inhibitors of necroptosis |
CN106496132A (en) * | 2016-10-13 | 2017-03-15 | 西华大学 | 2 replacement acetamides of N (4 substituted-phenyl) and its purposes as SIRT2 protein inhibitors |
CN106496118A (en) * | 2016-10-08 | 2017-03-15 | 红河学院 | A kind of quinolines ketones with Enamino-esters compound and preparation method thereof |
CN106543088A (en) * | 2016-10-25 | 2017-03-29 | 西华大学 | The new SIRT2 protein inhibitors of one class and its purposes in pharmacy |
US9657004B2 (en) | 2009-04-06 | 2017-05-23 | Agios Pharmaceuticals, Inc | Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use |
CN106800524A (en) * | 2015-02-13 | 2017-06-06 | 佛山市赛维斯医药科技有限公司 | Compound, preparation method and its usage of one class containing bishydrazide and naphthyl structure |
US9676747B2 (en) | 2011-12-21 | 2017-06-13 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
US9725452B2 (en) | 2013-03-15 | 2017-08-08 | Presidents And Fellows Of Harvard College | Substituted indoles and pyrroles as RIP kinase inhibitors |
US9884818B2 (en) | 2013-05-17 | 2018-02-06 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US9884831B2 (en) | 2015-03-19 | 2018-02-06 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis B infections |
CN107686482A (en) * | 2016-08-05 | 2018-02-13 | 首都医科大学 | New heptacyclic compound, it is synthesized, activity rating and application |
CN107686483A (en) * | 2016-08-05 | 2018-02-13 | 首都医科大学 | Seven cyclic ketals, it is prepared, anti-thrombus activity and application |
US9895349B2 (en) | 2013-04-03 | 2018-02-20 | Janssen Sciences Ireland Us | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US9905782B2 (en) | 2013-03-26 | 2018-02-27 | Semiconductor Energy Laboratory Co., Ltd. | Light-emitting element, compound, organic compound, display module, lighting module, light-emitting device, display device, lighting device, and electronic device |
US9980961B2 (en) | 2011-05-03 | 2018-05-29 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use in therapy |
CN108129486A (en) * | 2018-01-25 | 2018-06-08 | 华东理工大学 | Pyrimidone derivatives and application thereof |
CN108289448A (en) * | 2015-12-02 | 2018-07-17 | 先正达参股股份有限公司 | Kill microorganism oxadiazole derivatives |
US10029987B2 (en) | 2009-06-29 | 2018-07-24 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
CN108341831A (en) * | 2018-05-11 | 2018-07-31 | 贵州医科大学 | 7H- [1,2,4] triazole [3,4-b] [1,3,4] thiadiazine-phenylhydrazone type compound |
US10035801B2 (en) | 2013-03-13 | 2018-07-31 | Genentech, Inc. | Pyrazolo compounds and uses thereof |
CN108473498A (en) * | 2015-12-22 | 2018-08-31 | 豪夫迈·罗氏有限公司 | Pyrazolo [1,5a] pyrimidine derivatives as IRAK4 conditioning agents |
KR101886118B1 (en) * | 2017-05-22 | 2018-09-06 | 한국기초과학지원연구원 | A pharmaceutical composition for prevention or treatment of diabetes or fatty liver comprising CYP4A inhibitor |
CN108503640A (en) * | 2018-01-31 | 2018-09-07 | 广西田园生化股份有限公司 | Sparteine derivative and preparation method thereof and the utilization in pesticide |
US10071961B2 (en) | 2013-10-23 | 2018-09-11 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10077239B2 (en) | 2015-09-29 | 2018-09-18 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis B antiviral agent |
CN108558777A (en) * | 2018-07-31 | 2018-09-21 | 河北大学 | Pyrimidine salicylic acid derivative and the preparation method and application thereof |
US10091997B2 (en) | 2010-10-25 | 2018-10-09 | Vanderbilt University | Composition for inhibition of insect host sensing |
US10111859B2 (en) | 2011-11-14 | 2018-10-30 | Ligand Pharmaceuticals, Inc. | Methods and compositions associated with the granulocyte colony-stimulating factor receptor |
US10125094B2 (en) | 2013-02-28 | 2018-11-13 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
CN108822099A (en) * | 2018-06-08 | 2018-11-16 | 河南中医药大学 | A kind of 3-(2-[4-morpholinodithio amino)Isobenzofuran -1-(3H)-one and its preparation method and application |
CN108863892A (en) * | 2018-07-04 | 2018-11-23 | 温州医科大学 | A kind of gallicin analog of amide containing structure and application |
CN108997261A (en) * | 2017-06-07 | 2018-12-14 | 东莞市凯法生物医药有限公司 | A kind of compound and the preparation method and application thereof |
CN109081808A (en) * | 2018-09-11 | 2018-12-25 | 济南大学 | Anilid class compound of the one kind containing tetrahydroisoquinoline structure, purposes and preparation method thereof |
CN109232576A (en) * | 2018-10-22 | 2019-01-18 | 信阳师范学院 | 7- replaces deoxidation malabar nut ketone alkali and its preparation method and application |
US10188105B2 (en) | 2011-05-06 | 2019-01-29 | Vanderbilt University | Compositions for inhibition of insect sensing |
US10213420B2 (en) | 2014-02-05 | 2019-02-26 | Novira Therapeutics, Inc. | Combination therapy for treatment of HBV infections |
CN109438375A (en) * | 2018-12-10 | 2019-03-08 | 扬州工业职业技术学院 | A kind of preparation method for the triazole class compounds that 4,5- diphenyl replaces |
CN109535146A (en) * | 2017-09-21 | 2019-03-29 | 中国医学科学院医药生物技术研究所 | Antitubercular compounds and its preparation method and application |
CN109851570A (en) * | 2019-02-02 | 2019-06-07 | 贵州大学 | A kind of chalcone derivative, preparation method and the application of the triazine containing 1,2,4- |
CN109912626A (en) * | 2019-03-11 | 2019-06-21 | 河南湾流生物科技有限公司 | A kind of thiazole and triazole superoxide dismutase agonist and its preparation method and application |
CN108383805B (en) * | 2018-05-04 | 2019-07-23 | 上海应用技术大学 | A kind of neuraminidase inhibitor and preparation method thereof |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
CN110325516A (en) * | 2016-12-29 | 2019-10-11 | 米尼奥尔克斯治疗有限公司 | The purposes of heteroaryl compound and they |
US10441589B2 (en) | 2016-04-15 | 2019-10-15 | Novira Therapeutics, Inc. | Combinations and methods comprising a capsid assembly inhibitor |
US10450270B2 (en) | 2013-07-25 | 2019-10-22 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
EP2321303B1 (en) * | 2008-08-27 | 2019-11-27 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
CN110563709A (en) * | 2018-06-06 | 2019-12-13 | 中国科学院上海药物研究所 | Pyrimidine compounds and application thereof as TRPV2 inhibitor |
CN110615792A (en) * | 2019-11-01 | 2019-12-27 | 河北工业大学 | 2-benzylthio-5-methyl-4, 7-dihydro- [1,2,4] triazolo [1,5-a ] pyrimidine derivatives |
EP3253737B1 (en) * | 2015-02-06 | 2020-01-08 | Cancer Research Technology Ltd | Autotaxin inhibitory compounds |
CN111518021A (en) * | 2020-06-08 | 2020-08-11 | 沅江华龙催化科技有限公司 | Method for constructing 3,5-disubstituted pyridine by using mixed styrene derivative and N, N-dimethylformamide |
US10791739B2 (en) | 2015-03-25 | 2020-10-06 | Vanderbilt University | Binary compositions as disruptors of orco-mediated odorant sensing |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
CN112174903A (en) * | 2019-07-01 | 2021-01-05 | 清华大学 | Small molecule modulators of TLR8 |
CN112279835A (en) * | 2019-07-24 | 2021-01-29 | 中国医学科学院药物研究所 | Aromatic ring or aromatic heterocyclic imidazole compound, preparation method and pharmaceutical application thereof |
CN112375073A (en) * | 2014-12-05 | 2021-02-19 | 普尔莫赛德有限公司 | Antifungal compounds |
CN112409223A (en) * | 2019-10-12 | 2021-02-26 | 中国药科大学 | Amide compounds and medical application thereof as STING inhibitor |
US10973801B2 (en) | 2018-03-14 | 2021-04-13 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
US10995064B2 (en) | 2012-08-28 | 2021-05-04 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
WO2021126923A1 (en) * | 2019-12-19 | 2021-06-24 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Cd206 modulators their use and methods for preparation |
US11078193B2 (en) | 2014-02-06 | 2021-08-03 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US11096931B2 (en) | 2019-02-22 | 2021-08-24 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
US11234976B2 (en) | 2015-06-11 | 2022-02-01 | Agios Pharmaceuticals, Inc. | Methods of using pyruvate kinase activators |
CN114773302A (en) * | 2022-04-29 | 2022-07-22 | 中国药科大学 | Benzofuran derivative and medical application thereof |
WO2022194261A1 (en) * | 2021-03-19 | 2022-09-22 | 南京药石科技股份有限公司 | Pyrimidine-fused cyclic compound and use thereof in preparation of drug for treating pain and spinal cord injury |
EP3906241A4 (en) * | 2019-01-04 | 2022-11-02 | Bellbrook Labs, Llc | Inhibitors of cgas activity as therapeutic agents |
US11491148B2 (en) | 2019-05-06 | 2022-11-08 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
US11639345B2 (en) | 2018-01-17 | 2023-05-02 | Migal—Galilee Research Institute Ltd. | Methionine metabolic pathway inhibitors |
US11647748B2 (en) | 2018-01-17 | 2023-05-16 | Migal—Galilee Research Institute Ltd. | Sulphonamides as methionine metabolic pathway inhibitors |
WO2023137885A1 (en) * | 2022-01-21 | 2023-07-27 | 中国药科大学 | Compound having pyridoimidazole as parent nucleus, and preparation method for and use of compound |
US11730729B2 (en) | 2020-07-20 | 2023-08-22 | Neurodon Corporation | Quinolines that modulate SERCA and their use for treating disease |
US11827626B2 (en) | 2014-08-29 | 2023-11-28 | Neurodon Corporation | Quinolines that modulate SERCA and their use for treating disease |
CN112375073B (en) * | 2014-12-05 | 2024-04-16 | 普尔莫赛德有限公司 | Antifungal compounds |
Families Citing this family (924)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004037554A1 (en) * | 2004-08-03 | 2006-03-16 | Sanofi-Aventis Deutschland Gmbh | Substituted 8-aminoalkylthio-xanthines, process for their preparation and their use as medicaments |
DE102004039507A1 (en) * | 2004-08-14 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Substituted 8-aminoalkoxi-xanthines, process for their preparation and their use as medicaments |
US20120237446A1 (en) * | 2005-03-25 | 2012-09-20 | Bayer Pharma Aktiengesellschaft | Compounds for binding and imaging amyloid plaques and their use |
EP1872795A4 (en) * | 2005-04-21 | 2009-07-22 | Astellas Pharma Inc | Therapeutic agent for irritable bowel syndrome |
DK2559690T3 (en) | 2005-05-10 | 2016-04-25 | Incyte Holdings Corp | Modulators of indoleamine 2,3-dioxygenase and methods of use thereof |
US8450351B2 (en) * | 2005-12-20 | 2013-05-28 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
PL2069312T3 (en) * | 2006-07-25 | 2013-03-29 | Cephalon Inc | Pyridizinone derivatives |
EP2081905B1 (en) * | 2006-07-28 | 2012-09-12 | Boehringer Ingelheim International GmbH | Sulfonyl compounds which modulate the cb2 receptor |
EP2064207B1 (en) * | 2006-09-19 | 2013-11-06 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
CL2007002650A1 (en) | 2006-09-19 | 2008-02-08 | Incyte Corp | COMPOUNDS DERIVED FROM HETEROCICLO N-HIDROXIAMINO; PHARMACEUTICAL COMPOSITION, USEFUL TO TREAT CANCER, VIRAL INFECTIONS AND NEURODEGENERATIVE DISORDERS BETWEEN OTHERS. |
BRPI0718515A2 (en) * | 2006-09-25 | 2013-11-19 | Boehringer Ingelheim Int | COMPOUNDS THAT MODULATE THE CB2 RECEIVER |
ATE549336T1 (en) * | 2006-10-19 | 2012-03-15 | Signal Pharm Llc | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF AND THEIR USE AS PROTEIN KINASE INHIBITORS |
WO2008112164A2 (en) | 2007-03-08 | 2008-09-18 | The Board Of Trustees Of The Leland Stanford Junior University | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof |
US20080234297A1 (en) * | 2007-03-20 | 2008-09-25 | Changgeng Qian | HSP90 Inhibitors Containing a Zinc Binding Moiety |
TWI425945B (en) * | 2007-05-28 | 2014-02-11 | Seldar Pharma Inc | Tetrahydroisoquinolin-1-one derivatives or salt thereof |
WO2008156676A1 (en) | 2007-06-15 | 2008-12-24 | President And Fellows Of Harvard College | Methods and compositions for detecting and modulating o-glycosylation |
JP5460589B2 (en) * | 2007-07-13 | 2014-04-02 | アイカジェン, インコーポレイテッド | Sodium channel inhibitor |
US20110251212A1 (en) * | 2007-08-21 | 2011-10-13 | Shionogi & Co., Ltd. | Piperazine derivatives |
CA2698075C (en) * | 2007-08-27 | 2016-04-12 | Siga Technologies, Inc. | Antiviral drugs for treatment of arenavirus infection |
FR2920774B1 (en) * | 2007-09-06 | 2009-10-30 | Galderma Res & Dev | NOVEL N-PHENUL ACATAMIDE DERIVATIVES, ENZYME INHIBITORS SOAT-1, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THE SAME |
WO2009061652A1 (en) * | 2007-11-07 | 2009-05-14 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
US9216983B2 (en) * | 2007-12-21 | 2015-12-22 | Board Of Regents, University Of Texas System | Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity |
FR2925902B1 (en) * | 2008-01-02 | 2011-01-07 | Sanofi Aventis | IMIDAZO-1,2-α-PYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
FR2925901B1 (en) * | 2008-01-02 | 2011-03-04 | Sanofi Aventis | N-HETEROCYCLIC-IMIDAZO-1,2-α-PYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
CA2711603A1 (en) * | 2008-01-11 | 2009-07-16 | The Regents Of The University Of California | Activators of executioner procaspases 3, 6 and 7 |
RU2369600C1 (en) * | 2008-01-24 | 2009-10-10 | Андрей Александрович Иващенко | SUBSTITUTED 4-SULPHONYL-PYRAZOLES AND 3-SULPHONYL-PYRAZOLO[1,5-a]PYRIMIDINES-ANTAGONISTS OF SEROTONIN 5-HT6 RECEPTORS, ACTIVE COMPONENT, PHARMACEUTICAL COMPOSITION, MEDICINAL AGENT AND METHOD OF OBTAINING THEM |
US20130023498A1 (en) * | 2008-02-20 | 2013-01-24 | The Wistar Institute and North Carolina State University | MicroRNA Modulators and Method for Identifying and Using the Same |
EP2264029A4 (en) * | 2008-03-31 | 2011-08-24 | Kowa Co | 1,3-dihydroisobenzofuran derivative |
JP5774982B2 (en) * | 2008-05-19 | 2015-09-09 | サノビオン ファーマシューティカルズ インクSunovion Pharmaceuticals Inc. | Imidazo [1,2-a] pyridine compound |
EP2334380B1 (en) * | 2008-05-30 | 2021-09-01 | Mitologics | Ant-ligands molecules and biological applications |
EP2138498A1 (en) * | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted tricyclic derivatives against neurodegenerative diseases |
US8088803B2 (en) | 2008-07-08 | 2012-01-03 | Incyte Corporation | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
PL2307367T3 (en) | 2008-07-08 | 2015-03-31 | Univ Texas | Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (stats) |
WO2010005782A1 (en) * | 2008-07-10 | 2010-01-14 | Boehringer Ingelheim International Gmbh | Sulfone compounds which modulate the cb2 receptor |
WO2010011666A2 (en) * | 2008-07-21 | 2010-01-28 | University Of South Florida | Indoline scaffold shp-2 inhibitors and cancer treatment method |
WO2010027567A2 (en) * | 2008-07-23 | 2010-03-11 | Schering Corporation | Tricyclic spirocycle derivatives and methods of use thereof |
US8299093B2 (en) * | 2008-08-08 | 2012-10-30 | New York Blood Center, Inc. | Small molecule inhibitors of retroviral assembly and maturation |
US9540322B2 (en) | 2008-08-18 | 2017-01-10 | Yale University | MIF modulators |
US9643922B2 (en) * | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
GB0815947D0 (en) | 2008-09-02 | 2008-10-08 | Univ Dundee | Compounds |
WO2010028175A1 (en) | 2008-09-08 | 2010-03-11 | The Board Of Trustees Of The Leland Stanford Junior University | Modulators of aldehyde dehydrogenase activity and methods of use thereof |
AP2011005674A0 (en) | 2008-09-25 | 2011-04-30 | Boehringer Ingelheim Int | Sulfonyl compounds which selectively modulate the CB2 receptor. |
JP5611957B2 (en) | 2008-09-29 | 2014-10-22 | サートリス ファーマシューティカルズ, インコーポレイテッド | Quinazolinones, quinolones and related analogs as sirtuin modulators |
US8450337B2 (en) * | 2008-09-30 | 2013-05-28 | Moleculin, Llc | Methods of treating skin disorders with caffeic acid analogs |
US8841305B2 (en) * | 2008-10-09 | 2014-09-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Activators of the human pyruvate kinase M2 receptor |
LT3135672T (en) * | 2008-10-10 | 2020-05-25 | Vm Discovery, Inc. | Compositions and methods for treating alcohol use disorders, pain and other diseases |
CN102202669A (en) | 2008-10-28 | 2011-09-28 | 利兰·斯坦福青年大学托管委员会 | Modulators of aldehyde dehydrogenase and methods of use thereof |
PE20131197A1 (en) | 2008-10-31 | 2013-11-06 | Genentech Inc | PYRAZOLOPYRIMIDINE COMPOUNDS AS JAK INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US8389720B2 (en) * | 2008-11-13 | 2013-03-05 | Merck Sharp & Dohme Corp. | Quinolone neuropeptide S receptor antagonists |
US9000009B2 (en) * | 2008-12-10 | 2015-04-07 | The Trustees Of The University Of Pennsylvania | Small molecule activators of mitochondrial function |
WO2010066253A1 (en) * | 2008-12-12 | 2010-06-17 | Bunch, Lennart | Selective inhibitors of excitatory amino acid transporter subtype 1 (eaat1 /glast) |
EP2391602B1 (en) * | 2008-12-19 | 2013-12-04 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds useful as kinase inhibitors |
TW201026700A (en) | 2008-12-22 | 2010-07-16 | Hydra Biosciences Inc | Compositions useful for treating disorders related to TRPA1 |
WO2010073011A2 (en) * | 2008-12-23 | 2010-07-01 | Betagenon Ab | Compounds useful as medicaments |
CA2747784C (en) * | 2008-12-24 | 2018-07-31 | Bial - Portela & Ca, S.A. | Imidazole compounds for use as enzyme inhibitors |
WO2010080183A1 (en) | 2009-01-08 | 2010-07-15 | The Trustees Of Columbia University In The City Of New York | Potent non-urea inhibitors of soluble epoxide hydrolase |
US9962368B2 (en) | 2009-01-09 | 2018-05-08 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
US8362277B2 (en) | 2009-01-09 | 2013-01-29 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
US9162980B2 (en) | 2009-01-09 | 2015-10-20 | Board Of Regents Of The University Of Texas System | Anti-depression compounds |
CA2748813C (en) | 2009-01-09 | 2018-07-10 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
SG172958A1 (en) | 2009-01-23 | 2011-08-29 | Takeda Pharmaceutical | Poly (adp-ribose) polymerase (parp) inhibitors |
DE102009007038A1 (en) | 2009-02-02 | 2010-08-05 | Merck Patent Gmbh | metal complexes |
MX2011008305A (en) | 2009-02-05 | 2012-08-15 | Takeda Pharmaceutical | Pyridazinone compounds. |
WO2010093425A1 (en) * | 2009-02-11 | 2010-08-19 | Sepracor Inc. | Histamine h3 inverse agonists and antagonists and methods of use thereof |
ES2625891T3 (en) | 2009-02-13 | 2017-07-20 | The Regents Of The University Of California | Control of stress tolerance, efficiency of water use and gene expression in plants through the use of new ABA receptor proteins and synthetic agonists |
KR101705727B1 (en) * | 2009-02-26 | 2017-02-10 | 레비바 파마슈티칼스, 아이엔씨. | Compositions, synthesis, and methods of utilizing arylpiperazine derivatives |
US9301949B2 (en) * | 2009-02-27 | 2016-04-05 | Siga Technologies, Inc. | Thienopyridine derivatives for the treatment and prevention of dengue virus infections |
US8329239B2 (en) * | 2009-03-03 | 2012-12-11 | Givandan S.A. | Off-taste masking |
EP2404902A1 (en) | 2009-03-05 | 2012-01-11 | Shionogi&Co., Ltd. | Piperidine and pyrrolidine derivatives having npy y5 receptor antagonism |
ES2740424T3 (en) | 2009-03-13 | 2020-02-05 | Agios Pharmaceuticals Inc | Methods and compositions for disorders related to cell proliferation |
US8569512B2 (en) * | 2009-03-23 | 2013-10-29 | Merck Sharp & Dohme Corp. | P2X3 receptor antagonists for treatment of pain |
JP2012136437A (en) * | 2009-04-10 | 2012-07-19 | Fujifilm Corp | Heterocyclic 5-membered ring compound |
CU23844B1 (en) * | 2009-04-17 | 2012-10-15 | Ct De Neurociencias De Cuba | PROCEDURE FOR OBTAINING NEW DERIVATIVES OF NAFTALENE FOR THE LIVE DIAGNOSIS OF ALZHEIMER'S DISEASE |
WO2010123139A1 (en) * | 2009-04-24 | 2010-10-28 | 持田製薬株式会社 | Arylcarboxamide derivative having sulfamoyl group |
ES2619557T3 (en) | 2009-05-04 | 2017-06-26 | Agios Pharmaceuticals, Inc. | PKM2 activators for use in cancer treatment |
EP3144299A1 (en) | 2009-05-05 | 2017-03-22 | Cambria Pharmaceuticals, Inc. | Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis |
EP2438046A4 (en) | 2009-06-01 | 2013-04-17 | Harvard College | O-glcnac transferase inhibitors and uses thereof |
GB0909912D0 (en) | 2009-06-09 | 2009-07-22 | Univ Dundee | Compounds |
AR077033A1 (en) * | 2009-06-11 | 2011-07-27 | Hoffmann La Roche | INHIBITING COMPOUNDS OF JANUS KINASES AND THEIR USE IN THE TREATMENT OF IMMUNOLOGICAL DISEASES |
US8299103B2 (en) * | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
IN2012DN00352A (en) * | 2009-06-16 | 2015-08-21 | Bikam Pharmaceuticals Inc | |
FI20095678A0 (en) * | 2009-06-16 | 2009-06-16 | Biotie Therapies Oy | Urea substituted sulfonamide derivatives |
US8383615B2 (en) | 2009-06-16 | 2013-02-26 | Boehringer Ingelheim International Gmbh | Azetidine 2-carboxamide derivatives which modulate the CB2 receptor |
WO2010151711A1 (en) * | 2009-06-25 | 2010-12-29 | Alkermes, Inc. | Prodrugs of nh-acidic compounds |
EP2445495A1 (en) * | 2009-06-25 | 2012-05-02 | Bioversys AG | Composition for treatment of tuberculosis |
BRPI1015135B1 (en) | 2009-06-29 | 2021-08-03 | Incyte Holdings Corporation | PI3K-INHIBITING PYRIMIDINONES, COMPOSITION INCLUDING SUCH COMPOUNDS AS WELL AS USES THEREOF |
ES2618630T3 (en) | 2009-06-29 | 2017-06-21 | Agios Pharmaceuticals, Inc. | Therapeutic compositions and related methods of use |
US8624063B2 (en) | 2009-06-30 | 2014-01-07 | Wisconsin Alumni Research Foundation | Non-lactone carbocyclic and heterocyclic antagonists and agonists of bacterial quorum sensing |
UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
JPWO2011010715A1 (en) * | 2009-07-24 | 2013-01-07 | 国立大学法人 東京大学 | Pr-Set7 inhibitor |
WO2011014681A1 (en) | 2009-07-30 | 2011-02-03 | Takeda Pharmaceutical Company Limited | Poly (ADP-Ribose) Polymerase (PARP) INHIBITORS |
WO2011013752A1 (en) * | 2009-07-31 | 2011-02-03 | 塩野義製薬株式会社 | Pharmaceutical composition containing fused hetero-ring derivative |
JP2013501008A (en) * | 2009-08-05 | 2013-01-10 | バーシテック リミテッド | Antiviral compound and pharmaceutical composition containing the same |
US8168795B2 (en) * | 2009-08-11 | 2012-05-01 | Allergan, Inc. | Selective sphingosine-1-phosphate receptor antagonists |
EP2286808A1 (en) * | 2009-08-18 | 2011-02-23 | Rheinische Friedrich-Wilhelms Universität | Cytohesin inhibitors |
US20120149710A1 (en) * | 2009-08-24 | 2012-06-14 | The Regents Of The University Of California | Sortase a inhibitors |
WO2011028651A1 (en) * | 2009-09-01 | 2011-03-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of human 15-lipoxygenase-1 |
EP2473054B1 (en) * | 2009-09-04 | 2017-06-14 | The Regents of the University of Michigan | Compositions and methods for treatment of leukemia |
US8580783B2 (en) | 2009-09-10 | 2013-11-12 | Nerviano Medical Sciences S.R.L. | [1,2,4]triazolo [1,5-c]pyrimidine derivatives as Hsp90 modulators |
CA2772522A1 (en) * | 2009-09-11 | 2011-03-17 | Sunovion Pharmaceuticals Inc. | Histamine h3 inverse agonists and antagonists and methods of use thereof |
WO2011035332A1 (en) | 2009-09-21 | 2011-03-24 | Chemocentryx, Inc. | Pyrrolidinone carboxamide derivatives as chemerin-r ( chemr23 ) modulators |
WO2011037795A1 (en) * | 2009-09-22 | 2011-03-31 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the cb2 receptor |
JP5775519B2 (en) | 2009-09-25 | 2015-09-09 | ニヴァリス・セラピューティクス・インコーポレーテッド | Novel dihydropyrimidin-2 (1H) -one compounds as S-nitrosoglutathione reductase inhibitors |
EP2308883A1 (en) * | 2009-10-05 | 2011-04-13 | Centre National De La Recherche Scientifique | New derivatives of thieno[2,3-b]pyridine and 5,6,7,8 tetrahydrothieno[2,3 b]quinoline in particular useful in the treatment of malaria |
EP2486009B1 (en) * | 2009-10-06 | 2019-08-21 | Allergan, Inc. | 2h-pyrrol-5-amine derivatives as alpha adrenergic receptor modulators |
WO2011042145A1 (en) * | 2009-10-07 | 2011-04-14 | Siena Biotech S.P.A. | Wnt pathway antagonists |
KR101194995B1 (en) * | 2009-10-14 | 2012-10-29 | 주식회사 이큐스앤자루 | Novel 4-phenyl-benzimidazole or 4-phenyl-benzoxazole derivates or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical compositions for antivirus containing the same as an active gredient |
WO2011047156A1 (en) * | 2009-10-15 | 2011-04-21 | Hercules Technology Management Co V, Inc. | Sepiapterin reductase inhibitors for the treatment of pain |
EP3561077B1 (en) | 2009-10-21 | 2022-12-21 | Les Laboratoires Servier | Methods for cell-proliferation-related disorders |
BR112012009751A2 (en) | 2009-10-26 | 2020-09-24 | Signal Pharmaceuticals, Llc | methods of synthesis and purification of heteroaryl |
US8722939B2 (en) | 2009-10-29 | 2014-05-13 | Northwestern University | Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis |
EP3257854A1 (en) | 2009-11-05 | 2017-12-20 | University of Notre Dame du Lac | Imidazo[1,2-a]pyridine compounds, synthesis thereof, and methods of using same |
WO2011062964A1 (en) * | 2009-11-17 | 2011-05-26 | University Of Rochester | Compounds and methods for altering lifespan of eukaryotic organisms |
WO2011061277A1 (en) | 2009-11-20 | 2011-05-26 | Glaxo Group Limited | Amino aryl acetamides and their use in the treatment of malaria |
DE102010002558A1 (en) * | 2009-11-20 | 2011-06-01 | Symrise Ag | Use of physiological cooling agents and agents containing such agents |
US10640457B2 (en) | 2009-12-10 | 2020-05-05 | The Trustees Of Columbia University In The City Of New York | Histone acetyltransferase activators and uses thereof |
WO2011073929A1 (en) | 2009-12-16 | 2011-06-23 | Istituto Europeo Di Oncologia S.R.L. | 6-(2-furyl)-3-methyl-4-oxo-1,5,6,7-tetrahydroindole-2-carboxylate derivatives and uses thereof |
WO2011073339A1 (en) * | 2009-12-18 | 2011-06-23 | Janssen Pharmaceutica Nv | Bicyclic thiazoles as allosteric modulators of mglur5 receptors |
WO2011075699A2 (en) * | 2009-12-18 | 2011-06-23 | Sunovion Pharmaceuticals Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
TW201130842A (en) * | 2009-12-18 | 2011-09-16 | Incyte Corp | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors |
NZ600603A (en) | 2009-12-18 | 2013-07-26 | Janssen Pharmaceutica Nv | Bicyclic thiazoles as allosteric modulators of mglur5 receptors |
WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
US9452980B2 (en) * | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
TW201139370A (en) | 2009-12-23 | 2011-11-16 | Lundbeck & Co As H | Processes for the manufacture of a pharmaceutically active agent |
ES2610248T3 (en) * | 2009-12-28 | 2017-04-26 | General Incorporated Association Pharma Valley Project Supporting Organisation | 1,3,4-oxadiazol-2-carboxamide compound |
US8343977B2 (en) * | 2009-12-30 | 2013-01-01 | Arqule, Inc. | Substituted triazolo-pyrimidine compounds |
US8658170B2 (en) | 2010-01-06 | 2014-02-25 | Joseph P. Errico | Combination therapy with MDM2 and EFGR inhibitors |
AU2011204368B2 (en) | 2010-01-06 | 2014-11-27 | Joseph P. Errico | Methods and compositions of targeted drug development |
KR20130088002A (en) * | 2010-01-13 | 2013-08-07 | 재단법인 한국파스퇴르연구소 | Anti-infective pyrido(1,2-a)pyrimidines |
TW201139406A (en) * | 2010-01-14 | 2011-11-16 | Glaxo Group Ltd | Voltage-gated sodium channel blockers |
EP2357176A1 (en) * | 2010-01-15 | 2011-08-17 | Hybrigenics S.A. | Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7 |
AR079935A1 (en) | 2010-01-29 | 2012-02-29 | Abbott Healthcare Products Bv | SYNTHESIS OF DERIVATIVES OF PIRAZOLIN CARBOXAMIDINA REPLACED |
JP5937968B2 (en) * | 2010-01-29 | 2016-06-22 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | Small molecules that modulate MCL-1 and methods for modulating cell death, cell division, cell differentiation, and methods of treating diseases. |
JP6173693B2 (en) * | 2010-02-24 | 2017-08-02 | リサーチ・トライアングル・インスティチュート | Aryl piperazine opioid receptor antagonist |
US8912184B1 (en) | 2010-03-01 | 2014-12-16 | Alzheimer's Institute Of America, Inc. | Therapeutic and diagnostic methods |
US8329735B2 (en) | 2010-03-05 | 2012-12-11 | Boehringer Ingelheim International Gmbh | Tetrazole compounds which selectively modulate the CB2 receptor |
CN101805302B (en) * | 2010-03-26 | 2012-05-09 | 西北师范大学 | 2-(4-phenyl-3-aryloxy-1,2,4-triazole-5-sulfenyl) acetamide and synthesis and application thereof |
CN102918034B (en) * | 2010-03-30 | 2015-06-03 | 维颂公司 | Multisubstituted aromatic compounds as inhibitors of thrombin |
CN101791312B (en) * | 2010-03-31 | 2012-01-04 | 中国药科大学 | Use of tetrahydroisoquinoline derivatives |
US8481553B2 (en) * | 2010-04-06 | 2013-07-09 | Brigham Young University | Antimetastatic compounds |
JP5965387B2 (en) * | 2010-04-08 | 2016-08-03 | アメリカ合衆国 | Inverse agonists and neutral antagonists for the TSH receptor |
US9193721B2 (en) | 2010-04-14 | 2015-11-24 | Incyte Holdings Corporation | Fused derivatives as PI3Kδ inhibitors |
CN101879159B (en) * | 2010-04-15 | 2011-11-30 | 浙江大学 | Application of 3,5-dimethylpsoralen in preparing anti-tumor medicaments |
EP2560656A4 (en) * | 2010-04-23 | 2013-11-27 | Kineta Inc | Anti-viral compounds |
WO2011135491A1 (en) * | 2010-04-26 | 2011-11-03 | Basf Se | Herbicidal azolopyrimidines |
BR112012027660A2 (en) | 2010-04-27 | 2016-08-16 | Astellas Pharma Inc | imidazo [1,2-a] pyridine derivatives |
US20130029973A1 (en) | 2010-04-28 | 2013-01-31 | Astellas Pharma Inc. | Tetrahydrobenzothiophene compound |
WO2011137089A1 (en) * | 2010-04-29 | 2011-11-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Activators of human pyruvate kinase |
EP2566333A4 (en) * | 2010-05-07 | 2014-04-02 | Univ Leland Stanford Junior | Identification of stabilizers of multimeric proteins |
US20130096159A1 (en) * | 2010-05-18 | 2013-04-18 | The United States of America, as represented the Secretary Department of Health & Human Service | Inhibitors of human 12-lipoxygenase |
EP2578203B1 (en) * | 2010-05-28 | 2015-04-01 | Ajinomoto Co., Inc. | Cysteine derivative |
US20120142701A1 (en) * | 2010-05-28 | 2012-06-07 | The University Of Hong Kong | Compounds and methods for the treatment of proliferative diseases |
MX2012014273A (en) | 2010-06-07 | 2013-03-22 | Novomedix Llc | Furanyl compounds and the use thereof. |
FR2961098A1 (en) * | 2010-06-09 | 2011-12-16 | Oreal | COMPOSITION COMPRISING AT LEAST ONE 2-PYRROLIDONE FUNCTIONALIZED IN POSITION 4 BY A CARBOXYLIC OR AMIDE ACID, AND AT LEAST ONE DIRECT COLOR OR PIGMENT FOR DYING KERATIN FIBERS |
TWI411393B (en) * | 2010-06-14 | 2013-10-11 | Academia Sinica | Chemical inhibitors of ethylene biosynthesis |
EP2582668B1 (en) | 2010-06-16 | 2016-01-13 | Bristol-Myers Squibb Company | Carboline carboxamide compounds useful as kinase inhibitors |
KR20110137941A (en) * | 2010-06-18 | 2011-12-26 | (주) 에빅스젠 | Novel thiourea or urea derivative, process for preparing the same and pharmaceutical composition for preventing or treating aids comprising the same |
WO2011163195A1 (en) | 2010-06-21 | 2011-12-29 | Incyte Corporation | Fused pyrrole derivatives as pi3k inhibitors |
WO2011163280A1 (en) | 2010-06-21 | 2011-12-29 | Vanderbilt University | Indole compounds as positive allosteric modulators of the muscarinic receptor |
WO2011161035A1 (en) * | 2010-06-22 | 2011-12-29 | Bayer Cropscience Ag | 3-aryl-4-(2-thienylmethylene)-isoxazol-5(4h)-ones as fungicides |
WO2011161201A1 (en) | 2010-06-22 | 2011-12-29 | Kancera Ab | Bisarylsulfonamides useful as kinase inhibitors in the treatment of inflammation and cancer |
NZ604423A (en) | 2010-06-24 | 2015-01-30 | Alkermes Pharma Ireland Ltd | Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
WO2012006419A2 (en) | 2010-07-07 | 2012-01-12 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
EP2590953B1 (en) | 2010-07-09 | 2014-10-29 | Convergence Pharmaceuticals Limited | Tetrazole compounds as calcium channel blockers |
WO2012007426A1 (en) * | 2010-07-13 | 2012-01-19 | Basf Se | Azoline substituted isoxazoline benzamide compounds for combating animal pests |
AU2011202542A1 (en) * | 2010-07-14 | 2012-02-02 | Indian Institute Of Science | Benzothiophene carboxamide compounds, composition and applications thereof |
US8524740B2 (en) * | 2010-07-15 | 2013-09-03 | Tairx, Inc. | Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives |
FR2962649A1 (en) * | 2010-07-19 | 2012-01-20 | Conservatoire Nat Arts Et Metiers | TREATMENT OF A PATHOLOGY ASSOCIATED WITH EXCESSIVE TNF EFFECT BY A BENZENE SULFONAMIDE COMPOUND |
EP2595965B1 (en) | 2010-07-20 | 2016-06-22 | Vestaron Corporation | Insecticidal triazines and pyrimidines |
EP2595959B1 (en) | 2010-07-22 | 2015-11-04 | Boehringer Ingelheim International GmbH | Sulfonyl compounds which modulate the cb2 receptor |
RS54577B1 (en) * | 2010-07-22 | 2016-06-30 | Basf Se | Herbicidal isoxazolo[5,4-b]pyridines |
CA2807230A1 (en) * | 2010-08-03 | 2012-02-09 | The Regents Of The University Of California | Compounds and compositions for mitigating tissue damage and lethality |
ES2793723T3 (en) | 2010-08-10 | 2020-11-16 | Takeda Pharmaceuticals Co | Heterocyclic compound and its use as a positive allosteric modulator of the ampa receptor |
US9150588B2 (en) | 2010-08-10 | 2015-10-06 | Takeda Pharmaceutical Company Limited | Substituted pyridazin-4(1H)-ones as phosphodiesterase 10A inhibitors |
US9255088B2 (en) | 2010-08-11 | 2016-02-09 | The Regents Of The University Of California | Premature-termination-codons readthrough compounds |
EP2606130B1 (en) * | 2010-08-16 | 2019-03-13 | Duke University | Camkk-beta as a marker in prostate cancer |
KR20130100300A (en) | 2010-08-27 | 2013-09-10 | 그뤼넨탈 게엠베하 | Substituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators |
WO2012025237A1 (en) | 2010-08-27 | 2012-03-01 | Grünenthal GmbH | Substituted 2-amino-quinoline-3-carboxamides as kcnq2/3 modulators |
PE20140214A1 (en) * | 2010-08-27 | 2014-02-19 | Gruenenthal Chemie | 2-OXO- AND 2-THIOXO-DIHYDROQUINOLINE-3-CARBOXAMIDES SUBSTITUTED AS KCNQ2 / 3 MODULATORS |
WO2012030681A1 (en) * | 2010-08-31 | 2012-03-08 | Dow Agrosciences Llc | Pesticidal compositions |
WO2012028300A1 (en) | 2010-09-01 | 2012-03-08 | Grünenthal GmbH | Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as kcnq2/3 modulators |
US8906933B2 (en) | 2010-09-24 | 2014-12-09 | N30 Pharmaceuticals, Inc. | Dihydropyrimidin-2(1H)-one compounds as neurokinin-3 receptor antagonists |
AU2011310713A1 (en) * | 2010-09-27 | 2013-04-11 | Proximagen Ltd | 7-hydroxy-pyrazolo[1,5-a] pyrimidine compounds and their use as CCR2 receptor antagonists |
US8921381B2 (en) | 2010-10-04 | 2014-12-30 | Baruch S. Blumberg Institute | Inhibitors of secretion of hepatitis B virus antigens |
WO2012045726A2 (en) | 2010-10-07 | 2012-04-12 | Bayer Cropscience Ag | 5-heteroarylimino-1,2,3-dithiazoles |
RU2013120556A (en) | 2010-10-14 | 2014-11-20 | Иммунар Аб | 1,2-HYDROXY-2-OXO-QUINOLIN-3-CARBOXANANIDES AS AHR ACTIVATORS |
EP2444084A1 (en) | 2010-10-21 | 2012-04-25 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Use of PI3K inibitors for the treatment of obesity |
EP2632466A4 (en) | 2010-10-29 | 2014-03-19 | Univ Emory | Quinazoline derivatives, compositions, and uses related thereto |
WO2013074059A2 (en) * | 2010-11-05 | 2013-05-23 | Regents Of The University Of Minnesota | Cytosine deaminase modulators for enhancement of dna transfection |
CN102532159B (en) * | 2010-11-12 | 2015-02-11 | 姚雪彪 | Small molecule inhibitors Syntelin for centromere-associated protein E (CENP-E) |
WO2012071414A2 (en) | 2010-11-22 | 2012-05-31 | Board Of Regents Of The University Of Nebraska | Quinoxaline compounds and uses thereof |
US9169199B2 (en) | 2010-12-08 | 2015-10-27 | Lycera Corporation | Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof |
MX344590B (en) | 2010-12-08 | 2016-12-16 | Lycera Corp | Pyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof. |
EP2648710B1 (en) | 2010-12-08 | 2016-06-15 | Lycera Corporation | Pyridonyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof |
PL3366688T3 (en) | 2010-12-08 | 2022-05-23 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Substituted pyrazolopyrimidines as glucocerebrosidase activators |
EP2651405A2 (en) * | 2010-12-14 | 2013-10-23 | Electrophoretics Limited | Casein kinase 1 (ck1 ) inhibitors |
JP5961187B2 (en) | 2010-12-20 | 2016-08-02 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | N- (1- (substituted phenyl) ethyl) -9H-purin-6-amine as a PI3K inhibitor |
MX2013007166A (en) * | 2010-12-21 | 2013-08-01 | Janssen Pharmaceutica Nv | NOVEL ANTIFUNGAL 5,6-DIHYDRO-4H-PYRROLO[1,2-a][1,4]- BENZODIAZEPINES AND 6H-PYRROLO[1,2-a][1,4]BENZODIA ZEPINES SUBSTITUTED WITH BICYCLIC BENZENE DERIVATIVES. |
RU2443697C1 (en) * | 2010-12-21 | 2012-02-27 | Александр Васильевич Иващенко | Substituted methyl-amines, serotonin 5-ht6 receptor antagonists, methods of production and use |
US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
CN103347392B (en) * | 2010-12-22 | 2016-10-12 | 纽约市哥伦比亚大学理事会 | Histone acetyltransferase regulator and its purposes |
TWI549947B (en) | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | Therapeutic compounds and compositions |
WO2012090179A2 (en) * | 2010-12-30 | 2012-07-05 | Lupin Limited | Isoquinoline derivatives as cannabinoid receptor modulators |
WO2012097013A1 (en) * | 2011-01-10 | 2012-07-19 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
DE102011000207A1 (en) * | 2011-01-18 | 2012-07-19 | Forschungsverbund Berlin E.V. | N-Arylaminomethylenbenzothiophenone as a drug |
JP6010548B2 (en) | 2011-01-26 | 2016-10-19 | ユニバーシティー オブ ロチェスター | Small molecule RNase inhibitors and methods of use |
US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
US9062013B2 (en) * | 2011-02-02 | 2015-06-23 | Bionomics Limited | Positive allosteric modulators of the α7 nicotinic acetylcholine receptor and uses thereof |
FI20115234A0 (en) | 2011-03-08 | 2011-03-08 | Biotie Therapies Corp | New pyridazinone and pyridone compounds |
US9688673B2 (en) * | 2011-03-08 | 2017-06-27 | The Regents Of The University Of California | Deoxycytidine kinase binding compounds |
WO2012122534A2 (en) | 2011-03-10 | 2012-09-13 | The Trustees Of Columbia University In The City Of New York | N-quinolin-benzensulfonamides and related compounds for the treatment of cancer, autoimmune disorders and inflammation |
US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
CN103561746B (en) | 2011-03-18 | 2018-05-29 | 奥克梅斯制药爱尔兰有限公司 | Pharmaceutical composition comprising sorbitan ester |
CA2830773C (en) | 2011-03-22 | 2021-01-26 | Arnim Kohn | N-(1,3,4-oxadiazol-2-yl)arylcarboxamides and use thereof as herbicides |
US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
WO2012131297A1 (en) | 2011-03-28 | 2012-10-04 | Jonathan Bayldon Baell | Pyrido [3',2' :4,5] thieno [3, 2-d] pyrimidin- 4 - ylamine derivatives and their therapeutical use |
JP2014114212A (en) * | 2011-03-29 | 2014-06-26 | Dainippon Sumitomo Pharma Co Ltd | New benzimidazole derivative |
JP5716205B2 (en) * | 2011-03-29 | 2015-05-13 | 学校法人日本大学 | Composition for inhibiting glucosidase activity and screening method thereof |
KR101888658B1 (en) * | 2011-04-15 | 2018-08-14 | 에스에프씨 주식회사 | New compounds and organic light-emitting diode including the same |
KR101369584B1 (en) | 2011-04-19 | 2014-03-06 | 일양약품주식회사 | Phenyl-isoxazol derivatives and preparation process thereof |
US10457659B2 (en) | 2011-04-29 | 2019-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for increasing proliferation of adult salivary stem cells |
US8470866B2 (en) * | 2011-05-03 | 2013-06-25 | Hoffmann-La Roche Inc. | Isoindolinone derivatives |
US9056862B2 (en) * | 2011-05-10 | 2015-06-16 | National University Corporation Kobe University | Thioxothiazolidine derivative having Ras function inhibitory effect |
WO2012154967A1 (en) | 2011-05-12 | 2012-11-15 | Proteostasis Therapeutics, Inc. | Proteostasis regulators |
EP2522341A1 (en) * | 2011-05-13 | 2012-11-14 | Tragex Pharma | Pharmaceutical compositions comprising Neuropilin inhibitors, and their use for the prevention and/or treatment of angiogenic disorders and cancers |
US9221840B2 (en) | 2011-05-17 | 2015-12-29 | Discoverybiomed Inc. | Treating protein folding disorders with small molecule CFTR correctors |
WO2012160447A1 (en) * | 2011-05-25 | 2012-11-29 | Dynamix Pharmaceuticals Ltd. | 3, 5 -diphenyl- substituted pyrazolines for the treatment of cancer, proliferative, inflammatory or autoimmune diseases |
CA2837883C (en) * | 2011-06-08 | 2019-10-29 | Sunovion Pharmaceuticals, Inc. | Metabotropic glutamate receptor 5 modulators and methods of use thereof |
CN102827170A (en) * | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | Active treatment compositions and use method thereof |
CN102827073A (en) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | Therapeutically active compositions and application methods thereof |
WO2012177618A1 (en) | 2011-06-20 | 2012-12-27 | Emory University | Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto |
US20130005743A1 (en) * | 2011-07-01 | 2013-01-03 | H. Lundbeck A/S | New positive allosteric modulators of nicotinic acetylcholine receptor |
CN106166157B (en) * | 2011-07-01 | 2019-08-02 | 巴鲁·S·布隆伯格研究所 | As the sulfonamides heterocyclic carbamate derivatives for preventing hepatitis b virus infected antivirotic |
CN102329245A (en) * | 2011-07-04 | 2012-01-25 | 武汉大学 | Adamantine derivative with anti-avian influenza virus activity and preparation method for adamantine derivative |
WO2013006758A1 (en) * | 2011-07-06 | 2013-01-10 | President And Fellows Of Harvard College | Diphosphate mimetics and uses thereof |
WO2013007106A1 (en) * | 2011-07-09 | 2013-01-17 | 广东东阳光药业有限公司 | Spiro compounds as hepatitis c virus inhibitors |
EP2731942B1 (en) | 2011-07-13 | 2015-09-23 | Novartis AG | Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors |
CA2841932A1 (en) * | 2011-07-13 | 2013-01-17 | Novartis Ag | 4 - piperidinyl compounds for use as tankyrase inhibitors |
US9227982B2 (en) | 2011-07-13 | 2016-01-05 | Novartis Ag | 4-oxo-3,5,7,8-tetrahydro-4H-pyrano[4,3-d]pyrminidinyl compounds for use as tankyrase inhibitors |
CN103702993B (en) * | 2011-07-18 | 2015-11-25 | 默克专利有限公司 | Benzamide |
KR20140063605A (en) | 2011-07-19 | 2014-05-27 | 인피니티 파마슈티칼스, 인코포레이티드 | Heterocyclic compounds and uses thereof |
DK2736888T3 (en) | 2011-07-26 | 2016-02-01 | Sanofi Sa | 3-HETEROAROYLAMINOPROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS |
US9156837B2 (en) | 2011-07-29 | 2015-10-13 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
EP2744500A1 (en) * | 2011-08-18 | 2014-06-25 | Nuhope LLC | Compounds for use in cancer therapy |
US9416104B2 (en) | 2011-08-26 | 2016-08-16 | Uwm Research Foundation, Inc. | Vitamin D receptor-coregulator inhibitors |
WO2013033392A1 (en) | 2011-08-30 | 2013-03-07 | Wayne State University | Therapeutic compounds and methods |
WO2013033569A1 (en) | 2011-09-02 | 2013-03-07 | Incyte Corporation | Heterocyclylamines as pi3k inhibitors |
CN102285993B (en) * | 2011-09-06 | 2013-12-25 | 上海师范大学 | Tetrahydropyridine oxapicene derivative as well as preparation method and application thereof |
WO2013040321A1 (en) | 2011-09-15 | 2013-03-21 | University Of Kansas | Kappa opioid receptor effectors and uses thereof |
US9056111B1 (en) * | 2011-09-21 | 2015-06-16 | Stc.Unm | Selective efflux inhibitors and related pharmaceutical compositions and methods of treatment |
JP2014530202A (en) * | 2011-09-22 | 2014-11-17 | バーテックスファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticalsincorporated | Compounds useful as choline kinase inhibitors |
WO2013045519A1 (en) * | 2011-09-27 | 2013-04-04 | Genfit | Derivatives of 6-substituted triazolopyridazines as rev-erb agonists |
US20140227321A1 (en) * | 2011-09-30 | 2014-08-14 | Kineta, Inc. | Anti-viral compounds |
EP3799871B1 (en) | 2011-10-11 | 2024-02-28 | Dana Farber Cancer Institute, Inc. | Pyrazol-3-ones that activate pro-apototic bax |
US9708276B2 (en) | 2011-10-12 | 2017-07-18 | University of Pittsburgh—of the Commonwealth System of Higher Education | Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer |
SG10201912850WA (en) | 2011-10-19 | 2020-02-27 | Signal Pharm Llc | Treatment Of Cancer With TOR Kinase Inhibitors |
WO2013059594A1 (en) * | 2011-10-20 | 2013-04-25 | Sirtris Pharmaceuticals, Inc. | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
EP2768509B1 (en) * | 2011-10-20 | 2017-03-22 | Glaxosmithkline LLC | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
CN103889948A (en) * | 2011-10-26 | 2014-06-25 | 霍夫曼-拉罗奇有限公司 | 1-cycloalkyl- or 1-heterocyclyl-hydroxyimino-3-phenyl-propanes |
CA2853439A1 (en) | 2011-10-31 | 2013-05-10 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
KR20140105445A (en) * | 2011-10-31 | 2014-09-01 | 제논 파마슈티칼스 인크. | Biaryl ether sulfonamides and their use as therapeutic agents |
US20140256767A1 (en) * | 2011-10-31 | 2014-09-11 | The Broad Institute, Inc. | Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators |
CN103087001A (en) * | 2011-11-03 | 2013-05-08 | 南京大学 | Vanillic acid 1,3,4-oxadiazole derivatives, and preparation methods and uses thereof |
WO2013070659A1 (en) * | 2011-11-07 | 2013-05-16 | Sunovion Pharmaceuticals Inc. | Modulators of opioid receptors and methods of use thereof |
CN103086980A (en) * | 2011-11-07 | 2013-05-08 | 北京清美联创干细胞科技有限公司 | Pyrimidine compound for efficiently promoting stem cell proliferation and use thereof |
UA111640C2 (en) * | 2011-11-08 | 2016-05-25 | Ф. Хоффманн-Ля Рош Аг | DERIVATIVES [1,2,3] TRIAZOLO [4,5-d] PYRIMIDINE AS A cannabinoid receptor agonist 2 |
US20130116229A1 (en) * | 2011-11-09 | 2013-05-09 | Abbvie Inc. | Novel inhibitor compounds of phosphodiesterase type 10a |
US8541577B2 (en) * | 2011-11-10 | 2013-09-24 | Allergan, Inc. | Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators |
AR090037A1 (en) | 2011-11-15 | 2014-10-15 | Xention Ltd | DERIVATIVES OF TIENO AND / OR FURO-PYRIMIDINES AND PYRIDINES INHIBITORS OF THE POTASSIUM CHANNELS |
CN103122370B (en) * | 2011-11-21 | 2014-06-18 | 华中农业大学 | Application of triazin compound as mycobacterium tuberculosis inhibitor |
CN103127095A (en) * | 2011-11-23 | 2013-06-05 | 华东理工大学 | Synthesis and application of dihydrothiophenone derivative as pfDHODH inhibitor |
EP2785717B1 (en) | 2011-11-29 | 2016-01-13 | Novartis AG | Pyrazolopyrrolidine compounds |
WO2013082275A1 (en) * | 2011-11-30 | 2013-06-06 | Trustees Of Boston College | Inhibitors of phosphodiesterases 11 (pde11) and methods of use to elevate cortisol production |
JP2015504442A (en) | 2011-11-30 | 2015-02-12 | バイエル・インテレクチユアル・プロパテイー・ゲー・エム・ベー・ハー | Bactericidal N-bicycloalkyl and N-tricycloalkyl (thio) carboxamide derivatives |
CN104093398B (en) | 2011-12-02 | 2017-03-15 | 西格诺药品有限公司 | 7 (6 (2 hydroxy propane, 2 base) 3 base of pyridine) 1 ((trans) 4 methoxycyclohexyl) 3,4 dihydro pyrazines simultaneously [2,3 B] pyrazine 2 (1H) ketone, the pharmaceutical composition of its solid form and its using method |
US9238658B2 (en) | 2011-12-06 | 2016-01-19 | Janssen Pharmaceutica Nv | Substituted piperidinyl-carboxamide derivatives useful as SCD 1 inhibitors |
WO2013085957A1 (en) | 2011-12-06 | 2013-06-13 | Janssen Pharmaceutica Nv | Substituted piperidinyl-pyridazinyl derivatives useful as scd 1 inhibitors |
JP5952912B2 (en) | 2011-12-15 | 2016-07-13 | アルカーメス ファーマ アイルランド リミテッド | Prodrugs of secondary amine compounds |
US9663521B2 (en) | 2011-12-16 | 2017-05-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis |
JP2015500345A (en) * | 2011-12-16 | 2015-01-05 | トランスポサジェン・バイオファーマシューティカルズ・インコーポレイテッドTransposagen Biopharmaceuticals, Inc. | TRPC4 modulator used for the treatment or prevention of pain |
KR102097343B1 (en) * | 2011-12-21 | 2020-04-07 | 더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 | Anti-cancer compounds targeting Ral GTPases and methods of using the same |
WO2013093508A2 (en) * | 2011-12-22 | 2013-06-27 | Oslo University Hospital Hf | Wnt pathway inhibitors |
WO2013100027A1 (en) * | 2011-12-28 | 2013-07-04 | 武田薬品工業株式会社 | Heterocyclic compound |
KR101446738B1 (en) | 2011-12-29 | 2014-10-07 | 한국화학연구원 | 4-Thiopyrazole derivatives or pharmaceutically acceptable salts thereof process for the preparation thereof and pharmaceutical composition for the prevention and treatment of dyslipidemia containing the same as an active ingredient |
WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
WO2013103967A1 (en) | 2012-01-05 | 2013-07-11 | Northeastern University | Allosteric modulators of cb1 cannabinoid receptors |
CN115536635A (en) | 2012-01-06 | 2022-12-30 | 法国施维雅药厂 | Therapeutically active compounds and methods of use thereof |
WO2013104561A1 (en) | 2012-01-12 | 2013-07-18 | Basf Se | Herbicidal isoxazolo[5,4-b]pyridines |
US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
WO2013112323A1 (en) | 2012-01-23 | 2013-08-01 | Eli Lilly And Company | Phenyl methanesulfonamide derivatives useful as mgat - 2 inhibitors |
JO3357B1 (en) | 2012-01-26 | 2019-03-13 | Novartis Ag | Imidazopyrrolidinone compounds |
KR20150000875A (en) * | 2012-01-27 | 2015-01-05 | 내셔날 유니버시티 코포레이션 유니버시티 오브 토야마 | Serine racemase inhibitor |
CA2859992A1 (en) | 2012-01-31 | 2013-08-08 | Eli Lilly And Company | Novel morpholinyl derivatives useful as mogat-2 inhibitors |
TW201343629A (en) * | 2012-01-31 | 2013-11-01 | Lilly Co Eli | Novel benzyl sulfonamide derivatives useful as MOGAT-2 inhibitors |
TWI615143B (en) | 2012-02-24 | 2018-02-21 | 標誌製藥公司 | Methods for treating cancer using tor kinase inhibitor combination therapy |
WO2013130703A2 (en) * | 2012-02-29 | 2013-09-06 | Institute For Hepatitis And Virus Research | Binhibitors of hepatitis b virus convalently closed circular dna formation and their method of use |
EP2636673A1 (en) * | 2012-03-06 | 2013-09-11 | Compound Handling B.V. | Aminomethylene pyrazolones with therapeutic activity |
IN2014DN08368A (en) * | 2012-03-16 | 2015-05-08 | Glucox Biotech Ab | |
ES2764383T3 (en) | 2012-03-19 | 2020-06-03 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions comprising glycerol esters |
EP2827868B8 (en) | 2012-03-19 | 2019-12-18 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
ES2950418T3 (en) | 2012-03-19 | 2023-10-09 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions comprising benzyl alcohol |
CA2868081C (en) | 2012-03-20 | 2021-01-05 | Loren D. Walensky | Inhibition of mcl-1 and/or bfl-1/a1 |
US9321902B2 (en) | 2012-03-20 | 2016-04-26 | Basf Se | Isoindolo[2, 1-A]quinazoline derivatives for stabilization of organic materials |
EP2828249B1 (en) | 2012-03-23 | 2018-10-10 | The Regents of The University of California | Premature-termination-codons readthrough compounds |
ITRM20120131A1 (en) | 2012-03-30 | 2013-10-01 | Consiglio Nazionale Ricerche | USEFUL INHIBITORS OF THE TCR / MHCII-COLLAGEN INTERACTION FOR THE TREATMENT OF RHEUMATOID ARTHRITIS. |
AR090548A1 (en) | 2012-04-02 | 2014-11-19 | Incyte Corp | BICYCLIC AZAHETEROCICLOBENCILAMINS AS PI3K INHIBITORS |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
KR20130118612A (en) * | 2012-04-20 | 2013-10-30 | (주)네오믹스 | Novel aminopyridine derivatives and use thereof |
JP6141408B2 (en) * | 2012-04-27 | 2017-06-07 | ビーエーエスエフ ソシエタス・ヨーロピアBasf Se | Substituted N- (tetrazol-5-yl)-and N- (triazol-5-yl) arylcarboxamide compounds and their use as herbicides |
ES2929283T3 (en) * | 2012-05-04 | 2022-11-28 | Us Health | Relaxin 1 receptor modulators |
CN109512805B (en) | 2012-05-08 | 2021-12-31 | 埃罗米克斯公司 | Compounds for the treatment of aquaporin mediated diseases |
WO2013167984A2 (en) * | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of muscle pain |
CA2872883A1 (en) * | 2012-05-09 | 2013-11-14 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
JP6082457B2 (en) * | 2012-05-09 | 2017-02-15 | ウニヴェルスィタ デッリ ストゥディ ディ ミラノ | GPR17 receptor modulator |
KR101243696B1 (en) | 2012-05-22 | 2013-03-15 | 서울대학교산학협력단 | Quorum sensing inhibitor against pathogenic microorganism and antibiotic composition therefrom |
EA026393B1 (en) | 2012-05-22 | 2017-04-28 | Дженентек, Инк. | N-substituted benzamides and their use in the treatment of pain |
US9365576B2 (en) | 2012-05-24 | 2016-06-14 | Novartis Ag | Pyrrolopyrrolidinone compounds |
JO3407B1 (en) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | Tetrahydropyrazolopyrimidine Compounds |
WO2013181135A1 (en) | 2012-05-31 | 2013-12-05 | Emory University | Quinazoline derivatives, compositions, and uses related thereto |
EP2854780B1 (en) | 2012-06-05 | 2017-08-30 | University Of Kansas | Inhibitors of respiratory syncytial virus |
US9580391B2 (en) | 2012-06-08 | 2017-02-28 | Lycera Corporation | Saturated acyl guanidine for inhibition of F1F0-ATPase |
WO2013185045A1 (en) | 2012-06-08 | 2013-12-12 | Lycera Corporation | Indazole guanidine f1f0-atpase inhibitors and therapeutic uses thereof |
US9221814B2 (en) | 2012-06-08 | 2015-12-29 | Lycera Corporation | Heterocyclic guanidine F1F0-atpase inhibitors and therapeutic uses thereof |
AU2013287176C1 (en) | 2012-06-13 | 2023-01-19 | Incyte Holdings Corporation | Substituted tricyclic compounds as FGFR inhibitors |
CN102702109B (en) * | 2012-06-15 | 2014-07-23 | 华东理工大学 | Benzenesulfonamide compound and application thereof |
CA2877146C (en) | 2012-06-18 | 2020-10-20 | Dart Neuroscience (Cayman) Ltd | Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds |
WO2013192306A1 (en) * | 2012-06-21 | 2013-12-27 | Bristol-Myers Squibb Company | Positive allosteric modulators of mglur2 |
WO2014004902A2 (en) * | 2012-06-27 | 2014-01-03 | Amazentis Sa | Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof |
KR101190571B1 (en) | 2012-07-02 | 2012-10-17 | 대한민국 | Pharmaceutical composition comprising 3-fluoro-n-(4-methoxyphenethyl)-n-(1-(4-methoxyphenyl)-2,5-dioxopyrrolidin-3-yl)benzamide for preventing and treating of neurodegenerative disease |
CN104797555B (en) | 2012-07-06 | 2017-12-22 | 基因泰克公司 | The benzamide and its application method of N substitutions |
ES2595240T3 (en) | 2012-07-09 | 2016-12-28 | Lupin Limited | Tetrahydroquinazolinone derivatives as PARP inhibitors |
CN102746171A (en) * | 2012-07-10 | 2012-10-24 | 南开大学 | Preparation method and application research of water-soluble and oil-soluble novel phenoxy carboxylic acid ester derivative |
WO2014009891A1 (en) * | 2012-07-11 | 2014-01-16 | Piramal Enterprises Limited | Heterocyclic compounds for use in the treatment of cancers |
CN107266333A (en) | 2012-07-12 | 2017-10-20 | 日产化学工业株式会社 | Oxime substituted amide compound and noxious organism control agent |
FR2993563B1 (en) * | 2012-07-20 | 2015-12-18 | Metabrain Res | THIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF DIABETES |
ES2802049T3 (en) | 2012-07-20 | 2021-01-15 | Univ New York State Res Found | Derivatives of alpha- and gamma-truxilic acid and pharmaceutical compositions thereof |
MX2015001512A (en) * | 2012-08-01 | 2015-08-20 | Merck Sharp & Dohme | α7 nicotinic acetylcholine receptor modulators and uses thereof-i. |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
CA3090294C (en) * | 2012-08-16 | 2023-01-24 | Dongcheng Dai | Methods of preparing tecovirimat |
WO2014031759A2 (en) | 2012-08-21 | 2014-02-27 | Cornell University | Inhibitors of crl4 ubiquitin ligase and uses thereof |
ES2877570T3 (en) * | 2012-08-22 | 2021-11-17 | Univ Cornell | Methods to inhibit fascina |
EP2887803A4 (en) | 2012-08-24 | 2016-08-03 | Univ Texas | Pro-neurogenic compounds |
EP2703384A1 (en) * | 2012-08-27 | 2014-03-05 | Ludwig-Maximilians-Universität München | Inhibitors of CD40-TRAF6 interaction |
US9505749B2 (en) | 2012-08-29 | 2016-11-29 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
JP6139682B2 (en) * | 2012-08-30 | 2017-05-31 | チョン クン ダン ファーマシューティカル コーポレーション | N-acylhydrazone derivatives for selective T cell inhibitors and anti-lymphocytic malignancies |
CN102827056B (en) * | 2012-09-03 | 2014-07-23 | 华东理工大学 | N-aryl-substituted pyrrolidone derivative and application thereof |
CN103664783A (en) * | 2012-09-13 | 2014-03-26 | 南京大学 | Thiourea derivatives containing naphthalene rings and pyrazoline structures and preparation method of thiourea derivatives |
NZ631345A (en) | 2012-09-19 | 2017-06-30 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions having improved storage stability |
US10207989B2 (en) | 2012-09-20 | 2019-02-19 | Temple University—Of the Commonwealth System of Higher Education | Substituted alkyl diaryl derivatives, methods of preparation and uses |
WO2014045101A1 (en) | 2012-09-21 | 2014-03-27 | Cellzome Gmbh | Tetrazolo quinoxaline derivatives as tankyrase inhibitors |
US9216180B2 (en) * | 2012-10-02 | 2015-12-22 | New York University | Pharmaceutical compositions and treatment of genetic diseases associated with nonsense mediated RNA decay |
GB201218084D0 (en) * | 2012-10-09 | 2012-11-21 | Univ Aston | Novel compounds and methods for use in medicine |
TWI598325B (en) | 2012-10-12 | 2017-09-11 | H 朗德貝克公司 | Benzamides |
CN104822373B (en) * | 2012-10-15 | 2018-08-28 | 安吉奥斯医药品有限公司 | Therapeutic compound and composition |
US9944607B2 (en) | 2012-10-16 | 2018-04-17 | Whitehead Institute For Biomedical Research | Thiohydantoin derivatives and uses thereof |
AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
EP2722047A1 (en) * | 2012-10-19 | 2014-04-23 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | 2,3-dihydroquinazolin-4(1H)-one derivatives for use in the treatment of viral infections |
CN102925136B (en) * | 2012-10-23 | 2014-12-24 | 大连大学 | Zn<2+> ratiometric fluorescent probe compound and preparation method and use thereof |
IN2015DN03761A (en) * | 2012-10-24 | 2015-10-02 | Glucox Biotech Ab | |
CN102964326B (en) * | 2012-11-06 | 2015-11-18 | 北京大学 | There is compound of MEK inhibit feature and preparation method thereof and application |
US9546176B2 (en) | 2012-11-20 | 2017-01-17 | Discoverybiomed, Inc. | Small molecule bicyclic and tricyclic CFTR correctors |
CA2891962A1 (en) | 2012-11-20 | 2014-05-03 | Discoverybiomed, Inc. | Small molecule cftr correctors |
WO2014080615A1 (en) | 2012-11-21 | 2014-05-30 | 日本曹達株式会社 | Recording material produced using non-phenol compound |
WO2014086746A1 (en) * | 2012-12-07 | 2014-06-12 | Bayer Cropscience Ag | N-(isoxazol-3-yl)-aryl-carboxylic acid amides and use thereof as herbicides |
CA2893638A1 (en) * | 2012-12-10 | 2014-06-19 | F. Hoffmann-La Roche Ag | Benzyl sulfonamide derivatives as rorc modulators |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
PE20151055A1 (en) | 2012-12-19 | 2015-08-05 | Novartis Ag | TRICYCLIC COMPOUNDS TO INHIBIT THE CFTR CHANNEL |
EA201591175A1 (en) | 2012-12-19 | 2015-11-30 | Новартис Аг | TRICYCLIC COMPOUNDS AS CFTR INHIBITORS |
US9115122B2 (en) * | 2012-12-20 | 2015-08-25 | University Of Maryland, Baltimore | Non-ATP dependent inhibitors of extracellular signal-regulated kinase (ERK) |
US9868707B2 (en) | 2012-12-20 | 2018-01-16 | Sanford-Burnham Medical Research Institute | Small molecule agonists of neurotensin receptor 1 |
WO2014100734A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
CA2894126A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
EP2935243B1 (en) | 2012-12-21 | 2018-03-14 | Epizyme, Inc. | Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
US9365555B2 (en) | 2012-12-21 | 2016-06-14 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
UA118548C2 (en) | 2012-12-21 | 2019-02-11 | Епізайм, Інк. | Teatrahydro- and dihydro-isoquinoline prmt5 inhibitors and uses thereof |
CN105209031A (en) * | 2012-12-27 | 2015-12-30 | 德雷克塞尔大学 | Novel antiviral agents against HBV infection |
CN105439975B (en) * | 2012-12-27 | 2018-07-24 | 华东理工大学 | Heterocyclic substituted styrene compound and application thereof |
US9246108B2 (en) * | 2012-12-28 | 2016-01-26 | Dow Global Technologies Llc | Quinoline-benzoxazole derived compounds for electronic films and devices |
EP2943202A4 (en) | 2013-01-10 | 2016-08-24 | Nimbus Iris Inc | Irak inhibitors and uses thereof |
WO2014113495A1 (en) * | 2013-01-15 | 2014-07-24 | The Trustees Of Columbia University In The City Of New York | Activation or reactivation of ache |
SG11201505446WA (en) | 2013-01-16 | 2015-08-28 | Signal Pharm Llc | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith |
EP2948451B1 (en) | 2013-01-22 | 2017-07-12 | Novartis AG | Substituted purinone compounds |
US9556180B2 (en) | 2013-01-22 | 2017-01-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction |
ES2489297B1 (en) * | 2013-01-22 | 2015-06-10 | Consejo Superior De Investigaciones Científicas (Csic) | BENZOTIAZOLES REPLACED AND ITS THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF HUMAN DISEASES |
US9849135B2 (en) | 2013-01-25 | 2017-12-26 | President And Fellows Of Harvard College | USP14 inhibitors for treating or preventing viral infections |
JP6409004B2 (en) * | 2013-01-28 | 2018-10-17 | ハー・ルンドベック・アクチエゼルスカベット | N-substituted pentasubstituted phthalamic acids as sortilin inhibitors |
US8778365B1 (en) | 2013-01-31 | 2014-07-15 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
US9315464B1 (en) * | 2013-01-31 | 2016-04-19 | Nant Holdings Ip, Llc | Small molecule inhibitors of influenza A RNA-dependent RNA polymerase |
CA3217159A1 (en) | 2013-02-01 | 2014-08-07 | Wellstat Therapeutics Corporation | Substituted quinazolin-4-amine compounds and pharmaceutical compositions thereof having anti-inflammatory, antifungal, antiparasitic and anticancer activity |
JP6511606B2 (en) | 2013-03-01 | 2019-05-15 | 株式会社生命科学インスティテュート | Pharmaceutical composition comprising a chemotactic factor for inducing pluripotent stem cells to a site of injury |
MX2015010466A (en) * | 2013-03-05 | 2015-10-30 | Hoffmann La Roche | Inhibitors of bruton's tyrosine kinase. |
WO2014165128A2 (en) | 2013-03-12 | 2014-10-09 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
JP2016517412A (en) | 2013-03-13 | 2016-06-16 | フォーマ セラピューティクス,インコーポレイテッド | Novel compounds and compositions for inhibiting FASN |
US8937178B2 (en) * | 2013-03-13 | 2015-01-20 | Flatley Discovery Lab | Phthalazinone compounds and methods for the treatment of cystic fibrosis |
ES2684399T3 (en) | 2013-03-14 | 2018-10-02 | Mars, Incorporated | Aroma composition containing HMG glycosides |
TW201444844A (en) * | 2013-03-14 | 2014-12-01 | Hydra Biosciences Inc | Substituted xanthines and methods of use thereof |
CN104045642B (en) * | 2013-03-14 | 2016-08-24 | 上海医药工业研究院 | Containing pyrimidine or the fused ring compound of pyridine and the application as antitumor drug thereof |
WO2014160185A2 (en) | 2013-03-14 | 2014-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof |
WO2014153037A1 (en) | 2013-03-14 | 2014-09-25 | Genentech, Inc. | Substituted triazolopyridines and methods of use thereof |
CA2899088C (en) | 2013-03-14 | 2022-12-20 | Merck Patent Gmbh | Thiazole and oxazole compounds as glycosidase inhibitors |
BR112015023214A8 (en) | 2013-03-15 | 2019-12-24 | Verseon Corp | compound, pharmaceutical composition, and, use of a pharmaceutical compound or composition |
WO2014151529A1 (en) * | 2013-03-15 | 2014-09-25 | The Regents Of The University Of California | Therapeutic agents and methods for the treatment of dna repair deficiency disorders |
ES2702182T3 (en) | 2013-03-15 | 2019-02-27 | Verseon Corp | Aromatic compounds multisubstituted as serine protease inhibitors |
US9296754B2 (en) | 2013-03-15 | 2016-03-29 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
WO2014151729A1 (en) | 2013-03-15 | 2014-09-25 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
WO2014151630A2 (en) | 2013-03-15 | 2014-09-25 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
BR112015023397A2 (en) | 2013-03-15 | 2017-07-18 | Genentech Inc | substituted benzoxazole and methods of use thereof |
US9616065B2 (en) * | 2013-04-16 | 2017-04-11 | Drexel University | Compositions useful in treating brain-related diseases or disorders and methods using same |
ES2944478T3 (en) | 2013-04-17 | 2023-06-21 | Signal Pharm Llc | 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2 (1H)-one to treat glioblastoma multiforme |
CN105339008A (en) | 2013-04-17 | 2016-02-17 | 西格诺药品有限公司 | Combination therapy comprising tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer |
US9474757B2 (en) | 2013-04-17 | 2016-10-25 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy |
BR112015026247B1 (en) | 2013-04-17 | 2022-08-23 | Signal Pharmaceuticals, Llc | USE OF COMPOUNDS IN COMBINATION WITH A CYTIDINE ANALOG, PHARMACEUTICAL COMPOSITION THAT COMPRISES THEM, AND KIT |
SG11201508302PA (en) | 2013-04-17 | 2015-11-27 | Signal Pharm Llc | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer |
MX2015014590A (en) | 2013-04-17 | 2016-03-03 | Signal Pharm Llc | Treatment of cancer with dihydropyrazino-pyrazines. |
WO2014172423A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one |
UA120087C2 (en) | 2013-04-19 | 2019-10-10 | Інсайт Холдинґс Корпорейшн | Bicyclic heterocycles as fgfr inhibitors |
US9540389B2 (en) * | 2013-05-03 | 2017-01-10 | Microbiotix, Inc. | Antimicrobial potentiators |
WO2014186450A2 (en) | 2013-05-14 | 2014-11-20 | The Board Of Regents Of The University Of Texas System | Highly potent inhibitors of porcupine |
PL2997019T3 (en) | 2013-05-17 | 2019-03-29 | Janssen Sciences Ireland Uc | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
WO2014187291A1 (en) * | 2013-05-20 | 2014-11-27 | 中国人民解放军军事医学科学院微生物流行病研究所 | Mercaptonicotinic acid compound and preparation method and use thereof |
CN103254184B (en) * | 2013-05-27 | 2015-03-18 | 湖南科技大学 | 5-substituted-3-[5-hydroxy-4-pyrone-2-yl-methylmercapto]-4-amino-1,2,4-triazole compound and application thereof |
MX2015016344A (en) | 2013-05-27 | 2016-03-01 | Novartis Ag | Imidazopyrrolidinone derivatives and their use in the treatment of disease. |
US8975417B2 (en) | 2013-05-27 | 2015-03-10 | Novartis Ag | Pyrazolopyrrolidine derivatives and their use in the treatment of disease |
PT3004108T (en) | 2013-05-28 | 2018-01-24 | Novartis Ag | Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease |
WO2014191911A1 (en) | 2013-05-28 | 2014-12-04 | Novartis Ag | Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease |
CA2912627C (en) | 2013-05-29 | 2022-03-15 | Signal Pharmaceuticals, Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
WO2014205234A1 (en) * | 2013-06-21 | 2014-12-24 | MyoKardia, Inc. | Cycloalkyl-substituted pyrimidinedione compounds |
EA201891009A1 (en) * | 2013-06-21 | 2018-09-28 | Миокардиа, Инк. | CONNECTIONS OF PYRIMIDINDION |
WO2014210159A1 (en) * | 2013-06-26 | 2014-12-31 | Proteostasis Therapeutics, Inc. | Methods of modulating cftr activity |
WO2014207601A1 (en) | 2013-06-27 | 2014-12-31 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
US9914740B2 (en) | 2013-07-02 | 2018-03-13 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
JP6522602B2 (en) | 2013-07-02 | 2019-05-29 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as ROCK inhibitors |
ES2807582T3 (en) | 2013-07-11 | 2021-02-23 | Agios Pharmaceuticals Inc | Compounds N, 6-bis (aryl or heteroaryl) -1,3,5-triazine-2,4-diamine as inhibitors of IDH2 mutants for the treatment of cancer |
WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
EP3019480B1 (en) | 2013-07-11 | 2020-05-06 | Agios Pharmaceuticals, Inc. | 2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer |
WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
CN103396349B (en) * | 2013-07-19 | 2014-12-17 | 浙江工业大学 | Acyl thiourea compound containing 1-methyl cyclohexyl as well as preparation method and application thereof |
CN103351360B (en) * | 2013-07-19 | 2015-03-25 | 浙江工业大学 | Acylthiourea compound containing 1, 3, 4-thiadiazole group, and preparation method and application thereof |
WO2015010049A1 (en) * | 2013-07-19 | 2015-01-22 | Epizyme, Inc. | Substituted benzene compounds |
US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
WO2015010297A1 (en) * | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
GB201313664D0 (en) | 2013-07-31 | 2013-09-11 | Univ Cardiff | Bcl-3 inhibitors |
PL225258B1 (en) * | 2013-08-09 | 2017-03-31 | Univ Jagielloński | New derivatives of N-[(phenoxy)ethoxy]alkylamino alkanols and their application for manufacturing of medicines |
TWI636047B (en) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | Heterocyclic derivatives |
CA2915766C (en) * | 2013-09-06 | 2023-09-26 | F. Hoffmann-La Roche Ag | Triazolo[4,5-d]pyrimidine derivatives and their use as cannabinoid receptor 2 agonists |
MX2016003082A (en) * | 2013-09-10 | 2016-09-13 | Univ Texas | Therapeutics targeting truncated adenomatous polyposis coli (apc) proteins. |
US9751851B2 (en) * | 2013-09-20 | 2017-09-05 | The Trustees Of Princeton University | Molecules and compositions that inhibit gram negative bacteria and their uses |
US20160257657A1 (en) | 2013-09-20 | 2016-09-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
JP6564380B2 (en) | 2013-09-20 | 2019-08-21 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | Compounds for treating prostate cancer |
MX2016003843A (en) | 2013-09-27 | 2017-02-15 | Nimbus Iris Inc | Irak inhibitors and uses thereof. |
WO2015046595A1 (en) * | 2013-09-30 | 2015-04-02 | 国立大学法人東京大学 | Adiponectin receptor-activating compound |
HUE057734T2 (en) | 2013-10-04 | 2022-06-28 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and uses thereof |
GB201317609D0 (en) | 2013-10-04 | 2013-11-20 | Cancer Rec Tech Ltd | Inhibitor compounds |
WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CA2926950C (en) | 2013-10-10 | 2022-10-11 | Eastern Virginia Medical School | 4-((2-hydroxy-3-methoxybenzyl)amino) benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase |
CN103524419B (en) * | 2013-10-18 | 2016-03-23 | 孙家隆 | One group of 3-trifluoromethyl pyrazol compound |
CN103601721B (en) * | 2013-10-23 | 2016-04-27 | 江苏科技大学 | 3-furyl dibenzodiazepine-1-ketone series derivates and its preparation method and application |
WO2015058868A1 (en) * | 2013-10-25 | 2015-04-30 | Pangaea Biotech, S.L. | Compositions and methods for the treatment of cancer |
CA2929821A1 (en) | 2013-11-06 | 2015-05-14 | Aeromics, Inc. | 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate formulations and kits |
ES2799582T3 (en) | 2013-11-08 | 2020-12-18 | Incyte Holdings Corp | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor |
WO2015070237A1 (en) | 2013-11-11 | 2015-05-14 | Board Of Regents Of The University Of Texas System | Neuroprotective chemicals and methods for identifying and using same |
US9902713B2 (en) | 2013-11-11 | 2018-02-27 | Board Of Regents Of The University Of Texas System | Neuroprotective compounds and use thereof |
KR102265950B1 (en) * | 2013-11-12 | 2021-06-16 | 니혼노야쿠가부시키가이샤 | Amide compound or salt thereof, agricultural/horticultural insecticide/bactericide containing said compound, and method for using same |
WO2015073528A1 (en) | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
AU2014351413B2 (en) | 2013-11-21 | 2017-06-01 | Novartis Ag | Pyrrolopyrrolone derivatives and their use as BET inhibitors |
JP6383418B2 (en) | 2013-11-27 | 2018-08-29 | ジェネンテック, インコーポレイテッド | Substituted benzamide and method of use |
BR102013031043B1 (en) * | 2013-12-02 | 2018-03-13 | Fundação Butantan | USE OF CHEMICAL COMPOUNDS ABLE TO INHIBIT THE TOXIC ACTION OF SPXOMYELINASES D FROM LOXOSCEL SPIDEN POISON AND PHARMACEUTICAL COMPOSITION UNDERSTANDING THE COMPOUND COMPOUNDS |
UA115310C2 (en) * | 2013-12-03 | 2017-10-25 | Деніпер Лімітед | SPIROTSYKLICHNI compounds based on derivatives of 2-OKSINDOLU, CONTAINING CORE SPIRO [indole-3,1'-pyrrolo [3,4-c] pyrrole] and the remains of biogenic sulfur-containing amino acids, the way they receive and pharmaceutical compositions on their basis |
JP6486364B2 (en) | 2013-12-10 | 2019-03-20 | リセラ・コーポレイションLycera Corporation | Trifluoromethylpyrazolylguanidine F1F0-ATPase inhibitor and therapeutic use thereof |
JP2016539983A (en) | 2013-12-10 | 2016-12-22 | リセラ・コーポレイションLycera Corporation | Alkylpyrazolylguanidine F1F0-ATPase inhibitor and therapeutic use thereof |
CA2931792A1 (en) | 2013-12-10 | 2015-06-18 | Lycera Corporation | N-substituted pyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof |
AU2013407264B2 (en) * | 2013-12-11 | 2016-09-29 | Nant Holdings Ip, Llc | Small molecule inhibitors of influenza a RNA-dependent RNA polymerase |
GB201322334D0 (en) | 2013-12-17 | 2014-01-29 | Agency Science Tech & Res | Maleimide derivatives as modulators of WNT pathway |
CU24379B1 (en) | 2013-12-19 | 2019-02-04 | Novartis Ag | DERIVATIVES OF [1,2,4] TRIAZOLO [1,5-A] PYRIMIDINE AS PROTEASOME INHIBITORS FOR THE TREATMENT OF PARASITARY DISEASES SUCH AS LEISHMANIASIS |
CN103641803A (en) * | 2013-12-30 | 2014-03-19 | 南京农业大学 | Furandione compound containing substituted phenylhydrazine, preparation method and application |
EP3091984B1 (en) | 2014-01-09 | 2020-04-22 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Substituted benzoxazine and related compounds |
WO2015104677A1 (en) * | 2014-01-10 | 2015-07-16 | Piramal Enterprises Limited | Heterocyclic compounds as ezh2 inhibitors |
US9561227B2 (en) | 2014-01-15 | 2017-02-07 | Southern Methodist University | Inhibitors of multidrug resistance transporter P-glycoprotein |
US11234978B2 (en) | 2014-01-15 | 2022-02-01 | Southern Methodist University | Inhibitors of multidrug resistance transporter P-glycoprotein |
US11013739B2 (en) | 2014-01-15 | 2021-05-25 | Southern Methodist University | Inhibitors of multidrug resistance transporter p-glycoprotein |
US10292982B2 (en) | 2014-01-15 | 2019-05-21 | Southern Methodist University | Inhibitors of multidrug resistance transporter P-glycoprotein |
WO2015120304A1 (en) * | 2014-02-07 | 2015-08-13 | Boston Biomedical, Inc. | 3-substituted carbonyl-naphtho[2,3-b]furane derivative or pharmaceutically acceptable salt thereof |
CN104825452B (en) * | 2014-02-12 | 2017-08-11 | 北京大学 | The application of urea hydrolytic velocity inhibitor |
CN104825456B (en) * | 2014-02-12 | 2017-06-09 | 北京大学 | A kind of new opplication of the excellent body of urea hydrolytic velocity inhibitor |
GB201403595D0 (en) * | 2014-02-28 | 2014-04-16 | Isis Innovation | Quinoline compounds |
CN104892639B (en) * | 2014-03-06 | 2018-10-30 | 中国科学院上海药物研究所 | 3,6- bis- replaces [1,2,4] triazole [3,4-b] [1,3,4] thiadiazole compound and application thereof |
AU2015229188A1 (en) | 2014-03-13 | 2016-09-29 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing CFTR activity |
EP3116870A1 (en) | 2014-03-13 | 2017-01-18 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
MX2016011632A (en) * | 2014-03-14 | 2016-12-12 | Raqualia Pharma Inc | Azaspiro derivatives as trpm8 antagonists. |
WO2015138839A1 (en) | 2014-03-14 | 2015-09-17 | Agios Pharmaceuticals, Inc. | Pharmaceutical compositions of therapeutically active compounds |
UY36034A (en) | 2014-03-18 | 2015-09-30 | Astrazeneca Ab | DERIVATIVES OF 3,5-DIAMINO-6-CHLORINE-PIRAZINA-2-CARBOXAMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS OF THESE |
CN106573880B (en) * | 2014-03-19 | 2019-07-30 | 阿米达斯公司 | Amyloid protein targeting agent and its application method |
CN106456628A (en) | 2014-03-19 | 2017-02-22 | 无限药品股份有限公司 | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
JP6524110B2 (en) | 2014-03-20 | 2019-06-05 | アルカームス ファーマ アイルランド リミテッド | Aripiprazole formulations with increased injection rates |
WO2015143293A1 (en) | 2014-03-20 | 2015-09-24 | The Johns Hopkins University | Compounds which inhibit rna polymerase, compositions including such compounds, and their use |
US9394303B2 (en) * | 2014-04-04 | 2016-07-19 | The Regents Of The University Of Michigan | Small molecule inhibitors of MCL-1 and uses thereof |
EP3127898B1 (en) * | 2014-04-04 | 2021-08-25 | Adeka Corporation | Oxime ester compound and photopolymerization initiator containing said compound |
TWI690521B (en) * | 2014-04-07 | 2020-04-11 | 美商同步製藥公司 | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators |
EA031500B1 (en) | 2014-04-10 | 2019-01-31 | Басф Се | HERBICIDAL COMPOSITION COMPRISING ISOXAZOLO[5,4-b]PYRIDINE |
JP2017511367A (en) | 2014-04-16 | 2017-04-20 | シグナル ファーマシューティカルズ,エルエルシー | 1-ethyl-7- (2-methyl-6- (1H-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino [2,3-b] pyrazine-2 Solid forms comprising (1H) -one and coforms, compositions thereof and methods of use |
WO2015160882A1 (en) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
ES2823756T3 (en) | 2014-04-16 | 2021-05-10 | Signal Pharm Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy |
NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
EP3131881A4 (en) * | 2014-04-18 | 2017-09-06 | Millennium Pharmaceuticals, Inc. | Quinoxaline compounds and uses thereof |
WO2015163478A1 (en) * | 2014-04-24 | 2015-10-29 | 住友化学株式会社 | Diaryl-azole compound |
EP3134405B1 (en) | 2014-04-25 | 2019-08-28 | Pfizer Inc | Heteroaromatic compounds and their use as dopamine d1 ligands |
US10052332B2 (en) | 2014-04-29 | 2018-08-21 | Emory University | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto |
WO2015173656A1 (en) | 2014-05-14 | 2015-11-19 | Novartis Ag | Carboxamide derivatives |
US9403833B2 (en) | 2014-05-14 | 2016-08-02 | Novartis Ag | Carboxamide derivatives |
TW201946921A (en) * | 2014-05-14 | 2019-12-16 | 瑞士商諾華公司 | Carboxamide derivatives |
WO2015173659A2 (en) | 2014-05-14 | 2015-11-19 | Novartis Ag | Carboxamide derivatives |
SG11201609830RA (en) | 2014-05-23 | 2016-12-29 | Hoffmann La Roche | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors |
CN104059060B (en) * | 2014-05-30 | 2017-08-01 | 西安交通大学 | A kind of ketones derivant of 5 (methylene of 1H indoles 3) 1,3 thiazolidine 4 and its synthetic method and application |
US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
EP3157917B1 (en) | 2014-06-19 | 2020-03-18 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing cftr activity |
WO2015200674A1 (en) * | 2014-06-25 | 2015-12-30 | The General Hospital Corporation | Neuroactive compounds and methods of using the same |
US10118902B2 (en) | 2014-06-25 | 2018-11-06 | Sanford Burnham Prebys Medical Discovery Institute | Small molecule agonists of neurotensin receptor 1 |
JP6616790B2 (en) | 2014-06-27 | 2019-12-04 | ノグラ ファーマ リミテッド | Aryl receptor modulators and methods of making and using the same |
US20170166558A1 (en) * | 2014-07-01 | 2017-06-15 | President And Fellows Of Harvard College | O-glcnac transferase (ogt) inhibitors and uses thereof |
JP2017525677A (en) | 2014-07-07 | 2017-09-07 | ジェネンテック, インコーポレイテッド | Therapeutic compounds and methods of use thereof |
US10202397B2 (en) | 2014-07-10 | 2019-02-12 | The Regents Of The University Of Colorado, A Body Corporate | Anti-cancer compounds targeting Ral GTPases and methods of using the same |
EP3169686A4 (en) | 2014-07-14 | 2018-01-24 | Signal Pharmaceuticals, LLC | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
EP3177611B1 (en) * | 2014-08-04 | 2021-10-06 | Nuevolution A/S | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
JP2017530940A (en) | 2014-08-04 | 2017-10-19 | エピザイム,インコーポレイティド | PRMT5 inhibitors and uses thereof |
WO2016020892A1 (en) * | 2014-08-07 | 2016-02-11 | University Of Cape Town | Small molecule inhibitors for cancer therapy |
US10385040B2 (en) | 2014-08-12 | 2019-08-20 | Loyola University Of Chicago | Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same |
EA201790271A1 (en) | 2014-08-28 | 2017-08-31 | Асенейрон Са | GLYCOSIDASE INHIBITORS |
CN104230915B (en) * | 2014-08-29 | 2016-08-17 | 南京大学 | Phenylpiperazine derivatives containing thiazolidinedione and preparation method thereof and purposes |
RU2746405C2 (en) * | 2014-08-29 | 2021-04-13 | Тес Фарма С.Р.Л. | Inhibitors - amino - carboxymuconate - semialdehyde - decarboxylase |
WO2016033285A1 (en) | 2014-08-29 | 2016-03-03 | E. I. Du Pont De Nemours And Company | Herbicidal triazoles |
KR20190026962A (en) | 2014-09-05 | 2019-03-13 | 심바이오믹스 세러퓨틱스 엘엘씨 | Secnidazole for use in the treatment of bacterial vaginosis |
USRE49687E1 (en) | 2014-09-09 | 2023-10-10 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
US10082496B2 (en) | 2014-09-10 | 2018-09-25 | Board Of Regents Of The University Of Texas System | Targeting emopamil binding protein (EBP) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis |
AU2015317522A1 (en) | 2014-09-17 | 2017-03-23 | Verseon Corporation | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors |
WO2016049500A1 (en) | 2014-09-25 | 2016-03-31 | Duke University | Kinase inhibitors and related methods of use |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP3200792A4 (en) * | 2014-10-03 | 2018-05-09 | The Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center | Poly (adp-ribose) polymerase 1 inhibitors structurally unrelated to nad |
US9353093B2 (en) | 2014-10-07 | 2016-05-31 | Allergan, Inc. | Indole-1-carboxamides as kinase inhibitors |
US9907797B2 (en) | 2014-10-07 | 2018-03-06 | Emory University | Combination therapies for overcoming resistance to mitotic agents during chemotherapy |
CN104292233B (en) * | 2014-10-09 | 2016-03-16 | 武汉大学 | A kind of pyrazolo [1,5-a] pyrimidine derivatives and anticancer usage thereof |
US9371314B2 (en) | 2014-10-09 | 2016-06-21 | Allergan, Inc. | Pyridyl benzothiophenes as kinase inhibitors |
CN105524058B (en) * | 2014-10-21 | 2018-03-27 | 广州艾格生物科技有限公司 | Pyrazolo [1,5 a] pyridine compounds and their and its application |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
DK3212644T3 (en) * | 2014-10-29 | 2021-07-19 | Apoglyx Ab | Derivatives of 2- (1,2,4-triazol-3-ylsulfanyl) -N-1,3,4-thiadiazol-2-ylacetamide that can be used to treat diabetes |
CN104478780B (en) * | 2014-11-17 | 2017-04-19 | 华东师范大学 | Acylpyrrole small-molecular organic compound, derivatives of organic compound as well as application and preparation method of acylpyrrole small-molecular organic compound and derivatives of organic compound |
JO3719B1 (en) * | 2014-11-20 | 2021-01-31 | Takeda Pharmaceuticals Co | 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of gpr139 |
GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
EP3230279A1 (en) | 2014-12-10 | 2017-10-18 | Massachusetts Institute of Technology | Fused 1,3-azole derivatives useful for the treatment of proliferative diseases |
FR3030516B1 (en) * | 2014-12-19 | 2019-12-27 | Galderma Research & Development | BICYCLE SULFONAMIDE DERIVATIVES AS INVERTED AGONISTS OF THE ORPHAN GAMMA RECEPTOR ASSOCIATED WITH ROR GAMMA (T) RETINOIDS |
CA2971855A1 (en) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
WO2016105468A1 (en) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
MA41253A (en) | 2014-12-23 | 2017-10-31 | Proteostasis Therapeutics Inc | COMPOUNDS, COMPOSITIONS AND PROCESSES TO INCREASE THE ACTIVITY OF CFTR |
WO2016105477A1 (en) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc | Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
CN104606189B (en) * | 2015-01-08 | 2017-10-27 | 苏州大学 | A kind of application of compound in mTOR inhibitors are prepared |
WO2016115434A1 (en) | 2015-01-16 | 2016-07-21 | The General Hospital Corporation | Compounds for improving mrna splicing |
EP3250569B1 (en) * | 2015-01-30 | 2019-01-09 | Boehringer Ingelheim International GmbH | Aldosterone synthase inhibitors |
EP3257510B1 (en) * | 2015-02-09 | 2021-10-20 | National University Corporation Okayama University | Lactate dehydrogenase inhibitor and antiepileptic drug containing same |
CN104744455B (en) * | 2015-02-10 | 2018-03-13 | 南开大学 | A kind of NTR1 small molecular antagonists |
US10221168B1 (en) * | 2015-02-18 | 2019-03-05 | Xiao Hua Wu | Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof |
ES2751669T3 (en) | 2015-02-20 | 2020-04-01 | Incyte Corp | Bicyclic heterocycles as FGFR inhibitors |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
MA41551A (en) | 2015-02-20 | 2017-12-26 | Incyte Corp | BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS |
WO2016135140A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer |
WO2016135137A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer |
WO2016135138A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer |
WO2016135139A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | 2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer |
CR20170389A (en) | 2015-02-27 | 2018-01-26 | Incyte Corp | P13K INHIBITOR SALTS AND PREPARATION PROCESSES |
HRP20221287T1 (en) | 2015-02-27 | 2023-02-03 | Verseon International Corporation | Substituted pyrazole compounds as serine protease inhibitors |
CN104672145B (en) * | 2015-03-09 | 2017-04-12 | 广州英赛特生物技术有限公司 | Glycalpyramide derivative and application thereof in preparing anticoccidial drug |
WO2016149667A1 (en) * | 2015-03-19 | 2016-09-22 | University Of Maryland , Baltimore | Runx2 transcription factor inhibitors and uses thereof |
GB201505658D0 (en) | 2015-04-01 | 2015-05-13 | Cancer Rec Tech Ltd | Inhibitor compounds |
WO2016172498A1 (en) * | 2015-04-22 | 2016-10-27 | The Texas A&M University System | Substituted benzofuran derivatives as novel antimycobacterial agents |
WO2016172437A2 (en) * | 2015-04-24 | 2016-10-27 | The Johns Hopkins University | Small molecule compounds targeting pbx1 transcriptional complex |
US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
BR112017020977B1 (en) * | 2015-05-13 | 2021-03-30 | Nihon Nohyaku Co., Ltd | ANTHANLIC ACID ESTER COMPOUND OR ITS SALT, AGRICULTURAL AND VEGETABLE MICROBICIDES THAT UNDERSTAND THE COMPOUND, AND METHOD FOR USING THE MICROBICIDE |
NZ737536A (en) | 2015-05-22 | 2019-04-26 | Genentech Inc | Substituted benzamides and methods of use thereof |
AR104020A1 (en) | 2015-06-04 | 2017-06-21 | Kura Oncology Inc | METHODS AND COMPOSITIONS TO INHIBIT THE INTERACTION OF MENINA WITH MILL PROTEINS |
WO2016197027A1 (en) | 2015-06-04 | 2016-12-08 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
CN104974142A (en) * | 2015-06-12 | 2015-10-14 | 中国人民解放军第二军医大学 | Substituted triaminotriazine secreting-type aspartic protease inhibitor and preparation method thereof |
WO2016201288A1 (en) * | 2015-06-12 | 2016-12-15 | Brown University | Novel antibacterial compounds and methods of making and using same |
WO2017000277A1 (en) * | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Substituted triazolo bicycliccompounds as pde2 inhibitors |
CN107949279A (en) * | 2015-07-06 | 2018-04-20 | 得克萨斯系统大学评议会 | It can be used as the benzamide or benzamine compound of the anticancer for treating human cancer |
AU2016297886B2 (en) | 2015-07-24 | 2020-12-10 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing CFTR activity |
AU2016301188A1 (en) | 2015-08-06 | 2018-02-15 | Chimerix, Inc. | Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents |
CN106466313A (en) * | 2015-08-18 | 2017-03-01 | 中国科学院上海药物研究所 | The amide derivatives that one class sulfoamido replaces are used for the purposes in the medicine treating Alzheimer in preparation |
US11576892B2 (en) | 2015-08-18 | 2023-02-14 | Novation Pharmaceuticals Inc. | Benzopyran derivatives and uses thereof |
CN105061462B (en) * | 2015-08-18 | 2017-05-24 | 沈阳药科大学 | Tetrahydrobenzo [4,5] thieno [2,3-d] pyrimidines compound containing amide and application thereof |
CN108137477A (en) | 2015-08-27 | 2018-06-08 | 基因泰克公司 | Therapeutic compounds and its application method |
CN113292572A (en) | 2015-09-04 | 2021-08-24 | 株式会社半导体能源研究所 | Compound, light-emitting element, display device, electronic device, and lighting device |
EP3350183A1 (en) | 2015-09-14 | 2018-07-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
AU2015101598A4 (en) * | 2015-09-17 | 2015-12-03 | Macau University Of Science And Technology | Novel ros1 inhibitor and its use |
CA2998375A1 (en) | 2015-09-17 | 2017-03-23 | Marvin J. Miller | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection |
MX2018003828A (en) | 2015-09-28 | 2018-06-22 | Genentech Inc | Therapeutic compounds and methods of use thereof. |
BR112018007021B1 (en) | 2015-10-06 | 2024-01-09 | Proteostasis Therapeutics, Inc | Compound, composition comprising said compounds and use thereof to treat cystic fibrosis |
EP3359151A4 (en) * | 2015-10-07 | 2019-08-14 | Arizona Board of Regents on behalf of the University of Arizona | Crmp2 sumoylation inhibitors and uses thereof |
US9682072B2 (en) * | 2015-10-14 | 2017-06-20 | Children's Hospital Medical Center | Compositions and methods for treatment of lung dysfunction |
EA039829B1 (en) | 2015-10-15 | 2022-03-17 | Аджиос Фармасьютикалз, Инк. | Combination therapy for treating malignancies |
EP3362065B1 (en) | 2015-10-15 | 2024-04-03 | Les Laboratoires Servier | Combination therapy comprising ivosidenib, cytarabine and daunorubicin or idarubicin for treating acute myelogenous leukemia |
CN105111176A (en) * | 2015-10-16 | 2015-12-02 | 南开大学 | 3-phenoxyacetyl-4-hydroxycoumarin derivative, synthetic method and application |
US20170107216A1 (en) | 2015-10-19 | 2017-04-20 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
CN106632082B (en) * | 2015-11-04 | 2020-10-09 | 中国科学院上海药物研究所 | Compounds with agonism on GPR84 and preparation method and application thereof |
CN105287474B (en) * | 2015-11-12 | 2018-09-14 | 江苏康缘药业股份有限公司 | The application of anisic acid para hydroxybenzene ethyl ester |
RS63762B1 (en) | 2015-11-19 | 2022-12-30 | Incyte Corp | Heterocyclic compounds as immunomodulators |
US20170146519A1 (en) * | 2015-11-20 | 2017-05-25 | Oregon Health & Science University | Sting agonists and methods of selecting sting agonists |
CN108495851A (en) | 2015-11-25 | 2018-09-04 | 基因泰克公司 | Substituted benzamide and its application method |
CN105523988B (en) * | 2015-12-08 | 2018-05-15 | 南方科技大学 | A kind of preparation method of α-trifluoromethylthio-beta-amino ketones, ester, nitrile or amide compound and α-trifluoromethylthio-beta-amino acids |
US20190263799A1 (en) * | 2015-12-14 | 2019-08-29 | Zenith Epigenetics Ltd. | 1h-imidazo[4,5-b]pyridinyl and 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridinyl heterocyclic bet bromodomain inhibitors |
CN105478054B (en) * | 2015-12-14 | 2017-12-15 | 齐齐哈尔大学 | A kind of naphthol derivative quaternary cationics and preparation method thereof |
US10208000B2 (en) * | 2015-12-16 | 2019-02-19 | University Of Kentucky Research Foundation | Eis inhibitors |
CN105418505B (en) * | 2015-12-21 | 2018-02-02 | 浙江树人大学 | Pyrazol acid amide compounds and its preparation method and purposes |
KR20180100585A (en) | 2015-12-22 | 2018-09-11 | 인사이트 코포레이션 | Heterocyclic compounds as immunomodulators |
SG11201804901WA (en) | 2015-12-22 | 2018-07-30 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
EP3184514A1 (en) * | 2015-12-23 | 2017-06-28 | Deutsches Krebsforschungszentrum | Autophagy inhibitors |
CN108431010B (en) | 2015-12-25 | 2021-10-15 | 株式会社半导体能源研究所 | Compound, light-emitting element, display device, electronic device, and lighting device |
PT3398598T (en) * | 2015-12-31 | 2022-07-12 | Hitgen Ltd | Sulfonamide derivative and preparation method and use thereof |
AR107339A1 (en) * | 2016-01-13 | 2018-04-18 | Bayer Cropscience Ag | USE OF ACTIVE SUBSTANCES TO CONTROL VIRUS INFECTION IN PLANTS |
AR110456A1 (en) * | 2016-01-13 | 2019-04-03 | Bayer Cropscience Ag | USE OF ACTIVE SUBSTANCES TO CONTROL INFECTIONS BY VIRUSES IN PLANTS |
WO2017127627A1 (en) * | 2016-01-21 | 2017-07-27 | The University Of North Carolina At Chapel Hill | Compounds for treatment of trypanosomes and neurological pathogens and uses thereof |
CN106831437B (en) * | 2016-02-03 | 2019-06-21 | 华中师范大学 | Ester type compound and its preparation method and application containing nitroethenyl group |
RU2637928C2 (en) * | 2016-02-08 | 2017-12-08 | Закрытое Акционерное Общество "Вертекс" | Arylcycloalkylamines derivatives neuroprotector (versions), substances with combined neuroprotector, analgetic and antidepressive action, pharmaceutical compositions based thereon |
WO2017140728A1 (en) * | 2016-02-15 | 2017-08-24 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Taf1 inhibitors for the therapy of cancer |
RU2018132559A (en) | 2016-02-16 | 2020-03-17 | Массачусетс Инститьют Оф Текнолоджи | BINDING MOLECULES FOR MAX AS MYC MODULATORS AND THEIR APPLICATIONS |
AU2017222964B2 (en) | 2016-02-25 | 2020-01-02 | Asceneuron S. A. | Glycosidase inhibitors |
CN109071526B (en) | 2016-02-25 | 2023-02-28 | 阿森纽荣股份公司 | Acid addition salts of piperazine derivatives |
AU2017222958B2 (en) | 2016-02-25 | 2019-07-18 | Asceneuron S. A. | Glycosidase inhibitors |
US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
CN105585538B (en) * | 2016-03-01 | 2018-05-29 | 浙江工业大学 | A kind of 2- substitution benzylthio -5- (4,6- dimethyl pyrimidines -2-) sulfidomethyl -1,3,4- oxadiazole class compounds and its application |
CN105541805A (en) * | 2016-03-04 | 2016-05-04 | 南京大学 | Preparation method and application of indole acetyl pyrazole derivatives |
CN105541804A (en) * | 2016-03-04 | 2016-05-04 | 南京大学 | Preparation method and application of indole formylamino-pyrazole derivatives |
WO2017153952A1 (en) * | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
EP3452441A4 (en) * | 2016-03-11 | 2019-10-23 | The Research Foundation for The State University of New York | Alpha-truxillic acid derivatives and pharmaceutical compositions thereof |
BR112018068702A2 (en) | 2016-03-16 | 2019-01-15 | Kura Oncology Inc | menin-mll bridged bicyclic inhibitors and methods of use |
RS64261B1 (en) | 2016-03-16 | 2023-07-31 | Kura Oncology Inc | Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use |
WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
SG10201913878YA (en) | 2016-03-17 | 2020-03-30 | Hoffmann La Roche | 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar |
GEP20207149B (en) | 2016-03-22 | 2020-09-10 | Merck Sharp & Dohme | Allosteric modulators of nicotinic acetylcholine receptors |
CN105566323A (en) * | 2016-03-22 | 2016-05-11 | 中国药科大学 | Pyridinopyrazine compounds and preparation method thereof, and medical application of pyridinopyrazine compounds |
US10980806B2 (en) | 2016-03-24 | 2021-04-20 | University of Pittsburgh—of the Commonwealth System of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
CN109071426A (en) | 2016-03-30 | 2018-12-21 | 基因泰克公司 | Substituted benzamide and its application method |
MA43775A (en) | 2016-04-07 | 2021-05-05 | Proteostasis Therapeutics Inc | ANALOGUES OF IVACAFTOR CONTAINING SILICON ATOMS |
MD3442972T2 (en) | 2016-04-15 | 2020-08-31 | Abbvie Inc | Bromodomain inhibitors |
CN105949195A (en) * | 2016-04-26 | 2016-09-21 | 兰州大学 | Lead compound and application thereof in preparation of drugs against castration-resistant prostate cancer |
ES2906460T3 (en) | 2016-05-06 | 2022-04-18 | Incyte Corp | Heterocyclic compounds as immunomodulators |
TW201808902A (en) | 2016-05-26 | 2018-03-16 | 美商英塞特公司 | Heterocyclic compounds as immunomodulators |
US10596153B2 (en) * | 2016-05-27 | 2020-03-24 | Arkansas State University-Jonesboro | Antimicrobial agents and the method of synthesizing the antimicrobial agents |
RU2020140891A (en) | 2016-05-31 | 2021-02-10 | Калвиста Фармасьютикалз Лимитед | PYRAZOL DERIVATIVES AS CALLICREIN INHIBITORS |
GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
WO2017210527A1 (en) * | 2016-06-03 | 2017-12-07 | University Of Tennessee Research Foundation | Autotaxin inhibitors |
CN109563071B (en) * | 2016-06-08 | 2021-08-03 | 葛兰素史密斯克莱知识产权发展有限公司 | Chemical compounds as inhibitors of the ATF4pathway |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
KR101966351B1 (en) * | 2016-06-08 | 2019-04-08 | 한국과학기술연구원 | Quinoline derivatives for inhibiting histone methyltransferases and use thereof |
WO2017216792A1 (en) | 2016-06-13 | 2017-12-21 | Ramot At Tel-Aviv University Ltd. | Perk inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins |
RU2019101420A (en) * | 2016-06-20 | 2020-07-21 | Ратгерс, Де Стейт Юниверсити Оф Нью Джерси | Therapeutic compounds |
AU2017281285C1 (en) | 2016-06-20 | 2022-05-12 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
AU2017280206A1 (en) | 2016-06-21 | 2019-01-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing CFTR activity |
CN106070266B (en) * | 2016-06-29 | 2018-11-30 | 贵州大学 | Pyrazoles [3,4-d] pyrimidone Schiff bases compound is preparing the application in anti-plant virus agent |
WO2018013789A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
AU2017300336B2 (en) | 2016-07-18 | 2021-03-11 | National Institute Of Biological Sciences, Beijing | Apoptosis inhibitors |
ES2901059T3 (en) * | 2016-08-09 | 2022-03-21 | Zincure Corp | Pharmaceutical composition for the treatment of stroke based on AMPK inhibition |
CA3034211A1 (en) | 2016-08-18 | 2018-02-22 | Vidac Pharma Ltd. | Piperazine derivatives, pharmaceutical compositions and methods of use thereof |
CN107778262A (en) * | 2016-08-24 | 2018-03-09 | 尹玉新 | 1,5 disubstituted tetrazole compounds and its preparation method and application |
US20180057486A1 (en) | 2016-08-29 | 2018-03-01 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2018043399A1 (en) * | 2016-08-31 | 2018-03-08 | Jcrファーマ株式会社 | Novel therapeutic agent for diabetes |
AU2017330443B2 (en) * | 2016-09-26 | 2023-08-24 | Dana-Farber Cancer Institute, Inc. | Chromobox protein inhibitors and uses thereof |
GB201617103D0 (en) | 2016-10-07 | 2016-11-23 | Cancer Research Technology Limited | Compound |
TWI825663B (en) | 2016-10-14 | 2023-12-11 | 美商林伯士拉克許米公司 | Tyk2 inhibitors and uses thereof |
EP3526205A4 (en) | 2016-10-17 | 2020-05-27 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
CN108017588B (en) * | 2016-11-01 | 2020-04-10 | 中国石油化工股份有限公司 | Triazine natural gas drag reducer and synthesis method and application thereof |
JP7059268B2 (en) | 2016-11-02 | 2022-04-25 | エフ.ホフマン-ラ ロシュ アーゲー | Pyrazolo [1,5a] pyrimidine derivative as IRAK4 modulator |
WO2018089967A1 (en) * | 2016-11-14 | 2018-05-17 | Virginia Commonwealth University | Inhibitors of cancer invasion, attachment, and/or metastasis |
CN106727540A (en) * | 2016-11-28 | 2017-05-31 | 天津理工大学 | A kind of application of the 1,3,4 thiadiazoles disulfide compounds containing phenylurea based structures |
CN106727539A (en) * | 2016-11-28 | 2017-05-31 | 天津理工大学 | A kind of application of the 1,3,4 thiadiazoles disulfide compounds containing aniline based structures |
US10905120B2 (en) | 2016-11-28 | 2021-02-02 | The Regents Of The University Of California | ABA receptor agonists that modulate transpiration |
JP2020502070A (en) | 2016-11-30 | 2020-01-23 | ケース ウエスタン リザーブ ユニバーシティ | Combinations of 15-PGDH inhibitors with corticosteroids and / or TNF inhibitors and uses thereof |
CN107245050B (en) * | 2016-12-05 | 2019-10-25 | 徐州医科大学 | Vanillic aldehyde hydroxamic acid derivatives and its application |
MA47120A (en) | 2016-12-22 | 2021-04-28 | Incyte Corp | PYRIDINE DERIVATIVES USED AS IMMUNOMODULATORS |
PE20191532A1 (en) | 2016-12-22 | 2019-10-23 | Incyte Corp | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS |
EP3558989B1 (en) | 2016-12-22 | 2021-04-14 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
WO2018125983A1 (en) | 2016-12-30 | 2018-07-05 | Mitobridge, Inc. | Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors |
WO2018129381A1 (en) * | 2017-01-06 | 2018-07-12 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
CN106800549A (en) * | 2017-01-10 | 2017-06-06 | 青岛科技大学 | A kind of imidazoles acid naphthalimide base ethyl ester compound and application thereof |
US11377452B2 (en) * | 2017-01-16 | 2022-07-05 | Drexel University | Glutamate transporter activators and methods using same |
CN106749192B (en) * | 2017-01-16 | 2019-05-17 | 南京医科大学 | A kind of nicotinoyl pyrazoline class compound and its medicinal usage |
CN106822089B (en) * | 2017-01-23 | 2019-09-20 | 广州中大南沙科技创新产业园有限公司 | Acyl enester amide derivatives are preparing the application in osteosporosis resistant medicament in a kind of benzene |
WO2018145080A1 (en) | 2017-02-06 | 2018-08-09 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
JP7157752B2 (en) | 2017-02-17 | 2022-10-20 | エイドス セラピューティクス,インコーポレイティド | Methods for the preparation of AG-10, intermediates thereof and salts thereof |
RU2748419C2 (en) * | 2017-02-20 | 2021-05-25 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" | Derivatives of 4-phenylpyrrolidone with anticonvulsant and nootropic activity as means of treating epilepsy and paroxysmal conditions |
CN106928075B (en) * | 2017-02-27 | 2019-06-14 | 北京理工大学 | 1- phenyl -3- benzene methanamine base -2- propylene -1- ketone compounds, preparation method and its usage |
RU2650610C1 (en) | 2017-02-28 | 2018-04-16 | Васильевич Иващенко Александр | Antiviral composition and method of its application |
CN106866705B (en) * | 2017-03-06 | 2019-02-05 | 中国医学科学院医药生物技术研究所 | Compound F083-0063 and its antitumor application thereof |
GB2560713A (en) * | 2017-03-20 | 2018-09-26 | Eternygen Gmbh | Inhibitor of citrate transporter |
AR111295A1 (en) | 2017-03-20 | 2019-06-26 | Forma Therapeutics Inc | PIRROLOPIRROL COMPOSITIONS AS PIRUVATO QUINASA ACTIVATORS (PKR) |
US10793550B2 (en) | 2017-03-24 | 2020-10-06 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
JPWO2018174288A1 (en) * | 2017-03-24 | 2020-01-23 | 大正製薬株式会社 | 2 (1H) -quinolinone derivatives |
US11944627B2 (en) | 2017-03-24 | 2024-04-02 | Kura Oncology, Inc. | Methods for treating hematological malignancies and Ewing's sarcoma |
US10980781B2 (en) * | 2017-03-29 | 2021-04-20 | Purdue Research Foundation | 6-amino-2,4-dihydropyrano [2,3-c] pyrazoles and methods of use |
CN106749167B (en) * | 2017-03-29 | 2019-06-11 | 齐鲁工业大学 | The preparation and use of two (thiophene -2- methylene) propane -1,3- diamines |
WO2018178304A1 (en) * | 2017-03-31 | 2018-10-04 | Perenna Pharmaceuticals, Inc. | Compounds useful as inhibitors of alcat 1 |
US11633415B2 (en) * | 2017-03-31 | 2023-04-25 | The Broad Institute, Inc. | Compounds and methods useful for treating or preventing cancers |
US11426420B2 (en) | 2017-04-07 | 2022-08-30 | Case Western Reserve University | Inhibitors of short-chain dehydrogenase activity for treating coronary disorders |
JP7132211B2 (en) * | 2017-04-28 | 2022-09-06 | 株式会社富士薬品 | Crystal forms and salts of 3-(3,5-dichloro-4-hydroxybenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole |
CN110621656A (en) * | 2017-05-12 | 2019-12-27 | 研究三角协会 | Diaryl ureas as CB1 allosteric modulators |
CN108938612A (en) * | 2017-05-22 | 2018-12-07 | 苏州偶领生物医药有限公司 | The purposes of aminomethylene hexamethylene 1,3- dione compounds |
CN108947985A (en) * | 2017-05-22 | 2018-12-07 | 苏州偶领生物医药有限公司 | Compound and its preparation method and application as autophagy regulator |
CN108929373A (en) * | 2017-05-22 | 2018-12-04 | 苏州偶领生物医药有限公司 | A kind of method of covalent bond modification mammal ATG8 homologue |
EP3630766A1 (en) | 2017-05-22 | 2020-04-08 | H. Hoffnabb-La Roche Ag | Therapeutic compounds and compositions, and methods of use thereof |
CN108069943A (en) * | 2017-05-23 | 2018-05-25 | 湖北工业大学 | A kind of potential inhibitor of bollworm sterol carrier protein 2 |
AR111960A1 (en) | 2017-05-26 | 2019-09-04 | Incyte Corp | CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION |
SI3632912T1 (en) * | 2017-06-01 | 2021-08-31 | Oncostellae, S.L. | Pyridoquinazoline derivatives useful as protein kinase inhibitors |
US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
SG11201911929XA (en) | 2017-06-21 | 2020-01-30 | SHY Therapeutics LLC | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
GB2563642A (en) * | 2017-06-22 | 2018-12-26 | Curadev Pharma Ltd | Small molecule modulators of human STING |
EA202090103A1 (en) | 2017-06-22 | 2020-04-24 | Селджин Корпорейшн | TREATMENT OF HEPATOCELLULAR CARCINOMA, WHICH IS CHARACTERIZED BY VIRAL INFECTION OF HEPATITIS B |
CN107233340B (en) * | 2017-06-27 | 2023-07-07 | 中国科学院上海有机化学研究所 | Application of aromatic ring medicine in inhibiting key transcription factor of malignant melanoma |
WO2019005685A1 (en) * | 2017-06-30 | 2019-01-03 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Chemical inhibition of the e3 ligase subunit fbx07 confers neuroprotection and anti-inflammatory activity by stabilizing mitochondria |
EP3651752A1 (en) | 2017-07-11 | 2020-05-20 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
US11548893B2 (en) | 2017-07-15 | 2023-01-10 | Arisan Therapeutics Inc. | Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection |
CN109384694B (en) * | 2017-08-10 | 2022-04-05 | 上海爱乐维生物科技有限公司 | SIRT6 small-molecule agonist and application thereof |
RU2662161C1 (en) * | 2017-08-11 | 2018-07-24 | Васильевич Иващенко Александр | Hepatitis virus penetration inhibitor and pharmaceutical composition for treatment of hepatitis |
CN107417578B (en) * | 2017-08-23 | 2020-02-07 | 沈阳海诺威医药科技有限公司 | N- (3, 5-dimethyl adamantane-1-yl) -N' -substituted phenylurea compound and preparation method and application thereof |
US11213525B2 (en) | 2017-08-24 | 2022-01-04 | Asceneuron Sa | Linear glycosidase inhibitors |
GB201713780D0 (en) * | 2017-08-29 | 2017-10-11 | E-Therapeutics Plc | Modulators of hedgehog (Hh) signalling pathway |
EP3675809B1 (en) | 2017-08-31 | 2023-09-27 | Basf Se | Use of physiological cooling ingredients and agents containing such active ingredients |
US11529354B2 (en) | 2017-09-05 | 2022-12-20 | President And Fellows Of Harvard College | Methods and compositions for the treatment of tuberculosis |
CN109467538A (en) | 2017-09-07 | 2019-03-15 | 和记黄埔医药(上海)有限公司 | The heteroaryl cyclics and application thereof that cycloolefin replaces |
SG11202002218VA (en) | 2017-09-15 | 2020-04-29 | Aduro Biotech Inc | Pyrazolopyrimidinone compounds and uses thereof |
TW201920170A (en) | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | Substituted inhibitors of MENIN-MLL and methods of use |
WO2019060692A1 (en) | 2017-09-21 | 2019-03-28 | Chimerix, Inc. | MORPHIC FORMS OF 4-AMINO-7-(3,4-DIHYDROXY-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL)-2-METHYL-7H-PYRROLO[2,3-d]PYRIMIDINE-5-CARBOXAMIDE AND USES THEREOF |
RU2764243C2 (en) | 2017-09-22 | 2022-01-14 | ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи | Heterocyclic compounds as pad inhibitors |
JP6965083B2 (en) * | 2017-10-04 | 2021-11-10 | 公益財団法人微生物化学研究会 | Compounds and luminescent compounds |
KR20200071752A (en) | 2017-10-18 | 2020-06-19 | 주빌런트 에피파드 엘엘씨 | Imidazo-pyridine compounds as PAD inhibitors |
US10526278B2 (en) | 2017-10-19 | 2020-01-07 | Wisconsin Alumni Research Foundation | Inhibitors of quorum sensing receptor LasR |
CA3083000A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
TWI695000B (en) | 2017-10-29 | 2020-06-01 | 中國醫藥大學 | Adam9 inhibitor compound and pharmaceutical composition thereof and use thereof |
BR112020008851A2 (en) | 2017-11-06 | 2020-10-20 | Jubilant Prodel LLC | compound of formula i, process for preparing compounds of formula i, pharmaceutical composition, method for treating and / or preventing various diseases, use, method for treating cancer, method of treating cancer and method for treating and / or prevention of cancer and infectious diseases |
EP3704120B1 (en) | 2017-11-24 | 2024-03-06 | Jubilant Episcribe LLC | Heterocyclic compounds as prmt5 inhibitors |
DK3716952T3 (en) | 2017-11-29 | 2022-03-14 | Kalvista Pharmaceuticals Ltd | DOSAGE FORMS INCLUDING A PLASMA CALLICIRE INHIBITOR |
GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
CN109942523B (en) * | 2017-12-20 | 2023-06-09 | 华东师范大学 | Benzofuran and benzofuran coumarin derivatives, and preparation method and application thereof |
CN111356676B (en) * | 2017-12-21 | 2022-09-27 | 广东众生睿创生物科技有限公司 | Amorphous form of pyrrolidine derivatives as PPAR agonists and process for their preparation |
CN108084116B (en) * | 2017-12-27 | 2019-07-23 | 上海应用技术大学 | A kind of acylhydrazone class neuraminidase inhibitor and preparation method thereof |
GB201801355D0 (en) * | 2018-01-26 | 2018-03-14 | Enterprise Therapeutics Ltd | Compounds |
WO2019152437A1 (en) * | 2018-01-30 | 2019-08-08 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
CN110143932B (en) * | 2018-02-12 | 2022-09-16 | 南开大学 | Piperazinone derivatives, process for producing the same, inhibitor, and method for controlling root-parasitic weeds |
US20200392223A1 (en) * | 2018-02-22 | 2020-12-17 | Tokai University Educational System | Il-17a activity inhibitor and use thereof |
BR112020017184A2 (en) | 2018-02-23 | 2020-12-22 | The Regents Of The University Of Michigan | EGFR-DIMMER DISRUPTORS AND USE OF THE SAME |
TW202000651A (en) | 2018-02-26 | 2020-01-01 | 美商建南德克公司 | Therapeutic compounds and methods of use thereof |
JP7426939B2 (en) * | 2018-03-01 | 2024-02-02 | トーマス・ヘレデイズ・スティフテルス・フォー・メディシンスク・フォルスクニング | Substituted benzodiazoles and their use in therapy |
AU2019231208A1 (en) * | 2018-03-05 | 2020-09-17 | Goldfinch Bio, Inc. | Imidazodiazepinediones and methods of use thereof |
AU2019230014A1 (en) | 2018-03-05 | 2020-09-17 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
PT3762380T (en) | 2018-03-05 | 2022-01-25 | Bristol Myers Squibb Co | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
CA3093527A1 (en) | 2018-03-13 | 2019-09-19 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation |
WO2019182944A1 (en) * | 2018-03-23 | 2019-09-26 | Allcron Pharma Inc. | Novel kinase inhibitors exhibiting anti-cancer activity and their method of use |
DK3774791T3 (en) | 2018-03-30 | 2023-01-23 | Incyte Corp | HETEROCYCLIC COMPOUNDS AS IMMUNE MODULATORS |
JP2021519788A (en) | 2018-03-30 | 2021-08-12 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Condensation ring hydropyrido compound as a sodium channel inhibitor |
MX2020010469A (en) * | 2018-04-06 | 2021-04-19 | Praxis Biotech LLC | Atf6 inhibitors and uses thereof. |
WO2019199864A1 (en) * | 2018-04-10 | 2019-10-17 | Neuropore Therapies, Inc. | Tri-substituted aryl and heteroaryl derivatives as modulators of pi3-kinase and autophagy pathways |
US11731964B2 (en) * | 2018-04-12 | 2023-08-22 | Purdue Research Foundation | Benzamide antibacterial agents |
EP3556755B1 (en) * | 2018-04-17 | 2021-11-17 | Masarykova univerzita | Substituted aminothiazoles as inhibitors of nucleases |
WO2019201291A1 (en) * | 2018-04-20 | 2019-10-24 | 中国科学院上海药物研究所 | Histone acetyltransferase (hat) inhibitor and use thereof |
WO2019204816A1 (en) | 2018-04-20 | 2019-10-24 | Virginia Tech Intellectual Properties, Inc. | Imidazopyridines useful as mitochondrial uncouplers |
US10919885B2 (en) * | 2018-04-25 | 2021-02-16 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
WO2019209083A1 (en) * | 2018-04-26 | 2019-10-31 | 재단법인 의약바이오컨버젼스연구단 | Novel compound as mtor inhibitor and use thereof |
JP2021523121A (en) | 2018-05-04 | 2021-09-02 | インサイト・コーポレイションIncyte Corporation | Solid form of FGFR inhibitor and its preparation process |
CA3099116A1 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Salts of an fgfr inhibitor |
BR112020022936A2 (en) | 2018-05-11 | 2021-02-02 | Incyte Corporation | tetrahydro-imidazo [4,5-c] pyridine derivatives as pd-l1 immunomodulators |
WO2019217834A1 (en) | 2018-05-11 | 2019-11-14 | University Of Florida Research Foundation, Incorporated | Myelination stimulator compounds, and methods of treatment |
CN108689960B (en) * | 2018-06-07 | 2022-03-04 | 济南大学 | 5-benzylidene-2-phenyl thiazolone compound and preparation and application thereof |
US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
EP3807382A1 (en) * | 2018-06-14 | 2021-04-21 | ChampionX USA Inc. | Carboxy alkyl-ester anti-agglomerants for the control of natural gas hydrates |
GB201810581D0 (en) | 2018-06-28 | 2018-08-15 | Ctxt Pty Ltd | Compounds |
CN110746355B (en) * | 2018-07-24 | 2023-08-11 | 中国科学院上海有机化学研究所 | Phenylpyrazole compound, pharmaceutical composition, and preparation method and application thereof |
US20210355103A1 (en) * | 2018-07-25 | 2021-11-18 | City Of Hope | Parg inhibitors and method of use thereof |
US10703735B2 (en) * | 2018-07-25 | 2020-07-07 | Lead Discovery Center Gmbh | 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer |
CN111892517A (en) * | 2018-08-08 | 2020-11-06 | 中国人民解放军总医院 | Antitumor compounds |
BR112020026493A2 (en) | 2018-08-17 | 2021-03-23 | Eidos Therapeutics, Inc. | AG10 FORMULATIONS |
US11731972B2 (en) | 2018-08-22 | 2023-08-22 | Asceneuron Sa | Spiro compounds as glycosidase inhibitors |
WO2020039028A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Tetrahydro-benzoazepine glycosidase inhibitors |
CN109776541B (en) * | 2018-08-29 | 2021-04-06 | 湖北工业大学 | Small-molecule inhibitor containing acridine dihydrogen and application thereof in inhibition of Ornithine Decarboxylase (ODC) |
CN109875987B (en) * | 2018-08-29 | 2021-05-14 | 湖北工业大学 | Benzamide small molecule inhibitor and application thereof in inhibition of ornithine decarboxylase |
US10358425B1 (en) | 2018-09-04 | 2019-07-23 | King Abdulaziz Universkty | Dihydropyrimidones and pharmaceutical compositions thereof |
WO2020049124A1 (en) * | 2018-09-05 | 2020-03-12 | Lead Discovery Center Gmbh | Inhibitors of glucose transporters (gluts) |
US20200129485A1 (en) | 2018-09-19 | 2020-04-30 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
CN113226356A (en) | 2018-09-19 | 2021-08-06 | 福马治疗股份有限公司 | Activating pyruvate kinase R |
EP3873214A4 (en) | 2018-10-29 | 2022-07-13 | Forma Therapeutics, Inc. | Solid forms of (4-(2-fluoro-4-(1-methyl-1 h-benzo[d]imidazol-5-yl)benzoyl) piperazin-1-yl)(1-hydroxycyclopropyl)methanone |
GB201818013D0 (en) * | 2018-11-05 | 2018-12-19 | Syngenta Participations Ag | Improvements in or relating to organic compunds |
KR102343865B1 (en) * | 2018-11-09 | 2021-12-28 | 한국화학연구원 | Compound inhibiting YAP-TEAD interaction and pharmaceutical composition for treating or preventing cancer comprising the same as an active ingredient |
CA3120388A1 (en) * | 2018-11-19 | 2020-05-28 | 11949098 Canada Inc. | Modulators of rar related orphan receptors (rors) |
JP2022508268A (en) * | 2018-11-28 | 2022-01-19 | バイオヴァーシス・アーゲー | 3- (Phenylsulfonyl)-[1,2,3] triazolo [1,5a] quinazoline-5 (4H) -one derivative |
EP3890715A4 (en) * | 2018-12-04 | 2023-03-29 | The Board Of Regents Of The University Of Texas System | Therapeutics targeting mutant adenomatous polyposis coli (apc) for the treatment of cancer |
KR102068299B1 (en) * | 2018-12-21 | 2020-01-20 | 한국기초과학지원연구원 | A pharmaceutical composition for prevention or treatment of metabolic disease comprising CYP4A inhibitor |
CN111349038B (en) * | 2018-12-24 | 2022-09-16 | 天津师范大学 | Indolylhydrazone compounds, preparation method thereof and application thereof in preventing and treating plant diseases |
JP2022516057A (en) | 2018-12-31 | 2022-02-24 | バイオメア フュージョン,エルエルシー | Irreversible inhibitor of menin-MLL interaction |
US11174263B2 (en) | 2018-12-31 | 2021-11-16 | Biomea Fusion, Inc. | Inhibitors of menin-MLL interaction |
EP3908268A1 (en) * | 2019-01-09 | 2021-11-17 | Yeda Research and Development Co. Ltd | Modulators of pin1 activity and uses thereof |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
CN109758468A (en) * | 2019-03-12 | 2019-05-17 | 中国药科大学 | Medical usage of the N- benzene substitution -2- hypoxanthine sulfenyl acetamide derivative in Killing Mycobacterium Tuberculosis infection |
CN109758469A (en) * | 2019-03-12 | 2019-05-17 | 中国药科大学 | Medical usage of the N- substitution -2- hypoxanthine sulfenyl acetamide derivative in Killing Mycobacterium Tuberculosis infection |
KR20210151849A (en) * | 2019-03-28 | 2021-12-14 | 에피자임, 인코포레이티드 | Quinoline derivatives and their use for the treatment of cancer |
CN110105269B (en) * | 2019-04-01 | 2023-03-24 | 兰州大学 | 1,4-diionic sulfur-containing ylide derivative based on asymmetric alkyne and preparation method thereof |
US20220213088A1 (en) * | 2019-04-30 | 2022-07-07 | Valo Health, Inc. | Inhibiting usp36 |
CN110003117B (en) * | 2019-05-06 | 2022-04-19 | 贵阳学院 | Ferulic acid amide derivative containing trifluoromethylpyrimidine, and preparation and application thereof |
CN109942498A (en) * | 2019-05-07 | 2019-06-28 | 湖南省农业生物技术研究所 | Phenyl pyrimidine derivative of the structure containing hydrazone and its preparation method and application |
CN111909138A (en) * | 2019-05-09 | 2020-11-10 | 上海仕谱生物科技有限公司 | Compounds that inhibit TDG activity |
CN110156729B (en) * | 2019-05-14 | 2022-12-06 | 浙江大学 | Phenylpiperazine UBE2F small-molecule inhibitor and synthetic method thereof |
US20220235011A1 (en) * | 2019-05-29 | 2022-07-28 | St Pharm Co., Ltd. | Phthalazinone compounds and use thereof |
PE20221003A1 (en) * | 2019-06-12 | 2022-06-15 | Tmem16A Ltd | COMPOUNDS TO TREAT RESPIRATORY DISEASE |
PE20220808A1 (en) | 2019-06-18 | 2022-05-20 | Pfizer | BENZISOXAZOLE SULFONAMIDE DERIVATIVES |
CN110946861A (en) * | 2019-06-24 | 2020-04-03 | 南开大学 | Adenosine A1Molecules with selective and antagonistic activity at receptors |
KR102276327B1 (en) * | 2019-06-25 | 2021-07-12 | 연세대학교 산학협력단 | Novel oxadiazole compound and composition for preventing or treating diabetes comprising the same |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
WO2021016449A1 (en) * | 2019-07-23 | 2021-01-28 | Board Of Regents, The University Of Texas System | Bicyclic cx3cr1 receptor agonists |
US11555010B2 (en) | 2019-07-25 | 2023-01-17 | Brown University | Diamide antimicrobial agents |
WO2021030162A1 (en) | 2019-08-09 | 2021-02-18 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
CN114206852A (en) | 2019-08-09 | 2022-03-18 | 卡尔维斯塔制药有限公司 | Plasma kallikrein inhibitors |
CN110372630B (en) * | 2019-08-26 | 2022-08-19 | 浙江工业大学 | Stilbene analogue containing phenylthiazole structure and synthesis method and application thereof |
US20220288033A1 (en) * | 2019-09-04 | 2022-09-15 | Agency For Science, Technology And Research | Heterocyclic compounds as modulators of beta-catenin / tcf4 interaction |
CN110627767B (en) * | 2019-09-05 | 2020-08-25 | 中国药科大学 | Selective butyrylcholinesterase inhibitor or pharmaceutically acceptable salt thereof, preparation method and application thereof |
AU2020356570A1 (en) * | 2019-09-25 | 2022-05-12 | Goldfinch Bio, Inc. | Xanthine CB1 inhibitors |
CR20220190A (en) | 2019-09-30 | 2022-06-15 | Incyte Corp | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
CN110590724B (en) * | 2019-10-09 | 2022-09-30 | 陕西理工大学 | 4-arylpyran derivative containing aryl urea and application thereof |
CN112057443B (en) * | 2019-10-12 | 2022-10-14 | 中国药科大学 | Medical application of benzene sulfonamide compound and pharmaceutical composition thereof |
CR20220169A (en) | 2019-10-14 | 2022-10-27 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
AU2020365108A1 (en) | 2019-10-18 | 2022-04-21 | Atengen, Inc. | 3-phenylsulphonyl-quinoline derivatives as agents for treating pathogenic blood vessels disorders |
CN112745319B (en) * | 2019-10-30 | 2022-06-17 | 中国科学院上海药物研究所 | Compound with substituted tricyclic structure, preparation method and application thereof |
CN114728919A (en) * | 2019-11-05 | 2022-07-08 | 德米拉公司 | MrgprX2 antagonists and uses thereof |
CN112778156B (en) * | 2019-11-08 | 2023-03-14 | 中国科学院上海药物研究所 | Bishydrazide structure compound, preparation method and application thereof |
WO2021096849A1 (en) | 2019-11-11 | 2021-05-20 | Incyte Corporation | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
CN111067889B (en) * | 2019-11-15 | 2022-11-18 | 徐州医科大学 | Application of 2-methyl naphtho [1,2-b ] furan compound in preparation of medicine related to diabetic nephropathy |
KR20210061202A (en) * | 2019-11-19 | 2021-05-27 | 일동제약(주) | Benzonitrile-substituted Fused pyrimidine derivatives and their pharmaceutical use |
WO2021097552A1 (en) * | 2019-11-22 | 2021-05-27 | Critical Outcome Technologies Inc. | Peptides, compounds, compositions and methods for inhibiting sox9 dimerization |
KR20230154292A (en) | 2019-11-25 | 2023-11-07 | 암젠 인크 | Heterocyclic Compounds as Delta-5 Desaturase Inhibitors and Methods of Use |
CN111004276B (en) * | 2019-11-28 | 2023-01-13 | 万华化学集团股份有限公司 | Phosphamide derivative, preparation method and catalytic application thereof |
CN110885318B (en) * | 2019-11-28 | 2022-12-23 | 苏州大学 | Benzoxazole derivative and preparation method and application thereof |
CN110840897B (en) * | 2019-11-28 | 2023-08-08 | 河北旺发生物科技有限公司 | Metal beta-lactamase inhibitors |
CN110922349B (en) * | 2019-11-29 | 2022-04-26 | 四川大学 | Synthesis of anti-tumor compound and application of anti-tumor compound in multiple myeloma |
CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
BR112022010664A2 (en) | 2019-12-04 | 2022-08-16 | Incyte Corp | DERIVATIVES OF A FGFR INHIBITOR |
US11834441B2 (en) | 2019-12-06 | 2023-12-05 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofurans as modulators of sodium channels |
JP2023508908A (en) | 2019-12-19 | 2023-03-06 | バイエル、アクチエンゲゼルシャフト | Freundazole derivative |
US11447479B2 (en) | 2019-12-20 | 2022-09-20 | Nuevolution A/S | Compounds active towards nuclear receptors |
WO2021146543A1 (en) * | 2020-01-15 | 2021-07-22 | The Trustees Of Princeton University | Inhibitors of glucose-6-phosphate dehydrogenase and uses thereof |
CN113214097B (en) * | 2020-01-21 | 2022-08-30 | 厦门大学 | Compounds for the treatment of alzheimer's disease |
TR202002069A2 (en) * | 2020-02-11 | 2021-08-23 | Bahcesehir Ueniversitesi | Physics-driven discovery of novel small therapeutic compounds for use as a bcl-2 inhibitor |
CN111362948B (en) * | 2020-03-04 | 2022-04-29 | 成都睿智化学研究有限公司 | Method for synthesizing pyrrole [3,4-c ] pyrazole-4, 6(1H,5H) diketone derivative |
AU2021233810A1 (en) * | 2020-03-09 | 2022-09-29 | The Regents Of The University Of California | FEMIB protein binding agents and uses thereof |
CN111233790A (en) * | 2020-03-13 | 2020-06-05 | 上海应用技术大学 | Acylhydrazone neuraminidase inhibitor and preparation method and application thereof |
CN111233714B (en) * | 2020-03-18 | 2022-04-08 | 滨海吉尔多肽有限公司 | Preparation method of MAPS polypeptide |
CN111303187B (en) * | 2020-03-25 | 2023-06-23 | 烟台显华化工科技有限公司 | Organic luminescent material and organic electroluminescent device |
CN111407767B (en) * | 2020-03-28 | 2021-05-25 | 中山大学 | Application of sulfamonomethoxine derivative in preparation of antitumor drugs |
MX2022012260A (en) | 2020-03-31 | 2022-11-30 | Nuevolution As | Compounds active towards nuclear receptors. |
AU2021249530A1 (en) | 2020-03-31 | 2022-12-01 | Nuevolution A/S | Compounds active towards nuclear receptors |
CN111529527B (en) * | 2020-06-17 | 2023-03-21 | 西南医科大学 | Application of benzamide compound in IAP protein inhibitor and preparation of antitumor drug |
GR1010098B (en) * | 2020-07-02 | 2021-10-08 | Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε, | Indol-3-carboxy esters as autotaxin inhibitors |
WO2022003439A1 (en) * | 2020-07-03 | 2022-01-06 | King Faisal University | Therapeutic agents for treating and preventing autoimmune diseases and cancer and a screening method |
CN111808074B (en) * | 2020-07-23 | 2023-04-14 | 河南中医药大学 | Hydrazone bond-containing pyrimidinehydrazine derivative transition metal cobalt (II) complex as well as preparation method and application thereof |
CN111892550B (en) * | 2020-08-25 | 2022-07-19 | 苏州大学 | 4-phenyl-6H-1, 3-oxazine-6-one derivatives, preparation and application thereof |
CN114105927B (en) * | 2020-08-31 | 2023-10-24 | 湖南超亟检测技术有限责任公司 | Construction of benzopyran nitrile fluorescent molecular probe and in-vitro diagnosis application thereof |
GB2598624A (en) * | 2020-09-07 | 2022-03-09 | Lorico Aurelio | Use of triazole analogues for inhibition of a tripartite VOR protein complex in multicellular organisms |
KR102409345B1 (en) * | 2020-09-22 | 2022-06-16 | 가톨릭대학교 산학협력단 | Nlrp3 inflammasome inhibitor and uses thereof |
WO2022065424A1 (en) * | 2020-09-25 | 2022-03-31 | 国立研究開発法人理化学研究所 | Carcinostatic agent, carcinogenesis inhibitor and life-prolonging agent, comprising novel compound with mtorc1 inhibitory effect |
KR20230129384A (en) | 2020-11-02 | 2023-09-08 | 트레테라 코퍼레이션 | Crystalline forms of deoxycytidine kinase inhibitors and their uses |
US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
WO2022099075A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Crystalline form of a pd-1/pd-l1 inhibitor |
CN112250598B (en) * | 2020-11-06 | 2023-07-25 | 河南科技大学 | Paeonol hydrazone derivative, preparation method and application thereof, and pesticide |
IL302590A (en) | 2020-11-06 | 2023-07-01 | Incyte Corp | Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof |
CN114478537B (en) * | 2020-11-13 | 2024-02-02 | 上海拓界生物医药科技有限公司 | Cyclic amide parallel-ring compound and medical application thereof |
CN114504579A (en) * | 2020-11-17 | 2022-05-17 | 华东师范大学 | Compound for preventing and treating pain and inflammation and application thereof |
EP4247375A1 (en) | 2020-11-18 | 2023-09-27 | Southern Research Institute | Compounds for the treatment of acute and chronic kidney disease |
CN116507621A (en) * | 2020-11-24 | 2023-07-28 | 江苏恒瑞医药股份有限公司 | Pyrimidine diketone derivative, preparation method and medical application thereof |
CN112300094B (en) * | 2020-11-24 | 2022-12-16 | 中国人民解放军海军军医大学 | Substituted benzoyl piperazine compounds and application thereof in preparation of anti-chikungunya virus medicines |
CN116745267A (en) * | 2020-12-11 | 2023-09-12 | 跨膜蛋白16A有限公司 | Benzimidazole derivatives for the treatment of respiratory diseases |
CN115536655B (en) * | 2021-06-29 | 2024-01-05 | 深圳开悦生命科技有限公司 | Polycyclic compound for inhibiting RNA helicase DHX33 |
US20220194957A1 (en) * | 2020-12-17 | 2022-06-23 | Purdue Research Foundation | Inhibitors of cyclic mono- and di-nucleotide phosphodiesterases and the uses thereof |
CN114716409B (en) * | 2021-01-05 | 2024-01-12 | 西北农林科技大学 | Diphenyl pyrazole compound and preparation method and application thereof |
CN112920178A (en) * | 2021-01-29 | 2021-06-08 | 中国药科大学 | Compound with benzimidazole structure and preparation method and application thereof |
CN116981669A (en) * | 2021-02-05 | 2023-10-31 | 上海齐鲁制药研究中心有限公司 | Pyrimidine or pyrido heterocyclic adenosine receptor inhibitor, preparation method and application thereof |
CN112961091B (en) * | 2021-02-07 | 2022-06-17 | 深圳深信生物科技有限公司 | Amino lipide compound and preparation method and application thereof |
WO2022179940A1 (en) | 2021-02-23 | 2022-09-01 | Bayer Aktiengesellschaft | Furoindazole derivatives as gpr84 antagonists |
CN112979490B (en) * | 2021-03-03 | 2022-11-25 | 深圳海创生物科技有限公司 | Compound, composition and application thereof in preparation of product with antioxidant or anti-inflammatory effects |
US11834451B2 (en) * | 2021-03-29 | 2023-12-05 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for inhibiting virus protein 2C activity and for preventing and treating non-polio enterovirus infection |
JP2024513538A (en) * | 2021-04-12 | 2024-03-25 | インパクト セラピューティクス (シャンハイ), インコーポレイテッド | Substituted fused bicyclic compounds and their use as PARP inhibitors |
CN113101291A (en) * | 2021-04-14 | 2021-07-13 | 浙江大学 | Application of sulfonamide compound in preparation of medicine for treating autoimmune diseases |
CA3218018A1 (en) | 2021-04-29 | 2022-11-03 | Bayer Aktiengesellschaft | Furoindazole derivatives as antagonists or inhibitors of gpr84 |
CN113244208B (en) * | 2021-05-20 | 2022-07-12 | 云南中医药大学 | Application of HPA in preparation of medicine for treating non-alcoholic fatty liver disease |
CN113274391B (en) * | 2021-06-01 | 2022-07-05 | 苏州大学 | Preparation of pyrazole derivatives in P2Y6Application of R-related medicament for treating atherosclerosis and resisting inflammation |
IL308997A (en) * | 2021-06-02 | 2024-02-01 | Otsuka Pharma Co Ltd | Pyrazolo[1,5-a]pyrimidine compound for the treatment of dermal disorders |
EP4347031A1 (en) | 2021-06-04 | 2024-04-10 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
AR126102A1 (en) | 2021-06-09 | 2023-09-13 | Incyte Corp | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS |
CN113956215B (en) * | 2021-07-15 | 2022-08-12 | 暨南大学附属第一医院 | Application of polycyclic aryl compound in preparation of antifungal drugs |
IL310389A (en) * | 2021-07-29 | 2024-03-01 | Merck Patent Gmbh | Srpk inhibitors |
CN113416181B (en) * | 2021-08-02 | 2022-05-03 | 四川大学 | Quinazoline derivative and application thereof |
TW202321229A (en) * | 2021-08-18 | 2023-06-01 | 美商富曼西公司 | Fungicidal substituted heterocycles |
WO2023047107A1 (en) * | 2021-09-22 | 2023-03-30 | The University Of Durham | Aryl or heteroaryl derived compounds for the treatments of microbial infections |
CN113912595B (en) * | 2021-10-12 | 2024-03-15 | 中国药科大学 | Compound containing thiazole or thiadiazole structure and application thereof |
WO2023078252A1 (en) | 2021-11-02 | 2023-05-11 | Flare Therapeutics Inc. | Pparg inverse agonists and uses thereof |
WO2023081967A1 (en) * | 2021-11-10 | 2023-05-19 | The University Of Western Australia | Compounds and uses therefor |
KR20230072623A (en) * | 2021-11-18 | 2023-05-25 | 한국원자력의학원 | Compound for inhibiting tankyrase and medical use thereof |
CN114105963B (en) * | 2021-12-16 | 2023-08-18 | 贵州大学 | Anti-tubercle bacillus compound and preparation method and application thereof |
CN114308121B (en) * | 2022-01-04 | 2024-02-23 | 浙江工业大学 | Phosphine oxide catalyst and preparation method and application thereof |
CN116440142A (en) * | 2022-01-07 | 2023-07-18 | 南湖实验室 | Use of glycerophosphorylcholine for anti-aging and/or for prolonging life |
CN114539204B (en) * | 2022-03-23 | 2023-08-22 | 福建金兰厚普生物科技有限公司 | Hexokinase inhibitor and synthesis method and application thereof |
CN114478464B (en) * | 2022-03-23 | 2023-02-03 | 福建金兰厚普生物科技有限公司 | Inflammatory corpuscle selective inhibitor and synthetic method and application thereof |
CN114533726B (en) * | 2022-04-25 | 2022-09-09 | 北京大学第三医院(北京大学第三临床医学院) | Small molecule drug for inhibiting fibrosis and application thereof |
EP4273147A1 (en) | 2022-05-05 | 2023-11-08 | Bayer Aktiengesellschaft | Substituted spirolactams, salts thereof and their use as herbicidally active substances |
CN117137914A (en) * | 2022-05-24 | 2023-12-01 | 中国人民解放军军事科学院军事医学研究院 | Use of N- (pyridin-2-yl) pyridine-2-thioamides or salts thereof in the preparation of anti-hypoxic drugs |
KR20240002032A (en) * | 2022-06-28 | 2024-01-04 | 동국대학교 산학협력단 | Novel compounds as NADPH oxidase 2 inhibitors and pharmaceutical composition comprising the same |
CN115232101B (en) * | 2022-06-30 | 2024-02-27 | 河南科技大学 | 1-acyloxy sesamol derivative and preparation method and application thereof |
CN114948965B (en) * | 2022-07-18 | 2023-11-10 | 四川大学华西第二医院 | Application of compound in preparation of medicine for preventing and treating tissue injury |
CN115463132A (en) * | 2022-09-01 | 2022-12-13 | 中国人民解放军军事科学院军事医学研究院 | Application of compound way-235035 in preparing medicine related to HIV-1 virus |
CN115490669B (en) * | 2022-09-13 | 2024-02-09 | 哈尔滨工业大学(深圳) | Indolal compound and preparation method and application thereof |
CN115433164B (en) * | 2022-09-14 | 2023-12-12 | 南京师范大学 | Nicotinamide derivative, preparation method thereof and application thereof in resisting aging and prolonging life |
CN115626912B (en) * | 2022-09-27 | 2024-03-26 | 中山大学 | Thiourea compound and preparation method and application thereof |
CN115466229A (en) * | 2022-10-25 | 2022-12-13 | 上海中医药大学 | P-acylamino benzenesulfonyl compound and application thereof |
CN116210706A (en) * | 2023-02-03 | 2023-06-06 | 河北工业大学 | Application of alkaloid polyaurine B derivative in resisting plant virus and germ |
CN116808028B (en) * | 2023-08-25 | 2023-11-14 | 深圳市第三人民医院(深圳市肝病研究所) | Application of benzothiazole derivative compound as antituberculosis compound |
CN117285533B (en) * | 2023-11-24 | 2024-01-30 | 四川省医学科学院·四川省人民医院 | CD47/SIRP alpha small molecule inhibitor, application thereof and anti-tumor pharmaceutical composition |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5640634A (en) * | 1979-09-10 | 1981-04-16 | Eisai Co Ltd | Cyclohexane derivative, its preparation, and pharmaceutical containing the same |
US4350705A (en) * | 1979-03-31 | 1982-09-21 | Eisai Co., Ltd. | Cyclohexane derivatives, process for preparation thereof and medicines containing these cyclohexane derivatives |
US7618774B2 (en) * | 2003-02-28 | 2009-11-17 | University Of Rochester | Materials and methods for identifying genes and/or agents that alter replicative lifespan |
US20050096256A1 (en) * | 2003-07-01 | 2005-05-05 | President And Fellows Of Harvard College | Compositions for manipulating the lifespan and stress response of cells and organisms |
GB0419075D0 (en) * | 2004-08-26 | 2004-09-29 | Syngenta Participations Ag | Process |
GB0504103D0 (en) * | 2005-02-28 | 2005-04-06 | Syngenta Ltd | Novel method |
US8354451B2 (en) * | 2009-03-09 | 2013-01-15 | The Uwm Research Foundation, Inc. | Treatment of microbial infections with compounds that inhibit 4-hydroxyphenylpyruvate dioxygenase |
-
2008
- 2008-12-22 CA CA2709784A patent/CA2709784A1/en not_active Abandoned
- 2008-12-22 US US12/341,615 patent/US8642660B2/en active Active
- 2008-12-22 AU AU2008345225A patent/AU2008345225A1/en not_active Abandoned
- 2008-12-22 EP EP08867410A patent/EP2219646A4/en not_active Withdrawn
- 2008-12-22 JP JP2010539936A patent/JP2011507910A/en active Pending
- 2008-12-22 WO PCT/US2008/088016 patent/WO2009086303A2/en active Application Filing
Non-Patent Citations (1)
Title |
---|
See references of EP2219646A4 * |
Cited By (278)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8518960B2 (en) | 2007-05-23 | 2013-08-27 | Siga Technologies, Inc. | Antiviral drugs for treatment or prevention of dengue infection |
US9353051B2 (en) | 2007-05-23 | 2016-05-31 | Siga Technologies, Inc. | Antiviral drugs for treatment or prevention of dengue infection |
US8642597B2 (en) | 2007-08-27 | 2014-02-04 | Basf Se | Pyrazole compounds for controlling invertebrate pests |
US9204647B2 (en) | 2007-08-27 | 2015-12-08 | Basf Se | Pyrazole compounds for controlling invertebrate pests |
JP2014065729A (en) * | 2008-04-29 | 2014-04-17 | Novartis Ag | Spiro-indole derivative for treating parasitic diseases |
WO2010001365A1 (en) * | 2008-07-04 | 2010-01-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Nitrogen heterocycle derivatives as proteasome modulators |
US8481532B2 (en) | 2008-07-09 | 2013-07-09 | Envivo Pharmaceuticals, Inc. | PDE-10 inhibitors |
WO2010006130A3 (en) * | 2008-07-09 | 2010-04-22 | Envivo Pharmaceuticals, Inc. | Pde-10 inhibitors |
EP2310016A4 (en) * | 2008-08-05 | 2011-09-21 | Omeros Corp | Pde10 inhibitors and related compositions and methods |
US9783521B2 (en) | 2008-08-05 | 2017-10-10 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
EP2310016A1 (en) * | 2008-08-05 | 2011-04-20 | Omeros Corporation | Pde10 inhibitors and related compositions and methods |
US8377930B2 (en) | 2008-08-05 | 2013-02-19 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
EP2321303B1 (en) * | 2008-08-27 | 2019-11-27 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
JP2015120710A (en) * | 2008-08-29 | 2015-07-02 | ゼンション・リミテッドXention Limited | Novel potassium channel blocker |
JP2017014267A (en) * | 2008-08-29 | 2017-01-19 | 日本たばこ産業株式会社 | Novel potassium channel blocker |
EP2344456B1 (en) * | 2008-08-29 | 2018-07-25 | Japan Tobacco Inc. | Novel potassium channel blocker |
US8853125B2 (en) | 2008-09-24 | 2014-10-07 | Basf Se | Pyrazole compounds for controlling invertebrate pests |
US9375008B2 (en) | 2008-09-24 | 2016-06-28 | Basf Se | Pyrazole compounds for controlling invertebrate pests |
US8729083B2 (en) | 2008-09-24 | 2014-05-20 | Basf Se | Pyrazole compounds for controlling invertebrate pests |
WO2010034738A3 (en) * | 2008-09-24 | 2010-10-07 | Basf Se | Pyrazole compounds for controlling invertebrate pests |
US9586880B2 (en) | 2008-12-23 | 2017-03-07 | President And Fellows Of Harvard College | Small molecule inhibitors of necroptosis |
WO2010072805A3 (en) * | 2008-12-24 | 2011-04-28 | Unilever Plc | Method and composition for skin color modulation |
JP2012518038A (en) * | 2009-02-18 | 2012-08-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Heterocyclic compounds that modulate the CB2 receptor |
US8889670B2 (en) | 2009-02-18 | 2014-11-18 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds which modulate the CB2 receptor |
EP2405751A4 (en) * | 2009-03-12 | 2012-08-08 | Apogee Biotechnology Corp | Sphingosine kinase inhibitor prodrugs |
EP2405751A1 (en) * | 2009-03-12 | 2012-01-18 | Apogee Biotechnology Corporation | Sphingosine kinase inhibitor prodrugs |
EP2411529A4 (en) * | 2009-03-27 | 2012-09-19 | Zacharon Pharmaceuticals Inc | N-linked glycan biosynthesis modulators |
EP2411529A2 (en) * | 2009-03-27 | 2012-02-01 | Zacharon Pharmaceuticals, Inc. | N-linked glycan biosynthesis modulators |
US9657004B2 (en) | 2009-04-06 | 2017-05-23 | Agios Pharmaceuticals, Inc | Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use |
US9938259B2 (en) | 2009-04-06 | 2018-04-10 | Agios Pharmaceuticals, Inc. | Therapeutic compositions and related methods of use |
US11866411B2 (en) | 2009-06-29 | 2024-01-09 | Agios Pharmaceutical, Inc. | Therapeutic compounds and compositions |
US10029987B2 (en) | 2009-06-29 | 2018-07-24 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
USRE49582E1 (en) | 2009-06-29 | 2023-07-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
US10988448B2 (en) | 2009-06-29 | 2021-04-27 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
US9029639B2 (en) | 2009-07-06 | 2015-05-12 | Basf Se | Pyridazine compounds for controlling invertebrate pests |
US8710056B2 (en) | 2009-07-06 | 2014-04-29 | Basf Se | Pyridazine compounds for controlling invertebrate pests |
US9125414B2 (en) | 2009-07-24 | 2015-09-08 | Basf Se | Pyridine derivatives compounds for controlling invertebrate pests |
US9315454B2 (en) | 2010-01-15 | 2016-04-19 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
JP2013518129A (en) * | 2010-01-28 | 2013-05-20 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | Compositions and methods for improving proteasome activity |
JP2011213655A (en) * | 2010-03-31 | 2011-10-27 | Eci Inc | Inhibitor of interaction between front protein and ccr2b or ccr5 |
CN102947272A (en) * | 2010-05-12 | 2013-02-27 | 沃泰克斯药物股份有限公司 | 2 -aminopyridine derivatives useful as inhibitors of atr kinase |
CN103097340B (en) * | 2010-07-16 | 2018-03-16 | 安吉奥斯医药品有限公司 | Therapeutic activity composition and its application method |
CN103097340A (en) * | 2010-07-16 | 2013-05-08 | 安吉奥斯医药品有限公司 | Therapeutically active compositions and their method of use |
US8895606B2 (en) | 2010-08-24 | 2014-11-25 | Actelion Pharmaceuticals Ltd. | Proline sulfonamide derivatives as orexin receptor antagonists |
US9000029B2 (en) | 2010-08-24 | 2015-04-07 | Actelion Pharmaceuticals Ltd. | Proline sulfonamide derivatives as orexin receptor antagonists |
US9211279B2 (en) | 2010-08-24 | 2015-12-15 | Actelion Pharmaceuticals Ltd. | Proline sulfonamide derivatives as orexin receptor antagonists |
CN103282354B (en) * | 2010-09-01 | 2016-05-04 | 拜耳知识产权有限责任公司 | N-(tetrazolium-5-yl)-and N-(triazole-5-yl) aryl carboxamides and as the purposes of herbicide |
CN103282354A (en) * | 2010-09-01 | 2013-09-04 | 拜耳知识产权有限责任公司 | N-(tetrazol-5-l)- and n-(triazol-5-yl)arylcarboxamides and use thereof as herbicides |
US10701938B2 (en) | 2010-10-25 | 2020-07-07 | Vanderbilt University | Composition for inhibition of insect host sensing |
US10091997B2 (en) | 2010-10-25 | 2018-10-09 | Vanderbilt University | Composition for inhibition of insect host sensing |
US9371333B2 (en) | 2010-11-12 | 2016-06-21 | Deutsches Krebsforschungszentrum | Chromene derivatives and their analoga as Wnt pathway antagonists |
WO2012062905A3 (en) * | 2010-11-12 | 2013-01-03 | Deutsches Krebsforschungszentrum (Dkfz) | Chromene derivatives and their analoga as wnt pathway antagonists |
US10065939B2 (en) | 2010-11-12 | 2018-09-04 | Deutsches Krebsforschungszentrum | Chromene derivatives and their analogs as Wnt pathway antagonists |
US9221792B2 (en) | 2010-12-17 | 2015-12-29 | Agios Pharmaceuticals, Inc | N-(4-(azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase M2 (PMK2) modulators |
US10087169B2 (en) | 2010-12-21 | 2018-10-02 | Agios Pharmaceuticals, Inc. | Bicyclic PKM2 activators |
US9328077B2 (en) | 2010-12-21 | 2016-05-03 | Agios Pharmaceuticals, Inc | Bicyclic PKM2 activators |
WO2012097196A1 (en) * | 2011-01-12 | 2012-07-19 | Acea Biosciences Inc. | Pyrazolopyrimidine derivatives and uses as anticancer agents |
CN102993193B (en) * | 2011-03-09 | 2015-05-27 | 四川大学 | Use of nitrogen-3-isoxazolyl-3-4-thienyl-pyrimidyl sulfonyl propanamide derivative in preparing anti-tumor medicines |
CN102993193A (en) * | 2011-03-09 | 2013-03-27 | 四川大学 | Use of nitrogen-3-isoxazolyl-3-4-thienyl-pyrimidyl sulfonyl propanamide derivative in preparing anti-tumor medicines |
WO2012127214A1 (en) | 2011-03-18 | 2012-09-27 | Pronoxis Ab | Quinolinone derivatives for use in the treatment of an autoimmune disease and/or an inflammatory disease |
CN102190598B (en) * | 2011-03-28 | 2014-01-29 | 浙江工业大学 | Cyclopropane oxime ester derivatives and preparation method and application thereof |
CN102190598A (en) * | 2011-03-28 | 2011-09-21 | 浙江工业大学 | Cyclopropane oxime ester derivatives and preparation method and application thereof |
US10632114B2 (en) | 2011-05-03 | 2020-04-28 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use in therapy |
US9980961B2 (en) | 2011-05-03 | 2018-05-29 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use in therapy |
US11793806B2 (en) | 2011-05-03 | 2023-10-24 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use in therapy |
US9181231B2 (en) | 2011-05-03 | 2015-11-10 | Agios Pharmaceuticals, Inc | Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia |
EP2704575B1 (en) * | 2011-05-06 | 2020-06-03 | Vanderbilt University | Composition for inhibition of insect sensing |
US10813355B2 (en) | 2011-05-06 | 2020-10-27 | Vanderbilt University | Compositions for inhibition of insect sensing |
US10188105B2 (en) | 2011-05-06 | 2019-01-29 | Vanderbilt University | Compositions for inhibition of insect sensing |
WO2012152983A1 (en) * | 2011-05-06 | 2012-11-15 | Orion Corporation | Phenyl- sulfonyl derivatives as mediators of trpa1 receptor activity for the treatment of pain |
EP2520566A1 (en) * | 2011-05-06 | 2012-11-07 | Orion Corporation | New Pharmaceutical Compounds |
EP3653054A1 (en) * | 2011-05-06 | 2020-05-20 | Vanderbilt University | Composition for inhibition of insect sensing |
US11484032B2 (en) | 2011-05-06 | 2022-11-01 | Vanderbilt University | Compositions for inhibition of insect sensing |
CN102382127A (en) * | 2011-09-23 | 2012-03-21 | 复旦大学 | Myocardial small molecular compound for idiosyncratically promoting proliferation of myocardial cells and application thereof |
US10111859B2 (en) | 2011-11-14 | 2018-10-30 | Ligand Pharmaceuticals, Inc. | Methods and compositions associated with the granulocyte colony-stimulating factor receptor |
US10736875B2 (en) | 2011-11-14 | 2020-08-11 | Ligand Pharmaceuticals, Inc. | Methods and compositions associated with the granulocyte colony-stimulating factor receptor |
US11413274B2 (en) | 2011-11-14 | 2022-08-16 | Ligand Pharmaceuticals, Inc. | Methods and compositions associated with the granulocyte colony-stimulating factor receptor |
US9422276B2 (en) | 2011-11-25 | 2016-08-23 | Bayer Intellectual Property Gmbh | Use of aryl and hetaryl carboxamides as endoparasiticides |
US9751857B2 (en) | 2011-12-21 | 2017-09-05 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
US9676747B2 (en) | 2011-12-21 | 2017-06-13 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
US10196376B2 (en) | 2011-12-21 | 2019-02-05 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
US9399647B2 (en) | 2012-01-25 | 2016-07-26 | Proteostasis Therapeutics, Inc. | Proteasome activity modulating compounds |
EP2806875A4 (en) * | 2012-01-25 | 2015-10-21 | Proteostasis Therapeutics Inc | Proteasome activity modulating compounds |
US9453012B2 (en) | 2012-03-06 | 2016-09-27 | Compound Handling B.V. | Aminomethylene pyrazolones with therapeutic activity |
US9676764B2 (en) | 2012-03-06 | 2017-06-13 | Compound Handling B.V. | Aminomethylene pyrazolones with therapeutic activity |
WO2013131931A1 (en) | 2012-03-06 | 2013-09-12 | Compound Handling B.V. | Aminomethylene pyrazolones with therapeutic activity |
US9790205B2 (en) | 2012-03-06 | 2017-10-17 | Compound Handling B.V. | Aminomethylene pyrazolones with therapeutic activity |
US10071987B2 (en) | 2012-03-06 | 2018-09-11 | Compound Handling B.V. | Aminomethylene pyrazolones with therapeutic activity |
CN103373936B (en) * | 2012-04-16 | 2015-12-02 | 南京大学连云港高新技术研究院 | One class contains phenylacetamide analog derivative and the method for making thereof of class paracetamol structure |
CN103373936A (en) * | 2012-04-16 | 2013-10-30 | 南京大学连云港高新技术研究院 | Acetaminophen containing phenylacetamide derivatives and preparation methods thereof |
JP2020203948A (en) * | 2012-05-11 | 2020-12-24 | シンクロニシティ ファーマ, インコーポレイテッド | Carbazole-containing sulfonamides as cryptochrome modulators |
JP2019077722A (en) * | 2012-05-11 | 2019-05-23 | シンクロニシティ ファーマ, インコーポレイテッド | Carbazole-containing sulfonamides as cryptochrome modulators |
JP2015520152A (en) * | 2012-05-11 | 2015-07-16 | リセット セラピューティークス, インコーポレイテッド | Carbazole-containing sulfonamides as cryptochrome modulators |
US10995064B2 (en) | 2012-08-28 | 2021-05-04 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
WO2014057080A3 (en) * | 2012-10-12 | 2014-07-10 | H. Lundbeck A/S | N-(2-(cyclic amine)ethyl)benzamide derivatives as p2x7 inhibitors |
US9593105B2 (en) | 2012-10-12 | 2017-03-14 | H. Lundbeck A/S | Cyclic amines |
US10124010B2 (en) | 2012-10-12 | 2018-11-13 | Mindimmune Therapeutics, Inc. | Cyclic amines |
US9861639B2 (en) | 2012-10-12 | 2018-01-09 | H. Lundbeck A/S | Cyclic amines |
US9108938B2 (en) | 2012-10-12 | 2015-08-18 | H. Lundbeck A/S | Cyclic amines |
US9415055B2 (en) | 2012-10-12 | 2016-08-16 | H. Lundbeck A/S | Cyclic amines |
CN103739594A (en) * | 2012-10-17 | 2014-04-23 | 南京大学 | Schiff base derivatives containing pyrazine ring and triazole structure and preparation method of the derivatives |
CN102964279A (en) * | 2012-12-12 | 2013-03-13 | 中国药科大学 | Kappa-opioid receptor agonists with peripheral analgesic effect |
CN104837490B (en) * | 2012-12-13 | 2017-10-03 | 诺华股份有限公司 | It is used as (3H, 10H) diketone of pyrimido [4,5 b] quinoline 4,5 of nonsense mutation repressor |
CN104837490A (en) * | 2012-12-13 | 2015-08-12 | 诺华股份有限公司 | Pyrimido [4,5-b]quinoline-4,5 (3H,10H)-diones as nonsense mutation suppressors |
US9649314B2 (en) | 2012-12-13 | 2017-05-16 | Novartis Ag | Pyrimido[4,5-b]quinoline-4,5(3H,10H)-diones |
KR101760586B1 (en) | 2012-12-13 | 2017-07-21 | 노파르티스 아게 | Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors |
EA028673B1 (en) * | 2012-12-13 | 2017-12-29 | Новартис Аг | PYRIMIDO[4,5-b]QUINOLINE-4,5-(3H,10H)DIONES AS NONSENSE MUTATION SUPPRESSORS |
CN107569487A (en) * | 2012-12-13 | 2018-01-12 | 诺华股份有限公司 | Pyrimido [4,5 b] quinoline 4,5 (3H, 10H) diketone as nonsense mutation repressor |
WO2014091446A1 (en) * | 2012-12-13 | 2014-06-19 | Novartis Ag | Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors |
WO2014117919A1 (en) | 2013-02-04 | 2014-08-07 | Merck Patent Gmbh | Positive allosteric modulators of mglur3 |
US9862746B2 (en) | 2013-02-15 | 2018-01-09 | The Regents Of The University Of Michigan | Compositions and methods relating to hindering DOT1L recruitment by MLL-fusion proteins |
EP2956470A4 (en) * | 2013-02-15 | 2016-12-07 | Univ Michigan Regents | Compositions and methods relating to hindering dot1l recruitment by mll-fusion proteins |
US10941113B2 (en) | 2013-02-28 | 2021-03-09 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
US10125094B2 (en) | 2013-02-28 | 2018-11-13 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
US10035801B2 (en) | 2013-03-13 | 2018-07-31 | Genentech, Inc. | Pyrazolo compounds and uses thereof |
US9365545B2 (en) | 2013-03-15 | 2016-06-14 | Agios Pharmaceuticals, Inc | Therapeutic compounds and compositions |
US9725452B2 (en) | 2013-03-15 | 2017-08-08 | Presidents And Fellows Of Harvard College | Substituted indoles and pyrroles as RIP kinase inhibitors |
US10193086B2 (en) | 2013-03-26 | 2019-01-29 | Semiconductor Energy Laboratory Co., Ltd. | Light-emitting element, compound, Organic compound, display module, lighting module, light-emitting device, display device, lighting device, and electronic device |
US10700291B2 (en) | 2013-03-26 | 2020-06-30 | Semiconductor Energy Laboratory Co., Ltd. | Light-emitting element, compound, organic compound, display module, lighting module, light-emitting device, display device, lighting device, and electronic device |
US9905782B2 (en) | 2013-03-26 | 2018-02-27 | Semiconductor Energy Laboratory Co., Ltd. | Light-emitting element, compound, organic compound, display module, lighting module, light-emitting device, display device, lighting device, and electronic device |
US11600789B2 (en) | 2013-03-26 | 2023-03-07 | Semiconductor Energy Laboratory Co., Ltd. | Light-emitting element, compound, organic compound, display module, lighting module, light-emitting device, display device, lighting device, and electronic device |
US9895349B2 (en) | 2013-04-03 | 2018-02-20 | Janssen Sciences Ireland Us | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10398677B2 (en) | 2013-04-03 | 2019-09-03 | Janssen Sciences Ireland Uc | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US9067922B2 (en) | 2013-04-19 | 2015-06-30 | Pfizer Limited | Chemical compounds |
US11725004B2 (en) | 2013-05-17 | 2023-08-15 | Centrexion Therapeutics Corporation | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
US10112934B2 (en) | 2013-05-17 | 2018-10-30 | Centrexion Therapeutics Corporation | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
US9884818B2 (en) | 2013-05-17 | 2018-02-06 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US9650370B2 (en) | 2013-05-17 | 2017-05-16 | Centrexion Therapeutics Corporation | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
US10570125B2 (en) | 2013-05-17 | 2020-02-25 | Centrexion Therapeutics Corporation | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
US11084810B2 (en) | 2013-05-17 | 2021-08-10 | Centrexion Therapeutics Corporation | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
US8865744B1 (en) | 2013-05-17 | 2014-10-21 | Boehringer Ingelheim International Gmbh | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
US10457638B2 (en) | 2013-05-17 | 2019-10-29 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
CN105452248A (en) * | 2013-05-23 | 2016-03-30 | 新加坡科技研究局 | Purine diones as WNT pathway modulators |
CN109776537B (en) * | 2013-05-23 | 2021-12-14 | 新加坡科技研究局 | Purine diones as WNT pathway modulators |
CN109776537A (en) * | 2013-05-23 | 2019-05-21 | 新加坡科技研究局 | Purinedione as WNT pathway modulators |
CN105377849A (en) * | 2013-06-17 | 2016-03-02 | 巴斯夫欧洲公司 | Substituted pyrimidinium compounds and derivatives for combating animal pests |
CN105377849B (en) * | 2013-06-17 | 2018-01-26 | 巴斯夫欧洲公司 | For preventing and kill off the substituted pyrimidines * compounds and derivative of animal pest |
US10450270B2 (en) | 2013-07-25 | 2019-10-22 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
EP2832233A1 (en) | 2013-07-30 | 2015-02-04 | IMAX Discovery GmbH | 1H-pyrrole-2,4-dicarbonyl-derivatives and their use as flavoring agents |
WO2015022200A1 (en) * | 2013-08-13 | 2015-02-19 | Ernst-Moritz-Arndt-Universität Greifswald | Metallo-acylhydrazone complexes and use thereof in preventing the development of or eliminating tumoral resistance to cytostatics and for treating tumours (anti-tumour agents) |
US10377709B2 (en) | 2013-10-23 | 2019-08-13 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10071961B2 (en) | 2013-10-23 | 2018-09-11 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9505722B2 (en) | 2014-01-16 | 2016-11-29 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9873671B2 (en) | 2014-01-16 | 2018-01-23 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9339510B2 (en) | 2014-01-16 | 2016-05-17 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
CN103804273A (en) * | 2014-01-27 | 2014-05-21 | 贵州大学 | Oxindole and ninhydrin bis-quaternary carbon splicing derivative and preparation method thereof |
US10632112B2 (en) | 2014-02-05 | 2020-04-28 | Novira Therapeutics, Inc. | Combination therapy for treatment of HBV infections |
US10213420B2 (en) | 2014-02-05 | 2019-02-26 | Novira Therapeutics, Inc. | Combination therapy for treatment of HBV infections |
US11078193B2 (en) | 2014-02-06 | 2021-08-03 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
CN103755659A (en) * | 2014-02-25 | 2014-04-30 | 山东大学 | 6-cinnamon acyl-2H-benzo [b] [1, 4] oxazine-3 (4H)-ketone compound and application thereof |
CN103755659B (en) * | 2014-02-25 | 2015-07-15 | 山东大学 | 6-cinnamon acyl-2H-benzo [b] [1, 4] oxazine-3 (4H)-ketone compound and application thereof |
US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
WO2015186061A1 (en) | 2014-06-03 | 2015-12-10 | Novartis Ag | Pyridopyrimidinedione derivatives |
CN106414443B (en) * | 2014-06-03 | 2018-10-26 | 诺华股份有限公司 | Pyridopyrimidine dione derivative |
WO2015186062A1 (en) | 2014-06-03 | 2015-12-10 | Novartis Ag | PYRIMIDO[4,5-b]QUINOLINE-4,5(3H,10H)-DIONE DERIVATIVES |
WO2015186063A1 (en) | 2014-06-03 | 2015-12-10 | Novartis Ag | Naphthyridinedione derivatives |
CN106414443A (en) * | 2014-06-03 | 2017-02-15 | 诺华股份有限公司 | Pyridopyrimidinedione derivatives |
US9896448B2 (en) | 2014-06-03 | 2018-02-20 | Novartis Ag | Pyrimido[4,5-b]quinoline-4,5(3H, 10H)-dione derivatives |
CN106459041A (en) * | 2014-06-03 | 2017-02-22 | 诺华股份有限公司 | Pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione derivatives |
US9884862B2 (en) | 2014-06-03 | 2018-02-06 | Novartis Ag | Pyridopyrimidinedione derivatives |
US10138232B2 (en) | 2014-06-03 | 2018-11-27 | Novartis Ag | Naphthyridinedione derivatives |
CN106459041B (en) * | 2014-06-03 | 2018-10-16 | 诺华股份有限公司 | Pyrimido [4,5-b] quinoline -4,5 (3H, 10H)-derovatives |
US10202367B2 (en) | 2014-06-12 | 2019-02-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Heterocyclic compounds and methods of use thereof |
WO2015192077A1 (en) * | 2014-06-12 | 2015-12-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Heterocyclic compounds and methods of use thereof |
CN104193686A (en) * | 2014-08-11 | 2014-12-10 | 广西壮族自治区中医药研究院 | N-gallic amide-pyrimidine phenyl sulfonamide derivative as well as preparation method and application thereof |
CN104193690B (en) * | 2014-08-11 | 2017-04-05 | 广西大学 | A kind of preparation method of Galla Turcica (Galla Helepensis) amide benzenesulfonamides |
CN104193690A (en) * | 2014-08-11 | 2014-12-10 | 广西大学 | 3,4,5-trihydroxy gallic acrylamide benzene sulfonamide derivatives as well as preparation method and application thereof |
WO2016032569A1 (en) * | 2014-08-29 | 2016-03-03 | Celladon Corporation | Quinolines and their use for treating endoplasmic reticulum stress-caused diseases |
US11827626B2 (en) | 2014-08-29 | 2023-11-28 | Neurodon Corporation | Quinolines that modulate SERCA and their use for treating disease |
CN104230912B (en) * | 2014-09-03 | 2017-06-06 | 中国科学院福建物质结构研究所 | Quinoline, Its Preparation Method And Use |
CN104230912A (en) * | 2014-09-03 | 2014-12-24 | 中国科学院福建物质结构研究所 | Quinoline derivative as well as preparation method and application thereof |
CN104262289A (en) * | 2014-10-09 | 2015-01-07 | 武汉大学 | Benzothiazole derivative and anti-tumor purpose thereof |
CN104262289B (en) * | 2014-10-09 | 2016-06-08 | 武汉大学 | A kind of benzothiazole derivant and anticancer usage thereof |
CN112375073A (en) * | 2014-12-05 | 2021-02-19 | 普尔莫赛德有限公司 | Antifungal compounds |
CN112375073B (en) * | 2014-12-05 | 2024-04-16 | 普尔莫赛德有限公司 | Antifungal compounds |
EP3253737B1 (en) * | 2015-02-06 | 2020-01-08 | Cancer Research Technology Ltd | Autotaxin inhibitory compounds |
CN104610103B (en) * | 2015-02-13 | 2016-04-06 | 佛山市赛维斯医药科技有限公司 | Containing benzol sulfohydrazide and halogeno-benzene structure GPR119 agonist, preparation method and its usage |
CN104610105B (en) * | 2015-02-13 | 2016-04-06 | 佛山市赛维斯医药科技有限公司 | Benzol sulfohydrazide class GPR119 agonist, preparation method and its usage that alkyl replaces |
CN104592066A (en) * | 2015-02-13 | 2015-05-06 | 佛山市赛维斯医药科技有限公司 | Benzenesulfonyl hydrazide compound as well as preparation method and application thereof |
CN104592066B (en) * | 2015-02-13 | 2016-04-06 | 佛山市赛维斯医药科技有限公司 | One class benzol sulfohydrazide compound, preparation method and its usage |
CN104610105A (en) * | 2015-02-13 | 2015-05-13 | 佛山市赛维斯医药科技有限公司 | GPR119 agonist containing alkyl substituted benzenesulfonyl hydrazine as well as preparation method and application thereof |
CN104592065B (en) * | 2015-02-13 | 2016-04-06 | 佛山市赛维斯医药科技有限公司 | Halogeno-benzene sulfonyl hydrazines GPR119 agonist, preparation method and its usage |
CN104628612A (en) * | 2015-02-13 | 2015-05-20 | 佛山市赛维斯医药科技有限公司 | Nitrile benzenesulfonylhydrazine type GPR119 agonist, preparation method and application thereof |
CN104592065A (en) * | 2015-02-13 | 2015-05-06 | 佛山市赛维斯医药科技有限公司 | Halogenated benzene sulfonyl hydrazine GPR119 agonist, preparation method and application thereof |
CN106800524A (en) * | 2015-02-13 | 2017-06-06 | 佛山市赛维斯医药科技有限公司 | Compound, preparation method and its usage of one class containing bishydrazide and naphthyl structure |
CN104649938A (en) * | 2015-02-13 | 2015-05-27 | 佛山市赛维斯医药科技有限公司 | Nitrobenzenesulfonyl hydrazide type GPR119 agonist, as well as preparation method and application thereof |
CN104610103A (en) * | 2015-02-13 | 2015-05-13 | 佛山市赛维斯医药科技有限公司 | GPR119 agonist containing benzenesulfonyl hydrazine and halogenated benzene structures as well as preparation method and application thereof |
US9884831B2 (en) | 2015-03-19 | 2018-02-06 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis B infections |
US10537580B2 (en) | 2015-03-19 | 2020-01-21 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis B infections |
US10791739B2 (en) | 2015-03-25 | 2020-10-06 | Vanderbilt University | Binary compositions as disruptors of orco-mediated odorant sensing |
US11856955B2 (en) | 2015-03-25 | 2024-01-02 | Vanderbilt University | Binary compositions as disruptors of Orco-mediated odorant sensing |
CN104829546A (en) * | 2015-04-13 | 2015-08-12 | 天津师范大学 | Double-triazole substituted ethoxy benzene compound and preparation method and application thereof |
CN104817509B (en) * | 2015-04-13 | 2019-05-17 | 安徽省逸欣铭医药科技有限公司 | Lesinurad analog and preparation method thereof and medical usage |
CN104829546B (en) * | 2015-04-13 | 2017-03-15 | 天津师范大学 | Ethoxybenzene compound that double triazoles replace and preparation method and application |
CN104817509A (en) * | 2015-04-13 | 2015-08-05 | 安徽省逸欣铭医药科技有限公司 | Lesinurad analog and preparation method and medical application thereof |
US10899716B2 (en) | 2015-05-19 | 2021-01-26 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
WO2016185423A1 (en) | 2015-05-19 | 2016-11-24 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
US11485710B2 (en) | 2015-05-19 | 2022-11-01 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
US11234976B2 (en) | 2015-06-11 | 2022-02-01 | Agios Pharmaceuticals, Inc. | Methods of using pyruvate kinase activators |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
CN104961706A (en) * | 2015-07-06 | 2015-10-07 | 成都知普莱生物医药科技有限公司 | Method for synthesizing insulin degrading enzyme inhibitor ML345 |
US10077239B2 (en) | 2015-09-29 | 2018-09-18 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis B antiviral agent |
CN108289448A (en) * | 2015-12-02 | 2018-07-17 | 先正达参股股份有限公司 | Kill microorganism oxadiazole derivatives |
CN108289448B (en) * | 2015-12-02 | 2021-10-22 | 先正达参股股份有限公司 | Microbicidal oxadiazole derivatives |
CN108473498B (en) * | 2015-12-22 | 2021-11-02 | 豪夫迈·罗氏有限公司 | Pyrazolo [1,5a ] pyrimidine derivatives as IRAK4 modulators |
CN108473498A (en) * | 2015-12-22 | 2018-08-31 | 豪夫迈·罗氏有限公司 | Pyrazolo [1,5a] pyrimidine derivatives as IRAK4 conditioning agents |
CN105732468A (en) * | 2016-04-07 | 2016-07-06 | 昆明理工大学 | N'-(2-(1H-indole-3-yl)acetyl)arylhydrazide compound and preparation method and application thereof |
US10441589B2 (en) | 2016-04-15 | 2019-10-15 | Novira Therapeutics, Inc. | Combinations and methods comprising a capsid assembly inhibitor |
US11129834B2 (en) | 2016-04-15 | 2021-09-28 | Novira Therapeutics, Inc. | Combinations and methods comprising a capsid assembly inhibitor |
CN105963301A (en) * | 2016-04-26 | 2016-09-28 | 兰州大学 | Lead compound using human FKBP51 protein as target as well as screening method and application thereof |
CN105963301B (en) * | 2016-04-26 | 2018-12-28 | 兰州大学 | Using people FKBP51 albumen as the lead compound of target spot and screening technique and application |
CN107686483B (en) * | 2016-08-05 | 2020-01-14 | 首都医科大学 | Heptacyclic acetals, their preparation, antithrombotic activity and use |
CN107686483A (en) * | 2016-08-05 | 2018-02-13 | 首都医科大学 | Seven cyclic ketals, it is prepared, anti-thrombus activity and application |
CN107686482A (en) * | 2016-08-05 | 2018-02-13 | 首都医科大学 | New heptacyclic compound, it is synthesized, activity rating and application |
CN106496118B (en) * | 2016-10-08 | 2019-01-18 | 红河学院 | A kind of quinolines enamine ketone compound and preparation method thereof |
CN106496118A (en) * | 2016-10-08 | 2017-03-15 | 红河学院 | A kind of quinolines ketones with Enamino-esters compound and preparation method thereof |
CN106496132A (en) * | 2016-10-13 | 2017-03-15 | 西华大学 | 2 replacement acetamides of N (4 substituted-phenyl) and its purposes as SIRT2 protein inhibitors |
CN106496132B (en) * | 2016-10-13 | 2019-03-08 | 西华大学 | N- (4- substituted-phenyl) -2- replaces acetamides and its purposes as SIRT2 protein inhibitor |
CN106543088B (en) * | 2016-10-25 | 2019-03-29 | 西华大学 | A kind of SIRT2 protein inhibitor and its purposes in pharmacy |
CN106543088A (en) * | 2016-10-25 | 2017-03-29 | 西华大学 | The new SIRT2 protein inhibitors of one class and its purposes in pharmacy |
US11739072B2 (en) | 2016-12-29 | 2023-08-29 | Minoryx Therapeutics S.L. | Heteroaryl compounds and their use |
CN110325516A (en) * | 2016-12-29 | 2019-10-11 | 米尼奥尔克斯治疗有限公司 | The purposes of heteroaryl compound and they |
KR101886118B1 (en) * | 2017-05-22 | 2018-09-06 | 한국기초과학지원연구원 | A pharmaceutical composition for prevention or treatment of diabetes or fatty liver comprising CYP4A inhibitor |
CN108997261A (en) * | 2017-06-07 | 2018-12-14 | 东莞市凯法生物医药有限公司 | A kind of compound and the preparation method and application thereof |
CN109535146A (en) * | 2017-09-21 | 2019-03-29 | 中国医学科学院医药生物技术研究所 | Antitubercular compounds and its preparation method and application |
CN109535146B (en) * | 2017-09-21 | 2020-09-22 | 中国医学科学院医药生物技术研究所 | Antituberculous compound and its preparation method and use |
US11647748B2 (en) | 2018-01-17 | 2023-05-16 | Migal—Galilee Research Institute Ltd. | Sulphonamides as methionine metabolic pathway inhibitors |
US11639345B2 (en) | 2018-01-17 | 2023-05-02 | Migal—Galilee Research Institute Ltd. | Methionine metabolic pathway inhibitors |
CN108129486A (en) * | 2018-01-25 | 2018-06-08 | 华东理工大学 | Pyrimidone derivatives and application thereof |
CN108503640A (en) * | 2018-01-31 | 2018-09-07 | 广西田园生化股份有限公司 | Sparteine derivative and preparation method thereof and the utilization in pesticide |
CN108503640B (en) * | 2018-01-31 | 2019-11-12 | 广西田园生化股份有限公司 | Sparteine derivative and preparation method thereof and the utilization in pesticide |
US10973801B2 (en) | 2018-03-14 | 2021-04-13 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
CN108383805B (en) * | 2018-05-04 | 2019-07-23 | 上海应用技术大学 | A kind of neuraminidase inhibitor and preparation method thereof |
CN108341831A (en) * | 2018-05-11 | 2018-07-31 | 贵州医科大学 | 7H- [1,2,4] triazole [3,4-b] [1,3,4] thiadiazine-phenylhydrazone type compound |
CN108341831B (en) * | 2018-05-11 | 2020-10-09 | 贵州医科大学 | 7H- [1,2,4] triazolo [3,4-b ] [1,3,4] thiadiazine-phenylhydrazone type compounds |
CN110563709B (en) * | 2018-06-06 | 2023-01-24 | 中国科学院上海药物研究所 | Pyrimidine compounds and application thereof as TRPV2 inhibitor |
CN110563709A (en) * | 2018-06-06 | 2019-12-13 | 中国科学院上海药物研究所 | Pyrimidine compounds and application thereof as TRPV2 inhibitor |
CN108822099A (en) * | 2018-06-08 | 2018-11-16 | 河南中医药大学 | A kind of 3-(2-[4-morpholinodithio amino)Isobenzofuran -1-(3H)-one and its preparation method and application |
CN108822099B (en) * | 2018-06-08 | 2020-06-19 | 河南中医药大学 | 3- (2-benzothiazolylamino) isobenzofuran-1- (3H) -ketone and preparation method and application thereof |
CN108863892A (en) * | 2018-07-04 | 2018-11-23 | 温州医科大学 | A kind of gallicin analog of amide containing structure and application |
CN108863892B (en) * | 2018-07-04 | 2022-04-05 | 温州医科大学 | Gallic acid methyl ester analogue containing amide structure and application thereof |
CN108558777B (en) * | 2018-07-31 | 2021-01-26 | 河北大学 | Pyrimidine salicylic acid derivative and preparation method and application thereof |
CN108558777A (en) * | 2018-07-31 | 2018-09-21 | 河北大学 | Pyrimidine salicylic acid derivative and the preparation method and application thereof |
CN109081808A (en) * | 2018-09-11 | 2018-12-25 | 济南大学 | Anilid class compound of the one kind containing tetrahydroisoquinoline structure, purposes and preparation method thereof |
CN109232576A (en) * | 2018-10-22 | 2019-01-18 | 信阳师范学院 | 7- replaces deoxidation malabar nut ketone alkali and its preparation method and application |
CN109232576B (en) * | 2018-10-22 | 2020-07-17 | 信阳师范学院 | 7-substituted desoxypeganone base and preparation method and application thereof |
CN109438375A (en) * | 2018-12-10 | 2019-03-08 | 扬州工业职业技术学院 | A kind of preparation method for the triazole class compounds that 4,5- diphenyl replaces |
CN109438375B (en) * | 2018-12-10 | 2020-09-01 | 扬州工业职业技术学院 | Preparation method of 4, 5-diphenyl substituted triazole compound |
EP3906241A4 (en) * | 2019-01-04 | 2022-11-02 | Bellbrook Labs, Llc | Inhibitors of cgas activity as therapeutic agents |
CN109851570B (en) * | 2019-02-02 | 2022-04-19 | 贵州大学 | Chalcone derivative containing 1,2, 4-triazine, preparation method and application thereof |
CN109851570A (en) * | 2019-02-02 | 2019-06-07 | 贵州大学 | A kind of chalcone derivative, preparation method and the application of the triazine containing 1,2,4- |
US11096931B2 (en) | 2019-02-22 | 2021-08-24 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
CN109912626B (en) * | 2019-03-11 | 2021-07-23 | 浙江瑀美生物科技有限公司 | Thiazolotriazole superoxide dismutase agonist and preparation method and application thereof |
CN109912626A (en) * | 2019-03-11 | 2019-06-21 | 河南湾流生物科技有限公司 | A kind of thiazole and triazole superoxide dismutase agonist and its preparation method and application |
US11491148B2 (en) | 2019-05-06 | 2022-11-08 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
CN112174903B (en) * | 2019-07-01 | 2022-07-12 | 清华大学 | Small molecule modulators of TLR8 |
CN112174903A (en) * | 2019-07-01 | 2021-01-05 | 清华大学 | Small molecule modulators of TLR8 |
CN112279835A (en) * | 2019-07-24 | 2021-01-29 | 中国医学科学院药物研究所 | Aromatic ring or aromatic heterocyclic imidazole compound, preparation method and pharmaceutical application thereof |
CN112279835B (en) * | 2019-07-24 | 2022-07-22 | 中国医学科学院药物研究所 | Aromatic ring or aromatic heterocyclic imidazole compound, preparation method and pharmaceutical application thereof |
CN112409223A (en) * | 2019-10-12 | 2021-02-26 | 中国药科大学 | Amide compounds and medical application thereof as STING inhibitor |
CN112409223B (en) * | 2019-10-12 | 2023-01-31 | 中国药科大学 | Amide compound and medical application thereof as STING inhibitor |
WO2021068950A1 (en) * | 2019-10-12 | 2021-04-15 | 中国药科大学 | Amide compound and medical use thereof as sting inhibitor |
CN110615792B (en) * | 2019-11-01 | 2021-08-31 | 河北工业大学 | 2-benzylthio-5-methyl-4, 7-dihydro- [1,2,4] triazolo [1,5-a ] pyrimidine derivatives |
CN110615792A (en) * | 2019-11-01 | 2019-12-27 | 河北工业大学 | 2-benzylthio-5-methyl-4, 7-dihydro- [1,2,4] triazolo [1,5-a ] pyrimidine derivatives |
WO2021126923A1 (en) * | 2019-12-19 | 2021-06-24 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Cd206 modulators their use and methods for preparation |
CN115768757A (en) * | 2019-12-19 | 2023-03-07 | 美利坚合众国,由健康及人类服务部部长代表 | CD206 modulators and uses and methods of making thereof |
CN111518021B (en) * | 2020-06-08 | 2021-08-27 | 沅江华龙催化科技有限公司 | Method for constructing 3,5-disubstituted pyridine by using mixed styrene derivative and N, N-dimethylformamide |
CN111518021A (en) * | 2020-06-08 | 2020-08-11 | 沅江华龙催化科技有限公司 | Method for constructing 3,5-disubstituted pyridine by using mixed styrene derivative and N, N-dimethylformamide |
US11730729B2 (en) | 2020-07-20 | 2023-08-22 | Neurodon Corporation | Quinolines that modulate SERCA and their use for treating disease |
US11890279B2 (en) | 2020-07-20 | 2024-02-06 | Neurodon Corporation | Quinolines that modulate SERCA and their use for treating disease |
WO2022194261A1 (en) * | 2021-03-19 | 2022-09-22 | 南京药石科技股份有限公司 | Pyrimidine-fused cyclic compound and use thereof in preparation of drug for treating pain and spinal cord injury |
WO2023137885A1 (en) * | 2022-01-21 | 2023-07-27 | 中国药科大学 | Compound having pyridoimidazole as parent nucleus, and preparation method for and use of compound |
US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
CN114773302A (en) * | 2022-04-29 | 2022-07-22 | 中国药科大学 | Benzofuran derivative and medical application thereof |
CN114773302B (en) * | 2022-04-29 | 2024-04-02 | 中国药科大学 | Benzofuran derivative and medical application thereof |
Also Published As
Publication number | Publication date |
---|---|
EP2219646A2 (en) | 2010-08-25 |
AU2008345225A1 (en) | 2009-07-09 |
US8642660B2 (en) | 2014-02-04 |
JP2011507910A (en) | 2011-03-10 |
EP2219646A4 (en) | 2010-12-22 |
CA2709784A1 (en) | 2009-07-09 |
US20090163545A1 (en) | 2009-06-25 |
WO2009086303A3 (en) | 2009-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8642660B2 (en) | Method for altering the lifespan of eukaryotic organisms | |
Gonzalez et al. | The mind-body-microbial continuum | |
Ménard et al. | Induction of multidrug tolerance in Plasmodium falciparum by extended artemisinin pressure | |
Shade | The science behind NMN–A stable, reliable NAD+ activator and anti-aging molecule | |
Fomovska et al. | Salicylanilide inhibitors of Toxoplasma gondii | |
Tintó-Font et al. | A heat-shock response regulated by the PfAP2-HS transcription factor protects human malaria parasites from febrile temperatures | |
Mackiewicz et al. | What are microarrays teaching us about sleep? | |
Manneck et al. | Schistosoma mansoni: antischistosomal activity of the four optical isomers and the two racemates of mefloquine on schistosomula and adult worms in vitro and in vivo | |
Heller et al. | Quantification of free ferriprotoporphyrin IX heme and hemozoin for artemisinin sensitive versus delayed clearance phenotype Plasmodium falciparum malarial parasites | |
Fung et al. | Unbiased screening of marine sponge extracts for anti-inflammatory agents combined with chemical genomics identifies girolline as an inhibitor of protein synthesis | |
US20070207231A1 (en) | Composition and use of phyto-percolate for treatment of disease | |
JP2021105011A (en) | Therapeutic drug for lipid-peroxidation-induced diseases and screening method therefor | |
De Lazzari et al. | Antioxidant therapy in Parkinson’s disease: insights from Drosophila melanogaster | |
Zhang et al. | Genetic mapping of microbial and host traits reveals production of immunomodulatory lipids by Akkermansia muciniphila in the murine gut | |
Reynolds | Shortened lifespan and other age-related defects in bang sensitive mutants of Drosophila melanogaster | |
Al-Smadi et al. | Synthesis, characterization, antimicrobial activity, and genotoxicity assessment of two heterocyclic compounds containing 1, 2, 3-selena-or 1, 2, 3-thiadiazole rings | |
Myers et al. | Drugs that target aging: how do we discover them? | |
CN102428078A (en) | Antiepileptic, hypocholesterolemic and neuroprotective compound | |
Andrioli et al. | δ-Lactam derivative from thermophilic soil fungus exhibits in vitro anti-allergic activity | |
Herath et al. | Arylpyrrole and fipronil analogues that inhibit the motility and/or development of Haemonchus contortus in vitro | |
Kocaoğlu Cenkci et al. | Effects of Chlorophyll a and b in Reducing Genotoxicity of 2-Amino-3, 8-dimethylimidazo [4, 5-F] quinoxaline (MeIQx) | |
CN101355929A (en) | Means and methods for the treatment and prevention of allergic diseases | |
Turhan et al. | Genotoxic and antigenotoxic assessment of four newly synthesized dihydropyridine derivatives | |
Adesola et al. | Drosophila melanogaster (Meigen, 1830): A potential model for human diseases | |
Gunia-Krzyżak et al. | S (+)-(2 E)-N-(2-Hydroxypropyl)-3-Phenylprop-2-Enamide (KM-568): A Novel Cinnamamide Derivative with Anticonvulsant Activity in Animal Models of Seizures and Epilepsy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08867410 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008867410 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2709784 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010539936 Country of ref document: JP Ref document number: 2008345225 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2008345225 Country of ref document: AU Date of ref document: 20081222 Kind code of ref document: A |